Multisubstituted aromatic compounds as serine protease inhibitors

ABSTRACT

There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of kallikrein, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which disease or disorder is amenable to treatment or prevention by the inhibition of kallikrein.

CROSS-REFERENCES TO RELATED APPLICATIONS

This application is a division of U.S. application Ser. No. 15/605,566,filed May 25, 2017, which is a continuation of U.S. application Ser. No.15/354,756, filed Nov. 17, 2016, which is a division of U.S. applicationSer. No. 14/776,612, filed Sep. 14, 2015, which is a 371 nationalizationof PCT application PCT/US2014/030853, filed Mar. 17, 2014, which claimsthe benefit of U.S. Provisional Application No. 61/789,358, filed Mar.15, 2013, the entire contents of each of which are hereby incorporatedby reference herein and for all purposes.

BACKGROUND OF THE INVENTION

The present disclosure relates to compounds, e.g., multisubstitutedaromatic compounds, which exhibit biological activity, e.g., inhibitoryaction, against serine proteases, including thrombin and variouskallikreins.

Kallikreins are a subgroup of serine proteases, divided into plasmakallikrein and tissue kallikreins. Plasma kallikrein (KLKB1) liberateskinins (bradykinin and kallidin) from the kininogens, peptidesresponsible for the regulation of blood pressure and activation ofinflammation. In the contact activation pathway of the coagulationcascade, plasma kallikrein assists in the conversion of factor XII tofactor XIIa (Keel, M.; Trentz, O. Injury 2005, 36, 691-709). Factor XIIaconverts FXI into FXIa, which in turn activates FIX, which with itsco-factor FVIIIa forms the tenase complex, which finally activates FX toFXa. In the fibrinolysis part of the coagulation cascade, plasmakallikrein serves to convert plasminogen to plasmin. Thus, it has beenproposed that plasma kallikrein inhibitors can be useful in thetreatment of thrombotic and fibrinolytic diseases and disease conditions(U.S. Pat. No. 7,625,944; Bird et al. Thrombosis and Hemostasis 2012,107, 1141).

In rodent models, it has been shown that activation of plasma kallikreinin the eye increases retinal vascular permeability; whereas inhibitionof the kallikrein-kinin system reduces retinal leakage induced bydiabetes and hypertension. These findings suggest that intraocularactivation of the plasma kallikrein pathway can contribute to excessiveretinal vascular permeability that can lead to diabetic macular edema(DME). Thus, evidence suggests that plasma kallikrein inhibitors canprovide a new therapeutic opportunity to reduce retinal vascularpermeability (Feener, E. P. Curr Diab Rep 2010, 10, 270).

The Kallikrein-kinin system is involved in the regulation of vascularendothelial growth factor (VEGF), endothelial NO synthase, andfibroblast growth factor 2, all of which are involved in angiogenesis(Bader M. 2009, Arteriosclerosis, Thrombosis, and Vascular Biology, 29:617). Tissue kallikrein (KLK1) has been linked to blood vessel growth(Miura S., 2003, Hypertension, 41, 1118). Therapies that moderateangiogenesis have been proposed for the treatment of both diabeticmacular edema (DME) and age-related macular degeneration (AMD) (Syed, B.A.; Evans, J. B.; Bielory, L., 2012, Nature Reviews Drug Discovery, 11,827). Without further wishing to be bound by any theory, it is thereforereasonable to conclude that KLK1 inhibitors can be useful in thetreatment of diabetic retinopathy, DME, and AMD.

Studies have shown that inflammation plays an important role in theorigin and development of AMD, and treatment often includesanti-inflammatories such as corticosteroid (Telander, D., 2011, Seminarsin Ophthalmology, 26(3), 192). The connection between thekallikrein-kinin system and inflammation is also well established(Duchene, 2011, “Kallikrein-kinin kystem in inflammatory diseases”.Kinins. De Gruyter. 261). Without further wishing to be bound by anytheory, it is reasonable to conclude that the anti-inflammatory natureof kallikrein (e.g. KLK1 and KLKB1) inhibitors can be useful in thetreatment of AMD.

Ecallantide (Kalbitor) is a 60-amino acid recombinant protein that actsas a potent reversible inhibitor of plasma kallikrein (Schneider L, etal., J Allergy Clin Immunol 2007, 120, 416). Ecallantide has beenapprovied by the FDA for the treatment of acute attacks of hereditaryangioedema (HAE). Without further wishing to be bound by any theory, itis reasonable to believe that plasma kallikrein inhibition in generalcan be a useful treatment for HAE, and thus there is strong interest inthe development of plasma kallikrein inhibitors as a therapy for HAE.

Tissue kallikreins (KLKs, for example, KLK1) are subdivided into varioustypes, and have been extensively investigated in cancer and inflammationbiology. Various kallikrein KLKs have been found to be up- ordown-regulated in various cancer types, such as cervical-, testicular-,and non-small-cell lung adenocarcinoma (Caliendo et al. J. Med. Chem.,2012, 55, 6669). Furthermore, overexpression of various KLKs in the skinhas led to the recognition that certain kallikrein inhibitors can beuseful for certain dermatological conditions, including atopicdermatitis, psoriasis and rare skin diseases such as Netherton Syndrome(Freitas et al. Bioorganic & Medicinal Chemistry Letters 2012, 22,6072-6075). A thorough discussion of tissue kallikrein, plasmakallikreins, their functions and potential roles in various diseases canbe found in a variety of references, including the following which areincorporated herein by reference in their entireties and for allpurposes: Renné, T.; Gruber, A. Thromb Haemost 2012, 107, 1012-3;Sotiropoulou, G.; Pampalakis, G. Trends in Pharmacological Sciences2012, 33, 623-634; Pampalakis, G.; Sotiropoulou, G. Chapter 9Pharmacological Targeting of Human Tissue Kallikrein-Related Peptidases.In Proteinases as Drug Targets, Dunn, B., Ed. The Royal Society ofChemistry: 2012; pp 199-228; Caliendo, G.; Santagada, V.; Perissutti,E.; Severino, B.; Fiorino, F.; Frecentese, F.; Juliano, L. J Med Chem2012, 55, 6669-86.

In mammalian systems, blood vessel injuries result in bleeding events,which are dealt with by the blood coagulation cascade. The cascadeincludes the extrinsic and intrinsic pathways, involving the activationof at least 13 interconnected factors and a variety of co-factors andother regulatory proteins. Upon vascular injury, plasma factor VIIinteracts with exposed Tissue Factor (TF), and the resultant TF-fVIIacomplex initiates a complex series of events. Factor fXa is produceddirectly ‘downstream’ from the TF-fVIIa complex, and amplified manifoldvia the intrinsic Pathway. FXa then serves as the catalyst for formationof thrombin (fIIa), which in turn is the direct precursor tofibrinolysis. The outcome is a fibrinolytic clot, which stops thebleeding. Fibrinolysis of the polymeric clot into fibrin monomers leadsto dissolution and a return of the system to the pre-clot state. Thecascade is a complex balance of factors and co-factors and is tightlyregulated. In disease states, undesired up- or down-regulation of anyfactor leads to conditions such as bleeding or thrombosis. Historically,anticoagulants have been used in patients at risk of suffering fromthrombotic complications, such as angina, stroke and heart attack.Warfarin has enjoyed dominance as a first-in-line anticoagulanttherapeutic. Developed in the 1940s, it is a Vitamin K antagonist andinhibits factors II, VII, IX and X, amongst others. It is administeredorally, but its ease of use is tempered by other effects: it has a verylong half-life (>2 days) and has serious drug-drug interactions.Importantly, since Vitamin K is a ubiquitous cofactor within thecoagulation cascade, antagonism results in the simultaneous inhibitionof many clotting factors and thus can lead to significant bleedingcomplications.

Much attention has been focused on heparin, the naturally-occurringpolysaccharide that activates AT III, the endogenous inhibitor of manyof the factors in the coagulation cascade. The need for parenteraladministration for the heparin-derived therapeutics, and theinconvenient requirements for close supervision for the orally availablewarfarin, has resulted in a drive to discover and develop orallyavailable drugs with wide therapeutic windows for safety and efficacy.Indeed, the position of thrombin in the coagulation cascade has made ita popular target for drug discovery. Without wishing to be bound by anytheory, it is believed that the ultimate development of direct thrombininhibitors (DTIs) is usefully based upon the classical D-Phe-Pro-Argmotif, a sequence that mimics fibrinogen, which is a natural substrateof thrombin. Without further wishing to be bound by any theory, it isbelieved that the use of DTIs is very well precedented, such as with thehirudin-based anticoagulants, and thus there is strong interest in thediscovery and development of novel DTIs.

A thorough discussion of thrombin and its roles in the coagulationprocess can be found in a variety of references, including the followingwhich are incorporated herein by reference in their entireties and forall purposes: Wieland, H. A., et al., 2003, Curr Opin Investig Drugs,4:264-71; Gross, P. L. & Weitz, J. I., 2008, Arterioscler Thromb VascBiol, 28:380-6; Hirsh, J., et al., 2005, Blood, 105:453-63; Prezelj, A.,et al., 2007, Curr Pharm Des, 13:287-312.

BRIEF SUMMARY OF THE INVENTION

Embodiments of the invention encompass methods for treating orpreventing a kallikrein-related disease or disorder in a subject, themethods including administering a compound of Formula (Ia):

or a pharmaceutical composition including the compound and apharmaceutically acceptable excipient, to a subject in need thereof inan amount effective to treat or prevent said disease or disorder,wherein: Ring A can be substituted or unsubstituted pyrazolyl, orsubstituted or unsubstituted triazolyl; L¹, L², and L⁴ can beindependently absent, a bond, substituted or unsubstituted alkylene,substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO₂—, —O—,—NHSO₂—, or —NR⁷—; L³ can be a bond, substituted or unsubstitutedalkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO₂—,—O—, —NHSO₂—, or —NR⁷—; R¹, R², and R⁴ can be independently absent,hydrogen, halogen, substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted cycloalkenyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted heterocycloalkenyl,substituted or unsubstituted aryl, substituted or unsubstituted fusedring aryl, or substituted or unsubstituted heteroaryl, provided that R¹can be absent when L¹ can be absent, R² can be absent when L² can beabsent, and R⁴ can be absent when L⁴ can be absent; R³ can be hydrogen,halogen, substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted cycloalkenyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted heterocycloalkenyl,substituted or unsubstituted aryl, substituted or unsubstituted fusedring aryl, or substituted or unsubstituted heteroaryl, provided that R²can be absent when L² can be absent, R³ can be absent when L³ can beabsent, and R⁴ can be absent when L⁴ can be absent; and R⁷ can behydrogen, substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted alkylene,substituted or unsubstituted heteroalkylene, substituted orunsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted heterocycloalkenyl, substituted or unsubstituted aryl,substituted or unsubstituted fused ring aryl, or substituted orunsubstituted heteroaryl. In some embodiments of the methods L⁴ and R⁴can be absent.

In some embodiments, the compound can have the structure of Formula(IIa):

In some embodiments, L³ can be a bond, and R can be substituted orunsubstituted heterocycloalkyl, substituted or unsubstituted aryl,substituted or unsubstituted fused ring aryl, or substituted orunsubstituted heteroaryl. In some embodiments, the heteroaryl can bepyridyl, pyridazinyl, pyrimidinyl, thienyl, or furyl. In someembodiments, R³ can be substituted or unsubstituted phenyl, substitutedor unsubstituted morpholinyl, substituted or unsubstituted oxanyl,substituted or unsubstituted oxetanyl, substituted or unsubstitutednaphthyl or substituted or unsubstituted benzodioxinyl. In someembodiments, L³ can be a bond or substituted or unsubstituted alkylene,and R³ can be substituted or unsubstituted aryl, or substituted orunsubstituted heterocycloalkyl. In some embodiments, L³ can be —C(O)O—,and R³ can be substituted or unsubstituted alkyl. In some embodiments,L³ can be —C(O)NR⁵—, R⁵ can be hydrogen or alkyl, and R³ can besubstituted or unsubstituted alkyl, or substituted or unsubstitutedaryl. In some embodiments, L can be —S—, —NR⁴—, substituted orunsubstituted alkylene, or substituted or unsubstituted heteroalkylene,and R¹ can be hydrogen, substituted or unsubstituted alkyl, substitutedor unsubstituted aryl, substituted or unsubstituted fused ring aryl,substituted or unsubstituted heteroaryl, or substituted or unsubstitutedheterocycloalkyl. In some embodiments, the heteroaryl can be pyridyl,pyridazinyl, pyrimidinyl, thienyl, or furyl. In some embodiments, R¹ canbe chloro-substituted thienyl. In some embodiments, R¹ can besubstituted or unsubstituted phenyl, substituted or unsubstitutedmorpholinyl, substituted or unsubstituted oxanyl, substituted orunsubstituted oxetanyl, substituted or unsubstituted naphthyl orsubstituted or unsubstituted benzodioxinyl. In some embodiments, L² andR² can be absent. In some embodiments, L³ and R³ can be absent. In someembodiments, L² can be substituted or unsubstituted alkylene or —C(O)—,and R² can be hydrogen, substituted or unsubstituted alkyl, substitutedor unsubstituted aryl, substituted or unsubstituted fused ring aryl,substituted or unsubstituted heteroaryl, or substituted or unsubstitutedheterocycloalkyl. In some embodiments, the heteroaryl can be pyridyl,pyridazinyl, pyrimidinyl, thienyl, or furyl. In some embodiments, R² canbe substituted or unsubstituted phenyl, substituted or unsubstitutedmorpholinyl, substituted or unsubstituted oxanyl, substituted orunsubstituted oxetanyl, substituted or unsubstituted naphthyl orsubstituted or unsubstituted benzodioxinyl.

In some embodiments, the compound can have the structure of Formula(III):

In some embodiments, L³ can be a bond, or substituted or unsubstitutedalkylene, and R³ can be substituted or unsubstituted aryl, substitutedor unsubstituted fused ring aryl, substituted or unsubstitutedheteroaryl, substituted or unsubstituted heterocycloalkyl, orsubstituted or unsubstituted heterocycloalkyl. In some embodiments, R³can be phenyl, naphthyl, pyridyl, pyridazinyl, pyrimidinyl, thienyl,furyl, morpholinyl, oxanyl, oxetanyl, or benzodioxinyl. In someembodiments, L³ can be —C(O)O—, and R³ can be substituted orunsubstituted alkyl. In some embodiments, L³ can be —C(O)NR′—, R′ can behydrogen or alkyl, and R³ can be substituted or unsubstituted alkyl, orsubstituted or unsubstituted aryl. In some embodiments, L¹ can be —S—,—NR⁷—, substituted or unsubstituted alkylene, or substituted orunsubstituted heteroalkylene, R⁷ can be a hydrogen or alkyl, and R¹ canbe hydrogen, substituted or unsubstituted alkyl, substituted orunsubstituted aryl, substituted or unsubstituted fused ring aryl,substituted or unsubstituted heteroaryl, or substituted or unsubstitutedheterocycloalkyl. In some embodiments, the heteroaryl can be pyridyl,pyridazinyl, pyrimidinyl, thienyl, or furyl. In some embodiments, R¹ canbe chloro-substituted thienyl. In some embodiments, R¹ can besubstituted or unsubstituted phenyl, substituted or unsubstitutedmorpholinyl, substituted or unsubstituted oxanyl, substituted orunsubstituted oxetanyl, substituted or unsubstituted naphthyl orsubstituted or unsubstituted benzodioxinyl. In some embodiments, L² canbe a bond and R² can be hydrogen. In some embodiments, L² can besubstituted or unsubstituted alkylene or —C(O)—, and R² can be hydrogen,substituted or unsubstituted alkyl, substituted or unsubstituted aryl,substituted or unsubstituted fused ring aryl, substituted orunsubstituted heteroaryl, or substituted or unsubstitutedheterocycloalkyl. In some embodiments, the heteroaryl can be pyridyl,pyridazinyl, pyrimidinyl, thienyl, or furyl. In some embodiments, R² canbe substituted or unsubstituted phenyl, substituted or unsubstitutedmorpholinyl, substituted or unsubstituted oxanyl, substituted orunsubstituted oxetanyl, substituted or unsubstituted naphthyl orsubstituted or unsubstituted benzodioxinyl.

In some embodiments, the compound has the following structure of Formula(IV):

In some embodiments, L⁴ can be a bond, and R⁴ can be hydrogen, halogen,substituted or unsubstituted alkyl, substituted or unsubstitutedheteroalkyl, substituted or unsubstituted aryl, or substituted orunsubstituted heteroaryl. In some embodiments, R⁴ can be halogen. Insome embodiments, R⁴ can be unsubstituted alkyl. In some embodiments, R⁴can be phenyl, naphthyl, pyridyl, pyridazinyl, pyrimidinyl, thienyl, orfuryl.

In some embodiments, the compound can be selected from any of Tables Bor C. In some embodiments, the kallikrein-related disorder can be athrombotic disease, a fibrinolytic disease, a type of cancer, aninflammatory condition, or a dermatological condition. In someembodiments, the kallikrein-related disorder can be an ophthalmicdisease. In some embodiments, the ophthalmic disease can be diabeticmacular edema, age-related macular degeneration, or diabeticretinopathy. In some embodiments, the type of cancer can be cervical-,testicular-, or non-small-cell lung adenocarcinoma. In some embodiments,the inflammatory condition can be sepsis, inflammatory bowel disease,systemic inflammatory response syndrome, or rheumatoid arthritis. Insome embodiments, the dermatological condition can be atopic dermatitis,psoriasis, or Netherton Syndrome. In some embodiments, the compound actsby inhibiting kallikrein. In some embodiments, the compound acts byinhibiting tissue kallikrein. In some embodiments, the compound acts byinhibiting plasma kallikrein. In some embodiments, the compound orpharmaceutical composition can be administered in the form of anophthalmic composition applied topically to the eye. In someembodiments, the ophthalmic composition can be in the form of eye drops.In some embodiments, the compound or pharmaceutical composition can beadministered in the form of an ophthalmic composition via intravitrealinjection. Embodiments of the invention also encompass methods fortreating or preventing a kallikrein-related disease or disorder in asubject, including administering a compound from Table D or apharmaceutical composition including compound and a pharmaceuticallyacceptable excipient, to a subject in need thereof in an amounteffective to treat or prevent the disease or disorder.

Embodiments of the invention also encompass compounds with structure ofFormula (V):

or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof;wherein L¹ can be a bond, substituted or unsubstituted alkylene,substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO₂—, —O—,—NHSO₂—, or —NR⁷—; L² and L⁵ can be independently absent, a bond,substituted or unsubstituted alkylene, substituted or unsubstitutedheteroalkylene, —S—, —SO—, —SO₂—, —O—, —NHSO₂—, or —NR⁷—; R¹ can behydrogen, halogen, substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted cycloalkenyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted heterocycloalkenyl,substituted or unsubstituted aryl, substituted or unsubstituted fusedring aryl, or substituted or unsubstituted heteroaryl; R² and R⁵ can beindependently absent, hydrogen, halogen, substituted or unsubstitutedalkyl, substituted or unsubstituted heteroalkyl, substituted orunsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted heterocycloalkenyl, substituted or unsubstituted aryl,substituted or unsubstituted fused ring aryl, or substituted orunsubstituted heteroaryl; and R⁷ can be hydrogen, substituted orunsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted alkylene, substituted or unsubstitutedheteroalkylene, substituted or unsubstituted cycloalkyl, substituted orunsubstituted heterocycloalkyl, substituted or unsubstituted aryl, orsubstituted or unsubstituted heteroaryl. In some embodiments, L⁵ and R⁵can be absent. In some embodiments, L² and R² can be absent. In someembodiments, L² can be —C(O)—, and R² can be substituted orunsubstituted alkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted cycloalkenyl, substituted or unsubstitutedheteroalkyl, substituted or unsubstituted heterocycloalkyl, substitutedor unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl,substituted or unsubstituted fused ring aryl, or substituted orunsubstituted heteroaryl. In some embodiments, R² can be substituted orunsubstituted aryl or substituted or unsubstituted heteroaryl. In someembodiments, the heteroaryl can be pyridyl, pyridazinyl, pyrimidinyl,thienyl, or furyl. In some embodiments, R² can be substituted orunsubstituted alkyl, substituted or unsubstituted cycloalkyl, orsubstituted or unsubstituted heterocycloalkyl. In some embodiments, theheterocycloalkyl can be oxanyl, oxetanyl, or morpholinyl. In someembodiments, the fused ring aryl can be benzodioxinyl or naphthyl. Insome embodiments, L¹ can be bond, —S—, —NR⁷—, substituted orunsubstituted alkylene, or substituted or unsubstituted heteroalkylene,and R¹ can be hydrogen, substituted or unsubstituted alkyl, substitutedor unsubstituted aryl, substituted or unsubstituted fused ring aryl,substituted or unsubstituted heteroaryl, or substituted or unsubstitutedheterocycloalkyl. In some embodiments, the heteroaryl can be pyridyl,pyridazinyl, pyrimidinyl, thienyl, or furyl. In some embodiments, R¹ canbe chloro-substituted thienyl. In some embodiments, the heterocycloalkylcan be morpholinyl, oxanyl, or oxetanyl. In some embodiments, the fusedring aryl can be benzodioxinyl or naphthyl. In some embodiments, L⁵ canbe a bond or substituted or unsubstituted alkylene, and R⁵ can besubstituted or unsubstituted aryl, substituted or unsubstituted fusedring aryl, or substituted or unsubstituted heteroaryl. In someembodiments, the heteroaryl can be pyridyl, pyridazinyl, pyrimidinyl,thienyl, or furyl. In some embodiments, the fused ring aryl can bebenzodioxinyl or naphthyl. In some embodiments, L⁵ can be substituted orunsubstituted alkylene, and R⁵ can be substituted or unsubstitutedheterocycloalkyl. In some embodiments, the heterocycloalkyl can bemorpholinyl, oxanyl, or oxetanyl.

Embodiments of the invention also encompass pharmaceutical compositionsincluding such compounds, or a compound as set forth in Table A, and apharmaceutically acceptable excipient. Embodiments of the invention alsoencompass methods for treating a disease or disorder in a subject,including administering such compounds or pharmaceutical compositions toa subject in need thereof in an amount effective to treat or preventsaid disease or disorder. In some embodiments, the disease or disordercan be a thrombotic disorder. In some embodiments, the thromboticdisorder can be acute coronary syndrome, venous thromboembolism,arterial thromboembolism, cardiogenic thromboembolism, disseminatedintravascular coagulation, or a blood clot thrombus. In someembodiments, the disease or disorder can be fibrosis. In someembodiments, the disease or disorder can be Alzheimer's Disease. In someembodiments, the disease or disorder can be multiple sclerosis. In someembodiments, the disease or disorder can be pain. In some embodiments,the disease or disorder can be cancer. In some embodiments, the compoundacts by inhibiting thrombin. In some embodiments, the disease ordisorder can be a kallikrein-related disorder. In some embodiments, thekallikrein-related disorder can be a thrombotic disease, a fibrinolyticdisease, a type of cancer, an inflammatory condition, or adermatological condition. In some embodiments, the kallikrein-relateddisorder can be an ophthalmic disease. In some embodiments, theophthalmic disease can be diabetic macular edema, age-related maculardegeneration, or diabetic retinopathy. In some embodiments, the type ofcancer can be cervical-, testicular-, or non-small-cell lungadenocarcinoma. In some embodiments, the inflammatory condition can besepsis, inflammatory bowel disease, systemic inflammatory responsesyndrome, or rheumatoid arthritis. In some embodiments, thedermatological condition can be atopic dermatitis, psoriasis, orNetherton Syndrome. In some embodiments, the compound acts by inhibitingkallikrein. In some embodiments, the compound acts by inhibiting tissuekallikrein. In some embodiments, the compound acts by inhibiting plasmakallikrein. In some embodiments, the compound or pharmaceuticalcomposition can be administered in the form of an ophthalmic compositionapplied topically to the eye. In some embodiments, the ophthalmiccomposition can be in the form of eye drops. In some embodiments, thecompound or pharmaceutical composition can be administered in the formof an ophthalmic composition via intravitreal injection.

BRIEF DESCRIPTION OF THE DRAWINGS

Not applicable.

DETAILED DESCRIPTION OF THE INVENTION I. Definitions

The abbreviations used herein have their conventional meaning within thechemical and biological arts. The chemical structures and formulae setforth herein are constructed according to the standard rules of chemicalvalency known in the chemical arts.

Where substituent groups are specified by their conventional chemicalformulae, written from left to right, they equally encompass thechemically identical substituents that would result from writing thestructure from right to left, e.g., —CH₂O— is equivalent to —OCH₂—.

As used herein, the term “attached” signifies a stable covalent bond,certain preferred points of attachment being apparent to those ofordinary skill in the art.

The terms “halogen” or “halo” include fluorine, chlorine, bromine, andiodine. Additionally, terms such as “haloalkyl” are meant to includemonohaloalkyl and polyhaloalkyl. For example, the term“halo(C₁-C₄)alkyl” includes, but is not limited to, fluoromethyl,difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl,3-bromopropyl, and the like.

The term “alkyl,” by itself or as part of another substituent, means,unless otherwise stated, a straight (i.e., unbranched) or branchedchain, or combination thereof, which can be fully saturated, mono- orpolyunsaturated and can include di- and multivalent radicals, having thenumber of carbon atoms designated (i.e., C₁-C₁₀ means one to tencarbons). Examples of saturated hydrocarbon radicals include, but arenot limited to, groups such as methyl, ethyl, n-propyl, isopropyl,n-butyl, t-butyl, isobutyl, sec-butyl, (cyclohexyl)methyl, homologs andisomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and thelike. An unsaturated alkyl group is one having one or more double bondsor triple bonds. Examples of unsaturated alkyl groups include, but arenot limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl,2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and3-propynyl, 3-butynyl, and the higher homologs and isomers. Accordingly,the term “alkyl” can refer to C₁-C₁₆ straight chain saturated, C₁-C₁₆branched saturated, C₃-C₈ cyclic saturated and C₁-C₁₆ straight chain orbranched saturated aliphatic hydrocarbon groups substituted with C₃-C₈cyclic saturated aliphatic hydrocarbon groups having the specifiednumber of carbon atoms. For example, this definition shall include butis not limited to methyl (Me), ethyl (Et), propyl (Pr), butyl (Bu),pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, isopropyl (i-Pr),isobutyl (i-Bu), tert-butyl (t-Bu), sec-butyl (s-Bu), isopentyl,neopentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cycloheptyl, cyclooctyl, cyclopropylmethyl, and the like.

The term “alkylene,” by itself or as part of another substituent, means,unless otherwise stated, a divalent radical derived from an alkyl, asexemplified, but not limited by, —CH₂CH₂CH₂CH₂—. Typically, an alkyl (oralkylene) group will have from 1 to 24 carbon atoms, with those groupshaving 10 or fewer carbon atoms being preferred in the compoundsdisclosed herein. A “lower alkyl” or “lower alkylene” is a shorter chainalkyl or alkylene group, generally having eight or fewer carbon atoms.

The term “heteroalkyl,” by itself or in combination with another term,means, unless otherwise stated, a stable straight or branched chain, orcombinations thereof, consisting of at least one carbon atom and atleast one heteroatom selected from the group consisting of O, N, P, Si,and S, and wherein the nitrogen and sulfur atoms can optionally beoxidized, and the nitrogen heteroatom can optionally be quaternized. Theheteroatom(s) O, N, P, S, and Si can be placed at any interior positionof the heteroalkyl group or at the position at which the alkyl group isattached to the remainder of the molecule. Examples include, but are notlimited to: —CH₂—CH₂—O—CH₃, —CH₂—CH₂—NH—CH₃, —CH₂—CH₂—N(CH₃)—CH₃,—CH₂—S—CH₂—CH₃, —CH₂—CH₂, —S(O)—CH₃, —CH₂—CH₂—S(O)₂—CH₃, —CH═CH—O—CH₃,—Si(CH₃)₃, —CH₂—CH═N—OCH₃, —C—H═CH—N(CH₃)—CH₃, —O—CH₃, —O—CH₂—CH₃, and—CN. Up to two heteroatoms can be consecutive, such as, for example,—CH₂—NH—OCH₃.

Similarly, the term “heteroalkylene,” by itself or as part of anothersubstituent, means, unless otherwise stated, a divalent radical derivedfrom heteroalkyl, as exemplified, but not limited by,—CH₂—CH₂—S—CH₂—CH₂— and —CH₂—S—CH₂—CH₂—NH—CH₂—. For heteroalkylenegroups, heteroatoms can also occupy either or both of the chain termini(e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, andthe like). Still further, for alkylene and heteroalkylene linkinggroups, no orientation of the linking group is implied by the directionin which the formula of the linking group is written. For example, theformula —C(O)₂R′— represents both —C(O)₂R′— and —R′C(O)₂—. As describedabove, heteroalkyl groups, as used herein, include those groups that areattached to the remainder of the molecule through a heteroatom, such as—C(O)R′, —C(O)NR′, —NR′R″, —OR′, —SR′, and/or —SO₂R′. Where“heteroalkyl” is recited, followed by recitations of specificheteroalkyl groups, such as —NR′R″ or the like, it will be understoodthat the terms heteroalkyl and —NR′R″ are not redundant or mutuallyexclusive. Rather, the specific heteroalkyl groups are recited to addclarity. Thus, the term “heteroalkyl” should not be interpreted hereinas excluding specific heteroalkyl groups, such as —NR′R″ or the like.

The terms “cycloalkyl” and “heterocycloalkyl,” by themselves or incombination with other terms, mean, unless otherwise stated, cyclicversions of “alkyl” and “heteroalkyl,” respectively. Additionally, forheterocycloalkyl, a heteroatom can occupy the position at which theheterocycle is attached to the remainder of the molecule. Examples ofcycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl,cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl,and the like. Examples of heterocycloalkyl include, but are not limitedto, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl,3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl,tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl,1-piperazinyl, 2-piperazinyl, and the like. A “cycloalkylene” and a“heterocycloalkylene,” alone or as part of another substituent, means adivalent radical derived from a cycloalkyl and heterocycloalkyl,respectively.

The term “alkenyl” includes C₂-C₁₆ straight chain unsaturated, C₂-C₁₁branched unsaturated, C₅-C₈ unsaturated cyclic, and C₂-C₁₆ straightchain or branched unsaturated aliphatic hydrocarbon groups substitutedwith C₃-C₈ cyclic saturated and unsaturated aliphatic hydrocarbon groupshaving the specified number of carbon atoms. Double bonds can occur inany stable point along the chain and the carbon-carbon double bonds canhave either the cis or trans configuration. For example, this definitionshall include but is not limited to ethenyl, propenyl, butenyl,pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl,1,5-octadienyl, 1,4,7-nonatrienyl, cyclopentenyl, cyclohexenyl,cycloheptenyl, cyclooctenyl, ethylcyclohexenyl, butenylcyclopentyl,1-pentenyl-3-cyclohexenyl, and the like. Similarly, “heteroalkenyl”refers to heteroalkyl having one or more double bonds.

The term “alkynyl” refers in the customary sense to alkyl additionallyhaving one or more triple bonds. The term “cycloalkenyl” refers tocycloalkyl additionally having one or more double bonds. The term“heterocycloalkenyl” refers to heterocycloalkyl additionally having oneor more double bonds.

The term “acyl” means, unless otherwise stated, —C(O)R where R is asubstituted or unsubstituted alkyl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted heteroalkyl, substituted orunsubstituted heterocycloalkyl, substituted or unsubstituted aryl, orsubstituted or unsubstituted heteroaryl.

Each of the above terms (e.g., “alkyl,” “heteroalkyl,” “aryl,” and“heteroaryl”) includes both substituted and unsubstituted forms of theindicated radical. Preferred substituents for each type of radical areprovided herein.

Substituents for the alkyl and heteroalkyl radicals (including thosegroups often referred to as alkylene, alkenyl, heteroalkylene,heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, andheterocycloalkenyl) can be one or more of a variety of groups selectedfrom, but not limited to, —OR′, ═O, ═NR′, ═N—OR′, —NR′R″, —SR′,-halogen, —SiR′R″R′″, —OC(O)R′, —C(O)R′, —CO₂R′, —CONR′R″, —OC(O)NR′R″,—NR″C(O)R′, —NR′—C(O)NR″R′″, —NR″C(O)₂R′, —NR—C(NR′R″)═NR′″, —S(O)R′,—S(O)₂R′, —S(O)₂NR′R″, —NRSO₂R′, —CN, and —NO₂ in a number ranging fromzero to (2m′+1), where m′ is the total number of carbon atoms in suchradical. R′, R″, and R′″ each preferably independently refer tohydrogen, substituted or unsubstituted heteroalkyl, substituted orunsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl,substituted or unsubstituted aryl (e.g., aryl substituted with 1-3halogens), substituted or unsubstituted alkyl, alkoxy, or thioalkoxygroups, or arylalkyl groups. When a compound disclosed herein includesmore than one R group, for example, each of the R groups isindependently selected as are each R′, R″, and R′″ group when more thanone of these groups is present. When R′ and R″ are attached to the samenitrogen atom, they can be combined with the nitrogen atom to form a 4-,5-, 6-, or 7-membered ring. For example, —NR′R″ includes, but is notlimited to, 1-pyrrolidinyl and 4-morpholinyl. From the above discussionof substituents, one of skill in the art will understand that the term“alkyl” is meant to include groups including carbon atoms bound togroups other than hydrogen groups, such as haloalkyl (e.g., —CF₃ and—CH₂CF₃) and acyl (e.g., —C(O)CH₃, —C(O)CF₃, —C(O)CH₂OCH₃, and thelike).

Similar to the substituents described for the alkyl radical,substituents for the aryl and heteroaryl groups are varied and areselected from, for example: —OR′, —NR′R″, —SR′, -halogen, —SiR′R″R′″,—OC(O)R′, —C(O)R′, —CO₂R′, —CONR′R″, —OC(O)NR′R″, —NR″C(O)R′,—NR′—C(O)NR″R′″, —NR″C(O)₂R′, —NR—C(NR′R″)═NR′″, —S(O)R′, —S(O)₂R′,—S(O)₂NR′R″, —NRSO₂R′, —CN, —NO₂, —R′, —N₃, —CH(Ph)₂,fluoro(C₁-C₄)alkoxy, and fluoro(C₁-C₄)alkyl, in a number ranging fromzero to the total number of open valences on the aromatic ring system;and where R′, R″, and R′″ are preferably independently selected fromhydrogen, substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted aryl, and substituted or unsubstituted heteroaryl. When acompound disclosed herein includes more than one R group, for example,each of the R groups is independently selected as are each R′, R″, andR′″ groups when more than one of these groups is present.

Two or more substituents can optionally be joined to form aryl,heteroaryl, cycloalkyl, or heterocycloalkyl groups. Such so-calledring-forming substituents are typically, though not necessarily, foundattached to a cyclic base structure. In one embodiment, the ring-formingsubstituents are attached to adjacent members of the base structure. Forexample, two ring-forming substituents attached to adjacent members of acyclic base structure create a fused ring structure. In anotherembodiment, the ring-forming substituents are attached to a singlemember of the base structure. For example, two ring-forming substituentsattached to a single member of a cyclic base structure create aspirocyclic structure. In yet another embodiment, the ring-formingsubstituents are attached to non-adjacent members of the base structure.

Two of the substituents on adjacent atoms of the aryl or heteroaryl ringcan optionally form a ring of the formula -T-C(O)—(CRR′)_(q)—U—, whereinT and U are independently —NR—, —O—, —CRR′—, or a single bond, and q isan integer of from 0 to 3. Alternatively, two of the substituents onadjacent atoms of the aryl or heteroaryl ring can optionally be replacedwith a substituent of the formula -A-(CH₂)_(r)—B—, wherein A and B areindependently —CRR′—, —O—, —NR—, —S—, —S(O)—, —S(O)₂—, —S(O)₂NR′—, or asingle bond, and r is an integer of from 1 to 4. One of the single bondsof the new ring so formed can optionally be replaced with a double bond.Alternatively, two of the substituents on adjacent atoms of the aryl orheteroaryl ring can optionally be replaced with a substituent of theformula —(CRR′)_(s)—X′— (C″R′″)_(d)—, where s and d are independentlyintegers of from 0 to 3, and X′ is —O—, —NR′—, —S—, —S(O)—, —S(O)₂—, or—S(O)₂NR′—. The substituents R, R′, R″, and R′″ are preferablyindependently selected from hydrogen, substituted or unsubstitutedalkyl, substituted or unsubstituted cycloalkyl, substituted orunsubstituted heterocycloalkyl, substituted or unsubstituted aryl, andsubstituted or unsubstituted heteroaryl.

As used herein, the terms “heteroatom” or “ring heteroatom” are meant toinclude oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), andsilicon (Si).

The term “alkyloxy” (e.g. methoxy, ethoxy, propyloxy, allyloxy,cyclohexyloxy) represents an alkyl group as defined above having theindicated number of carbon atoms attached through an oxygen bridge(—O—).

The term “alkylthio” (e.g. methylthio, ethylthio, propylthio,cyclohexylthio and the like) represents an alkyl group as defined abovehaving the indicated number of carbon atoms attached through a sulfurbridge (—S—).

The term “alkylamino” represents one or two alkyl groups as definedabove having the indicated number of carbon atoms attached through anamine bridge. The two alkyl groups can be taken together with thenitrogen to which they are attached forming a cyclic system containing 3to 8 carbon atoms with or without one C₁-C₁₆alkyl, arylC₀-C₁₆alkyl, orC₀-C₁₆alkylaryl substituent.

The term “alkylaminoalkyl” represents an alkylamino group attachedthrough an alkyl group as defined above having the indicated number ofcarbon atoms.

The term “alkyloxy(alkyl)amino” (e.g. methoxy(methyl)amine,ethoxy(propyl)amine) represents an alkyloxy group as defined aboveattached through an amino group, the amino group itself having an alkylsubstituent.

The term “alkylcarbonyl” (e.g. cyclooctylcarbonyl, pentylcarbonyl,3-hexylcarbonyl) represents an alkyl group as defined above having theindicated number of carbon atoms attached through a carbonyl group.

The term “alkylcarboxy” (e.g. heptylcarboxy, cyclopropylcarboxy,3-pentenylcarboxy) represents an alkylcarbonyl group as defined abovewherein the carbonyl is in turn attached through an oxygen.

The term “alkylcarboxyalkyl” represents an alkylcarboxy group attachedthrough an alkyl group as defined above having the indicated number ofcarbon atoms.

The term “alkylcarbonylamino” (e.g. hexylcarbonylamino,cyclopentylcarbonylaminomethyl, methylcarbonylaminophenyl) represents analkylcarbonyl group as defined above wherein the carbonyl is in turnattached through the nitrogen atom of an amino group.

The nitrogen group can itself be substituted with an alkyl or arylgroup.

The term “aryl” means, unless otherwise stated, a polyunsaturated,aromatic, hydrocarbon substituent, which can be a single ring ormultiple rings (preferably from 1 to 3 rings) that are fused together(i.e., a fused ring aryl) or linked covalently. A fused ring aryl refersto multiple rings fused together wherein at least one of the fused ringsis an aryl ring. The term “heteroaryl” refers to aryl groups (or rings)that contain from one to four heteroatoms selected from N, O, and S,wherein the nitrogen and sulfur atoms are optionally oxidized, and thenitrogen atom(s) are optionally quaternized. Thus, the term “heteroaryl”includes fused ring heteroaryl groups (i.e., multiple rings fusedtogether wherein at least one of the fused rings is a heteroaromaticring). A 5,6-fused ring heteroarylene refers to two rings fusedtogether, wherein one ring has 5 members and the other ring has 6members, and wherein at least one ring is a heteroaryl ring. Likewise, a6,6-fused ring heteroarylene refers to two rings fused together, whereinone ring has 6 members and the other ring has 6 members, and wherein atleast one ring is a heteroaryl ring. And a 6,5-fused ring heteroarylenerefers to two rings fused together, wherein one ring has 6 members andthe other ring has 5 members, and wherein at least one ring is aheteroaryl ring. A heteroaryl group can be attached to the remainder ofthe molecule through a carbon or heteroatom. Non-limiting examples ofaryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl,4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl,2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl,2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl,5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl,2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl,4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl,1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl,3-quinolyl, and 6-quinolyl. Substituents for each of the above notedaryl and heteroaryl ring systems are selected from the group ofacceptable substituents described below. An “arylene” and a“heteroarylene,” alone or as part of another substituent, mean adivalent radical derived from an aryl and heteroaryl, respectively.Accordingly, the term “aryl” can represent an unsubstituted, mono-, di-or trisubstituted monocyclic, polycyclic, biaryl and heterocyclicaromatic groups covalently attached at any ring position capable offorming a stable covalent bond, certain preferred points of attachmentbeing apparent to those skilled in the art (e.g. 3-indolyl,4-imidazolyl). The aryl substituents are independently selected from thegroup consisting of halo, nitro, cyano, trihalomethyl, C₁₋₁₆alkyl,arylC₁₋₁₆alkyl, C₀₋₁₆alkyloxyC₀₋₁₆alkyl, arylC₀₋₁₆alkyloxyC₀₋₁₆alkyl,C₀₋₁₆alkylthioC₀₋₁₆alkyl, arylC₀₋₁₆alkylthioC₀₋₁₆alkyl,C₀₋₁₆alkylaminoC₀₋₁₆alkyl, arylC₀₋₁₆alkylaminoC₀₋₁₆alkyl,di(arylC₁₋₁₆alkyl)aminoC₀₋₁₆alkyl, C₁₋₁₆alkylcarbonylC₀₋₁₆alkyl,arylC₁₋₁₆alkylcarbonylC₀₋₁₆alkyl, C₁₋₁₆alkylcarboxyC₀₋₁₆alkyl,arylC₁₋₁₆alkylcarboxyC₀₋₁₆alkyl, C₁₋₁₆alkylcarbonylaminoC₀₋₁₆alkyl,arylC₁₋₁₆alkylcarbonylaminoC₀₋₁₆alkyl, —C₀₋₁₆alkylCOOR₄,—C₀₋₁₆alkylCONR₅R₆ wherein R₄, R₅ and R₆ are independently selected fromhydrogen, C₁-C₁₁alkyl, arylC₀-C₁₁alkyl, or R₅ and R₆ are taken togetherwith the nitrogen to which they are attached forming a cyclic systemcontaining 3 to 8 carbon atoms with or without one C₁₋₁₆alkyl,arylC₀-C₁₆alkyl, or C₀-Cl₁₆alkylaryl substituent. Aryl includes but isnot limited to pyrazolyl and triazolyl.

For brevity, the term “aryl” when used in combination with other terms(e.g., aryloxy, arylthioxy, arylalkyl) includes both aryl and heteroarylrings as defined above. Thus, the terms “arylalkyl,” “aralkyl” and thelike are meant to include those radicals in which an aryl group isattached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl, andthe like) including those alkyl groups in which a carbon atom (e.g., amethylene group) has been replaced by, for example, an oxygen atom(e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naphthyloxy)propyl, andthe like), or a sulfur atom. Accordingly, the terms “arylalkyl” and thelike (e.g. (4-hydroxyphenyl)ethyl, (2-aminonaphthyl)hexyl,pyridylcyclopentyl) represents an aryl group as defined above attachedthrough an alkyl group as defined above having the indicated number ofcarbon atoms.

The term “oxo,” as used herein, means an oxygen that is double bonded toa carbon atom.

The term “alkylsulfonyl,” as used herein, means a moiety having theformula —S(O₂)—R′, where R′ is an alkyl group as defined above. R′ canhave a specified number of carbons (e.g., “C₁-C₄ alkylsulfonyl”).

The term “carbonyloxy” represents a carbonyl group attached through anoxygen bridge.

In the above definitions, the terms “alkyl” and “alkenyl” can be usedinterchangeably in so far as a stable chemical entity is formed, aswould be apparent to those skilled in the art.

The term “linker” refers to attachment groups interposed betweensubstituents, e.g., R¹, R², R³ or R⁴ described herein, e.g., Formula(Ia) and generically referred to as R^(n), and the group which issubstituted, e.g., “ring A” group of e.g., Formula (Ia). In someembodiments, the linker includes amido (—CONH—R^(n) or —NHCO—R^(n)),thioamido (—CSNH—R^(n) or —NHCS—R^(n)), carboxyl (—CO₂—R^(n) or—OCOR^(n)), carbonyl (—CO—R^(n)), urea (—NHCONH—R^(n)), thiourea(—NHCSNH—R^(n)), sulfonamido (—NHSO₂—R^(n) or —SO₂NH—R^(n)), ether(—O—R^(n)), sulfonyl (—SO₂—R^(n)), sulfoxyl (—SO—R^(n)), carbamoyl(—NHCO₂—R^(n) or —OCONH—R^(n)), or amino (—NHR″) linking moieties.

A “substituent group,” as used herein, means a group selected from thefollowing moieties:

-   -   (A) —OH, —NH₂, —SH, —CN, —CF₃, —NO₂, oxo, halogen, —COOH,        unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted        cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl,        unsubstituted heteroaryl, and    -   (B) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and        heteroaryl, substituted with at least one substituent selected        from:        -   (i) oxo, —OH, —NH₂, —SH, —CN, —CF₃, —NO₂, halogen, —COOH,            unsubstituted alkyl, unsubstituted heteroalkyl,            unsubstituted cycloalkyl, unsubstituted heterocycloalkyl,            unsubstituted aryl, unsubstituted heteroaryl, and        -   (ii) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl,            and heteroaryl, substituted with at least one substituent            selected from:            -   (a) oxo, —OH, —NH₂, —SH, —CN, —CF₃, —NO₂, halogen,                —COOH, unsubstituted alkyl, unsubstituted heteroalkyl,                unsubstituted cycloalkyl, unsubstituted                heterocycloalkyl, unsubstituted aryl, unsubstituted                heteroaryl, and            -   (b) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl,                aryl, or heteroaryl, substituted with at least one                substituent selected from:            -   oxo, —OH, —NH₂, —SH, —CN, —CF₃, —NO₂, halogen, —COOH,                unsubstituted alkyl, unsubstituted heteroalkyl,                unsubstituted cycloalkyl, unsubstituted                heterocycloalkyl, unsubstituted aryl, and unsubstituted                heteroaryl.

A “size-limited substituent” or “size-limited substituent group,” asused herein, means a group selected from all of the substituentsdescribed above for a “substituent group,” wherein each substituted orunsubstituted alkyl is a substituted or unsubstituted C₁-C₂₀ alkyl, eachsubstituted or unsubstituted heteroalkyl is a substituted orunsubstituted 2-20-membered heteroalkyl, each substituted orunsubstituted cycloalkyl is a substituted or unsubstituted C₄-C₈cycloalkyl, and each substituted or unsubstituted heterocycloalkyl is asubstituted or unsubstituted 4-8-membered heterocycloalkyl.

A “lower substituent” or “lower substituent group,” as used herein,means a group selected from all of the substituents described above fora “substituent group,” wherein each substituted or unsubstituted alkylis a substituted or unsubstituted C₁-C₈ alkyl, each substituted orunsubstituted heteroalkyl is a substituted or unsubstituted 2-8-memberedheteroalkyl, each substituted or unsubstituted cycloalkyl is asubstituted or unsubstituted C₅-C₇ cycloalkyl, and each substituted orunsubstituted heterocycloalkyl is a substituted or unsubstituted5-7-membered heterocycloalkyl.

The term “about” used in the context of a numeric value indicates arange of +/−10% of the numeric value, unless expressly indicatedotherwise.

II. Compounds

In one aspect, there is provided a compound with structure of Formula(Ia):

or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof.Ring A is substituted or unsubstituted pyrazolyl, or substituted orunsubstituted triazolyl. L¹, L² and L³ are independently absent, a bond,substituted or unsubstituted alkylene, substituted or unsubstitutedheteroalkylene, —S—, —SO—, —SO₂—, —O—, —NHSO₂—, or —NR⁷—. L⁴ is absent,a bond, substituted or unsubstituted alkylene, substituted orunsubstituted heteroalkylene, —S—, —SO—, —SO₂—, —O—, —NHSO₂—, or —NR⁷—.R¹, R², and R⁴ are independently absent, hydrogen, halogen, substitutedor unsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedcycloalkenyl, substituted or unsubstituted heterocycloalkyl, substitutedor unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl,substituted or unsubstituted heteroaryl, substituted or unsubstitutedcycloalkenyl, substituted or unsubstituted heterocycloalkenyl, orsubstituted or unsubstituted fused ring aryl. In some embodiments, R¹can be absent provided L¹ is also absent. In some embodiments, R² can beabsent provided L² is also absent. In some embodiments, R⁴ can be absentprovided L⁴ is also absent. R³ is hydrogen, halogen, substituted orunsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedcycloalkenyl, substituted or unsubstituted heterocycloalkyl, substitutedor unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl,substituted or unsubstituted fused ring aryl, or substituted orunsubstituted heteroaryl. R⁷ is hydrogen, substituted or unsubstitutedalkyl, substituted or unsubstituted heteroalkyl, substituted orunsubstituted alkylene, substituted or unsubstituted heteroalkylene,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedcycloalkenyl, substituted or unsubstituted heterocycloalkyl, substitutedor unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl,substituted or unsubstituted fused ring aryl, or substituted orunsubstituted heteroaryl.

In some embodiments, the compound is a pharmaceutically acceptable salt,ester, solvate, or prodrug of a compound of Formula (Ia). In someembodiments, the compound is not an ester, not a solvate, and not aprodrug.

In some embodiments, L⁴ and R⁴ are absent, providing a compound withstructure of Formula (Ib) following.

In some embodiments, there is provided a compound according to Formula(Ib) with structure of Formula (IIa) following.

In some embodiments, the compound has the structure of Formula (IIa),wherein L³ is a bond, and R³ is substituted or unsubstituted aryl,substituted or unsubstituted fused ring aryl, substituted orunsubstituted heterocycloalkyl, or substituted or unsubstitutedheteroaryl. In some embodiments, R³ is unsubstituted aryl, preferablyphenyl. In some embodiments, R³ is substituted aryl, preferablyhalogen-substituted phenyl. In some embodiments, R³ is substituted orunsubstituted phenyl, or substituted or unsubstituted thienyl. In someembodiments, R³ is unsubstituted thienyl. In some embodiments, R³ is achloro-substituted thienyl. In some embodiments, R³ is substituted orunsubstituted pyridyl, or substituted or unsubstituted pyridazinyl. Insome embodiments, R³ is unsubstituted pyridyl. In some embodiments, R³is unsubstituted pyridazinyl. In some embodiments, R³ is substituted orunsubstituted pyrimidinyl, or substituted or unsubstituted furyl. Insome embodiments, R³ is unsubstituted pyrimidinyl. In some embodiments,R³ is unsubstituted furyl. In some embodiments, R³ is substituted orunsubstituted morpholinyl, or substituted or unsubstituted oxanyl, orsubstituted or unsubstituted oxetanyl. In some embodiments, R³ isunsubstituted morpholinyl. In some embodiments, R³ is unsubstitutedoxanyl. In some embodiments, R³ is unsubstituted oxetanyl. In someembodiments, R³ is substituted or unsubstituted benzodioxinyl, orsubstituted or unsubstituted naphthyl. In some embodiments, R³ isunsubstituted benzodioxinyl. In some embodiments, R³ is unsubstitutednaphthyl.

In some embodiments, a compound is provided with structure of Formula(IIa), wherein L³ is a bond, substituted or unsubstituted alkylene, andR³ is substituted or unsubstituted aryl, or substituted or unsubstitutedheterocycloalkyl.

In some embodiments, the compound has the structure of Formula (IIa),wherein L³ is —C(O)O—, and R³ is substituted or unsubstituted alkyl,preferably unsubstituted alkyl, more preferably unsubstituted loweralkyl.

In some embodiments, the compound has the structure of Formula (IIa),wherein L³ is —C(O)NR⁵—, R⁵ is hydrogen or alkyl, and R³ is substitutedor unsubstituted alkyl, or substituted or unsubstituted aryl.

Further to any embodiment above wherein the compound has the structureof Formula (IIa), in some embodiments L¹ is —S—, —NR⁷—, substituted orunsubstituted alkylene, or substituted or unsubstituted heteroalkylene,where R⁷ is as described in formula Ia, and R¹ is hydrogen, substitutedor unsubstituted alkyl, substituted or unsubstituted aryl, substitutedor unsubstituted fused ring aryl, substituted or unsubstitutedheteroaryl, or substituted or unsubstituted heterocycloalkyl. In someembodiments, R¹ is substituted or unsubstituted phenyl. In someembodiments is an R¹ is unsubstituted phenyl. In some embodiments, R¹ isa substituted or unsubsituted pyridyl. In some embodiments, R¹ is asubstituted or unsubsituted pyridazinyl. In some embodiments, R¹ is asubstituted or unsubsituted pyrimidinyl. In some embodiments, R¹ is asubstituted or unsubsituted thienyl. In some embodiments, R¹ is asubstituted or unsubsituted furyl. In some embodiments, R¹ is anunsubsituted pyridyl. In some embodiments, R¹ is an unsubsitutedpyridazinyl. In some embodiments, R¹ is an unsubsituted pyrimidinyl. Insome embodiments, R¹ is an unsubsituted thienyl. In some embodiments, R¹is a chloro-substituted thienyl. In some embodiments, R¹ is anunsubsituted furyl. In some embodiments, R¹ is a substituted orunsubsituted morpholinyl. In some embodiments, R¹ is a substituted orunsubsituted oxanyl. In some embodiments, R¹ is a substituted orunsubsituted oxetanyl. In some embodiments, R¹ is an unsubsitutedmorpholinyl. In some embodiments, R¹ is an unsubsituted oxanyl. In someembodiments, R¹ is an unsubsituted oxetanyl. In some embodiments, R¹ issubstituted or unsubstituted benzodioxinyl. In some embodiments, R¹ issubstituted or unsubstituted naphthyl. In some embodiments, R¹ isunsubstituted benzodioxinyl. In some embodiments, R¹ is unsubstitutednaphthyl. In some embodiments, R³ is substituted or unsubstituted aryl.In some embodiments, R³ is unsubstituted aryl. In some embodiments, L³and R³ are absent. In some embodiments, L² and R² are absent. In someembodiments, L² is a bond. In some embodiments, L² is a bond and R² ishydrogen.

Further to any embodiment above wherein the compound has the structureof Formula (IIa), R² is hydrogen, substituted or unsubstituted alkyl,substituted or unsubstituted heteroalkyl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted cycloalkenyl, substituted orunsubstituted heterocycloalkyl, substituted or unsubstitutedheterocycloalkenyl, substituted or unsubstituted aryl, substituted orunsubstituted fused ring aryl, or substituted or unsubstitutedheteroaryl. In some embodiments, R² is substituted or unsubstitutedphenyl. In some embodiments is an R² is unsubstituted phenyl. In someembodiments, R² is a substituted or unsubsituted pyridyl. In someembodiments, R² is a substituted or unsubsituted pyridazinyl. In someembodiments, R² is a substituted or unsubsituted pyrimidinyl. In someembodiments, R² is a substituted or unsubsituted thienyl. In someembodiments, R² is a substituted or unsubsituted furyl. In someembodiments, R² is an unsubsituted pyridyl. In some embodiments, R² isan unsubsituted pyridazinyl. In some embodiments, R² is an unsubsitutedpyrimidinyl. In some embodiments, R² is an unsubsituted thienyl. In someembodiments, R² is a chloro-substituted thienyl. In some embodiments, R²is an unsubsituted furyl. In some embodiments, R² is a substituted orunsubsituted morpholinyl. In some embodiments, R² is a substituted orunsubsituted oxanyl. In some embodiments, R² is a substituted orunsubsituted oxetanyl. In some embodiments, R² is an unsubsitutedmorpholinyl. In some embodiments, R² is an unsubsituted oxanyl. In someembodiments, R² is an unsubsituted oxetanyl. In some embodiments, R² issubstituted or unsubstituted benzodioxinyl. In some embodiments, R² issubstituted or unsubstituted naphthyl. In some embodiments, R² isunsubstituted benzodioxinyl. In some embodiments, R² is unsubstitutednaphthyl.

In some embodiments, the compound of Formula (IIa) has the structure ofFormula (IIb) following, wherein L¹ is —NH—(CH₂)_(n)—, n is 0 to 6,preferably 1, and R¹ is hydrogen, substituted or unsubstituted alkyl,substituted or unsubstituted aryl, substituted or unsubstitutedheteroaryl, or substituted or unsubstituted heterocycloalkyl.

In some embodiments of the compound of Formula (IIb), L¹ is —NHCH₂— or—NH(CH₂)₂—, and R¹ is substituted or unsubstituted aryl. In someembodiments, R¹ is unsubstituted aryl. In some embodiments, R¹ is aryl,preferably phenyl, substituted with halogen, —CN or alkyloxy, preferablymethoxy. In some embodiments, R¹ is unsubstituted alkyl, preferablylower alkyl, more preferably methyl or ethyl. In some embodiments, n is0, and R¹ is hydrogen.

In some embodiments, the compound of Formula (IIa) has the structure ofFormula (IIc) following, wherein L is a bond, and R¹ is unsubstitutedalkyl, or substituted or unsubstituted aryl. In some embodiments, R¹ isunsubstituted alkyl, preferably lower alkyl. In some embodiments, R¹ issubstituted aryl, preferably halogen-substituted phenyl.

In some embodiments, there is provided a compound according to Formula(Ib) with structure of Formula (III) following.

In some embodiments, the compound has the structure of Formula (III). Insome embodiments, L³ is a bond, or substituted or unsubstitutedalkylene, and R³ is substituted or unsubstituted aryl, substituted orunsubstituted fused ring aryl, substituted or unsubstitutedheterocycloalkyl, or substituted or unsubstituted heterocycloalkyl. Insome embodiments, R³ is substituted or unsubstituted phenyl, orsubstituted or unsubstituted thienyl. In some embodiments, R³ isunsubstituted phenyl. In some embodiments, R³ is unsubstituted thienyl.In some embodiments, R³ is a chloro-substituted thienyl. In someembodiments, R³ is substituted or unsubstituted pyridyl, or substitutedor unsubstituted pyridazinyl. In some embodiments, R³ is unsubstitutedpyridyl. In some embodiments, R³ is unsubstituted pyridazinyl. In someembodiments, R³ is substituted or unsubstituted pyrimidinyl, orsubstituted or unsubstituted furyl. In some embodiments, R³ isunsubstituted pyrimidinyl. In some embodiments, R³ is unsubstitutedfuryl. In some embodiments, R³ is substituted or unsubstitutedmorpholinyl, or substituted or unsubstituted oxanyl, or substituted orunsubstituted oxetanyl. In some embodiments, R³ is unsubstitutedmorpholinyl. In some embodiments, R³ is unsubstituted oxanyl. In someembodiments, R³ is unsubstituted oxetanyl. In some embodiments, R³ issubstituted or unsubstituted benzodioxinyl, or substituted orunsubstituted naphthyl. In some embodiments, R³ is unsubstitutedbenzodioxinyl. In some embodiments, R³ is unsubstituted naphthyl.

In some embodiments, the compound has the structure of Formula (III)wherein L³ is —C(O)O—, and R³ is substituted or unsubstituted alkyl. Insome embodiments, the compound has the structure of Formula (III)wherein L³ is —C(O)NR⁷, R⁷ is hydrogen or alkyl, and R³ is substitutedor unsubstituted alkyl, or substituted or unsubstituted aryl.

Further to any embodiment above wherein the compound has the structureof Formula (III), in some embodiments, L¹ is —S—, —NR⁷—, substituted orunsubstituted alkylene, or substituted or unsubstituted heteroalkylene,where R⁷ is as described in Formula (Ia), and R¹ is hydrogen,substituted or unsubstituted alkyl, substituted or unsubstituted aryl,substituted or unsubstituted fused ring aryl, substituted orunsubstituted heteroaryl, or substituted or unsubstitutedheterocycloalkyl. In some embodiments, R¹ is substituted orunsubstituted phenyl. In some embodiments is an R¹ is unsubstitutedphenyl. In some embodiments, R¹ is a substituted or unsubsitutedpyridyl. In some embodiments, R¹ is a substituted or unsubsitutedpyridazinyl. In some embodiments, R¹ is a substituted or unsubsitutedpyrimidinyl. In some embodiments, R¹ is a substituted or unsubsitutedthienyl. In some embodiments, R¹ is a substituted or unsubsituted furyl.In some embodiments, R¹ is an unsubsituted pyridyl. In some embodiments,R¹ is an unsubsituted pyridazinyl. In some embodiments, R¹ is anunsubsituted pyrimidinyl. In some embodiments, R¹ is an unsubsitutedthienyl. In some embodiments, R¹ is a chloro-substituted thienyl. Insome embodiments, R¹ is an unsubsituted furyl. In some embodiments, R¹is a substituted or unsubsituted morpholinyl. In some embodiments, R¹ isa substituted or unsubsituted oxanyl. In some embodiments, R¹ is asubstituted or unsubsituted oxetanyl. In some embodiments, R¹ is anunsubsituted morpholinyl. In some embodiments, R¹ is an unsubsitutedoxanyl. In some embodiments, R¹ is an unsubsituted oxetanyl. In someembodiments, R¹ is substituted or unsubstituted benzodioxinyl. In someembodiments, R¹ is substituted or unsubstituted naphthyl. In someembodiments, R¹ is unsubstituted benzodioxinyl. In some embodiments, R¹is unsubstituted naphthyl.

Further to any embodiment above wherein the compound has the structureof Formula (III), in some embodiments, L² is a bond. In someembodiments, R² is hydrogen. In some embodiments, L² is substituted orunsubstituted alkylene or —C(O)—, and R² is hydrogen, substituted orunsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedcycloalkenyl, substituted or unsubstituted heterocycloalkyl, substitutedor unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl,substituted or unsubstituted fused ring aryl, or substituted orunsubstituted heteroaryl. In some embodiments, R² is substituted orunsubstituted phenyl. In some embodiments is an R² is unsubstitutedphenyl. In some embodiments, R² is a substituted or unsubsitutedpyridyl. In some embodiments, R² is a substituted or unsubsitutedpyridazinyl. In some embodiments, R² is a substituted or unsubsitutedpyrimidinyl. In some embodiments, R² is a substituted or unsubsitutedthienyl. In some embodiments, R² is a substituted or unsubsituted furyl.In some embodiments, R² is an unsubsituted pyridyl. In some embodiments,R² is an unsubsituted pyridazinyl. In some embodiments, R² is anunsubsituted pyrimidinyl. In some embodiments, R² is an unsubsitutedthienyl. In some embodiments, R² is a chloro-substituted thienyl. Insome embodiments, R² is an unsubsituted furyl. In some embodiments, R²is a substituted or unsubsituted morpholinyl. In some embodiments, R² isa substituted or unsubsituted oxanyl. In some embodiments, R² is asubstituted or unsubsituted oxetanyl. In some embodiments, R² is anunsubsituted morpholinyl. In some embodiments, R² is an unsubsitutedoxanyl. In some embodiments, R² is an unsubsituted oxetanyl. In someembodiments, R² is substituted or unsubstituted benzodioxinyl. In someembodiments, R² is substituted or unsubstituted naphthyl. In someembodiments, R² is unsubstituted benzodioxinyl. In some embodiments, R²is unsubstituted naphthyl.

In some embodiments, there is provided a compound according to Formula(Ia) with structure of Formula (IV) following.

In some embodiments, there is provided a compound according to Formula(IV) wherein L⁴ is a bond; and R⁴ is hydrogen, halogen, substituted orunsubstituted alkyl, or substituted or unsubstituted heteroalkyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl. In some embodiments, R⁴ is halogen. In some embodiments, R⁴is unsubstituted alkyl. In some embodiments, R⁴ is substituted orunsubstituted aryl or substituted or unsubstituted heteroaryl. In someembodiments, R⁴ is phenyl, naphthyl, pyridyl, pyridazinyl, pyrimidinyl,thienyl, or furyl.

In some embodiments, there is provided a compound according to Formula(III) with structure of Formula (V) following.

In some embodiments, the compound is a pharmaceutically acceptable salt,ester, solvate, or prodrug of a compound of Formula (V). In someembodiments, the compound is not an ester, not a solvate, and not aprodrug. In some embodiments, there is provided a compound according toFormula (V) wherein L¹ is a bond, substituted or unsubstituted alkylene,substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO₂—, —O—,—NHSO₂—, or —NR⁷—. R¹ is hydrogen, a halogen, substituted orunsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted aryl, substituted orunsubstituted cycloalkenyl, substituted or unsubstitutedheterocycloalkenyl, substituted or unsubstituted fused ring aryl, orsubstituted or unsubstituted heteroaryl. L² is absent, a bond,substituted or unsubstituted alkylene, substituted or unsubstitutedheteroalkylene, —S—, —SO—, —SO₂—, —O—, —NHSO₂—, or —NR⁷. L⁵ is absent, abond, substituted or unsubstituted alkylene, substituted orunsubstituted heteroalkylene, —S—, —SO—, —SO₂—, —O—, —NHSO₂—, or —NR⁷.R² is absent, hydrogen, a halogen, substituted or unsubstituted alkyl,substituted or unsubstituted heteroalkyl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted heterocycloalkyl, substitutedor unsubstituted aryl, substituted or unsubstituted cycloalkenyl,substituted or unsubstituted heterocycloalkenyl, substituted orunsubstituted fused ring aryl, or substituted or unsubstitutedheteroaryl. In some embodiments, R² is absent provided L² is alsoabsent. R⁵ is absent, hydrogen, a halogen, substituted or unsubstitutedalkyl, substituted or unsubstituted heteroalkyl, substituted orunsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl,substituted or unsubstituted aryl, substituted or unsubstitutedcycloalkenyl, substituted or unsubstituted heterocycloalkenyl,substituted or unsubstituted fused ring aryl, or substituted orunsubstituted heteroaryl. In some embodiments, R⁵ is absent provided L⁵is also absent. R⁷ is hydrogen, substituted or unsubstituted alkyl,substituted or unsubstituted heteroalkyl, substituted or unsubstitutedalkylene, substituted or unsubstituted heteroalkylene, substituted orunsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl,substituted or unsubstituted aryl, substituted or unsubstitutedcycloalkenyl, substituted or unsubstituted heterocycloalkenyl,substituted or unsubstituted fused ring aryl, or substituted orunsubstituted heteroaryl.

Further to any embodiment above wherein the compound has the structureof Formula (V), in some embodiments, L² is a bond. In some embodiments,R² is hydrogen. In some embodiments, L² is substituted or unsubstitutedalkylene or —C(O)—, and R² is hydrogen, substituted or unsubstitutedalkyl, substituted or unsubstituted heteroalkyl, substituted orunsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted heterocycloalkenyl, substituted or unsubstituted aryl,substituted or unsubstituted fused ring aryl, or substituted orunsubstituted heteroaryl. In some embodiments, R² is substituted orunsubstituted phenyl. In some embodiments is an R² is unsubstitutedphenyl. In some embodiments, R² is a substituted or unsubsitutedpyridyl. In some embodiments, R² is a substituted or unsubsitutedpyridazinyl. In some embodiments, R² is a substituted or unsubsitutedpyrimidinyl. In some embodiments, R² is a substituted or unsubsitutedthienyl. In some embodiments, R² is a substituted or unsubsituted furyl.In some embodiments, R² is an unsubsituted pyridyl. In some embodiments,R² is an unsubsituted pyridazinyl. In some embodiments, R² is anunsubsituted pyrimidinyl. In some embodiments, R² is an unsubsitutedthienyl. In some embodiments, R² is a chloro-substituted thienyl. Insome embodiments, R² is an unsubsituted furyl. In some embodiments, R²is a substituted or unsubsituted morpholinyl. In some embodiments, R² isa substituted or unsubsituted oxanyl. In some embodiments, R² is asubstituted or unsubsituted oxetanyl. In some embodiments, R² is anunsubsituted morpholinyl. In some embodiments, R² is an unsubsitutedoxanyl. In some embodiments, R² is an unsubsituted oxetanyl. In someembodiments, R² is substituted or unsubstituted benzodioxinyl. In someembodiments, R² is substituted or unsubstituted naphthyl. In someembodiments, R² is unsubstituted benzodioxinyl. In some embodiments, R²is unsubstituted naphthyl.

Further to any embodiment above wherein the compound has the structureof Formula (V), in some embodiments, L⁵ is a bond, or substituted orunsubstituted alkylene, and R⁵ is substituted or unsubstituted aryl,substituted or unsubstituted fused ring aryl, substituted orunsubstituted heterocycloalkyl, or substituted or unsubstitutedheterocycloalkyl. In some embodiments, R⁵ is substituted orunsubstituted phenyl, or substituted or unsubstituted thienyl. In someembodiments, R⁵ is unsubstituted phenyl. In some embodiments, R⁵ isunsubstituted thienyl. In some embodiments, R⁵ is a chloro-substitutedthienyl. In some embodiments, R⁵ is substituted or unsubstitutedpyridyl, or substituted or unsubstituted pyridazinyl. In someembodiments, R⁵ is unsubstituted pyridyl. In some embodiments, R⁵ isunsubstituted pyridazinyl. In some embodiments, R⁵ is substituted orunsubstituted pyrimidinyl, or substituted or unsubstituted furyl. Insome embodiments, R⁵ is unsubstituted pyrimidinyl. In some embodiments,R⁵ is unsubstituted furyl. In some embodiments, R⁵ is substituted orunsubstituted morpholinyl, or substituted or unsubstituted oxanyl, orsubstituted or unsubstituted oxetanyl. In some embodiments, R⁵ isunsubstituted morpholinyl. In some embodiments, R⁵ is unsubstitutedoxanyl. In some embodiments, R⁵ is unsubstituted oxetanyl. In someembodiments, R⁵ is substituted or unsubstituted benzodioxinyl, orsubstituted or unsubstituted naphthyl. In some embodiments, R⁵ isunsubstituted benzodioxinyl. In some embodiments, R⁵ is unsubstitutednaphthyl.

Further to any embodiment above wherein the compound has the structureof Formula (V), in some embodiments, L¹ is —S—, —NR⁷—, substituted orunsubstituted alkylene, or substituted or unsubstituted heteroalkylene,where R⁷ is as described in formula Ia, and R¹ is hydrogen, substitutedor unsubstituted alkyl, substituted or unsubstituted aryl, substitutedor unsubstituted fused ring aryl, substituted or unsubstitutedheteroaryl, or substituted or unsubstituted heterocycloalkyl. In someembodiments, R¹ is substituted or unsubstituted phenyl. In someembodiments is an R¹ is unsubstituted phenyl. In some embodiments, R¹ isa substituted or unsubsituted pyridyl. In some embodiments, R¹ is asubstituted or unsubsituted pyridazinyl. In some embodiments, R¹ is asubstituted or unsubsituted pyrimidinyl. In some embodiments, R¹ is asubstituted or unsubsituted thienyl. In some embodiments, R¹ is asubstituted or unsubsituted furyl. In some embodiments, R¹ is anunsubsituted pyridyl. In some embodiments, R¹ is an unsubsitutedpyridazinyl. In some embodiments, R¹ is an unsubsituted pyrimidinyl. Insome embodiments, R¹ is an unsubsituted thienyl. In some embodiments, R¹is a chloro-substituted thienyl. In some embodiments, R¹ is anunsubsituted furyl. In some embodiments, R¹ is a substituted orunsubsituted morpholinyl. In some embodiments, R¹ is a substituted orunsubsituted oxanyl. In some embodiments, R¹ is a substituted orunsubsituted oxetanyl. In some embodiments, R¹ is an unsubsitutedmorpholinyl. In some embodiments, R¹ is an unsubsituted oxanyl. In someembodiments, R¹ is an unsubsituted oxetanyl. In some embodiments, R¹ issubstituted or unsubstituted benzodioxinyl. In some embodiments, R¹ issubstituted or unsubstituted naphthyl. In some embodiments, R¹ isunsubstituted benzodioxinyl. In some embodiments, R¹ is unsubstitutednaphthyl.

In some embodiments, there is provided a compound according to Formula(V) and its listed embodiments, wherein L² and R² are absent, providinga compound with structure of Formula (VI) following.

In some embodiments, the compound is a pharmaceutically acceptable salt,ester, solvate, or prodrug of a compound of Formula (VI). In someembodiments, the compound is not an ester, not a solvate, and not aprodrug.

In some embodiments, there is provided a compound according to Formula(V) and its listed embodiments, wherein L⁵ and R⁵ are absent, providinga compound with structure of Formula (VII) following.

In some embodiments, the compound is a pharmaceutically acceptable salt,ester, solvate, or prodrug of a compound of Formula (VII). In someembodiments, the compound is not an ester, not a solvate, and not aprodrug.

Exemplary compounds, e.g., multisubstituted aromatic compounds, inaccordance with the present disclosure are provided herein. In Table A,B, C, and D following, compound (Cmpd) number, chemical name (i.e.,International Union of Pure and Applied Chemistry [IUPAC] name),calculated molecular weight (MW) and biological activity (i.e.,inhibition activity in thrombin, KLK1 and KLKB1 assays) are disclosed.

For Table A following, the disclosed compounds were assayed forinhibition of the protease activity of thrombin as described herein. InTable A, the level of inhibition in the thrombin assay is indicated asfollows: a IC₅₀≤0.1 μM; b: 0.1 μM<IC₅₀<1 μM; c: 1 μM<IC₅₀<10 μM; d: 10μM<IC₅₀<100 μM; e: IC₅₀≥100 μM. Accordingly, in some embodiments, thereis provided a compound as expressly set forth in Table A following.

TABLE A Cmpd Thrombin No. IUPAC name MW Activity 13-(5-amino-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 176 e 23-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol-3- 307 eyl)-1,2-dihydropyridin-2-one 33-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 391 adimethylpropanoyl)-1H-pyrazol-3-yl)-1,2-dihydropyridin-2- one 43-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 401 ayl)carbonyl]-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 53-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 497 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(thiophen-2-ylmethyl)-1,2-dihydropyridin-2-one 63-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 492 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-4-ylmethyl)-1,2-dihydropyridin-2-one 233-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 415 ayl)carbonyl]-1H-pyrazol-3-yl)-1-methyl-1,2-dihydropyridin- 2-one 253-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 492 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 263-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 481 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(furan-2-ylmethyl)-1,2-dihydropyridin-2-one 271-[(2-chlorophenyl)methyl]-3-(5-[(5-chlorothiophen-2- 516 ayl)methyl]amino-1-(2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 281-[(2-chlorophenyl)methyl]-3-(5-[(5-chlorothiophen-2- 566 ayl)methyl]amino-1-[(2-methoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 291-[(2-chlorophenyl)methyl]-3-(5-[(5-chlorothiophen-2- 525 ayl)methyl]amino-1-[(furan-3-yl)carbonyl]-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 301-[(2-chlorophenyl)methyl]-3-(5-[(5-chlorothiophen-2- 431 dyl)methyl]amino-1H-pyrazol-3-yl)-1,2-dihydropyridin-2- one 311-[(3-chlorophenyl)methyl]-3-(5-[(5-chlorothiophen-2- 516 ayl)methyl]amino-1-(2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 321-[(3-chlorophenyl)methyl]-3-(5-[(5-chlorothiophen-2- 566 ayl)methyl]amino-1-[(2-methoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 331-[(3-chlorophenyl)methyl]-3-(5-[(5-chlorothiophen-2- 525 ayl)methyl]amino-1-[(furan-3-yl)carbonyl]-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 341-[(3-chlorophenyl)methyl]-3-(5-[(5-chlorothiophen-2- 431 cyl)methyl]amino-1H-pyrazol-3-yl)-1,2-dihydropyridin-2- one 351-[(4-chlorophenyl)methyl]-3-(5-[(5-chlorothiophen-2- 516 ayl)methyl]amino-1-(2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 361-[(4-chlorophenyl)methyl]-3-(5-[(5-chlorothiophen-2- 566 ayl)methyl]amino-1-[(2-methoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 371-[(4-chlorophenyl)methyl]-3-(5-[(5-chlorothiophen-2- 525 ayl)methyl]amino-1-[(furan-3-yl)carbonyl]-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 381-[(4-chlorophenyl)methyl]-3-(5-[(5-chlorothiophen-2- 431 eyl)methyl]amino-1H-pyrazol-3-yl)-1,2-dihydropyridin-2- one 391-[(5-chlorothiophen-2-yl)methyl]-3-(5-[(5-chlorothiophen- 522 a2-yl)methyl]amino-1-(2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 401-[(5-chlorothiophen-2-yl)methyl]-3-(5-[(5-chlorothiophen- 572 a2-yl)methyl]amino-1-[(2-methoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 411-[(5-chlorothiophen-2-yl)methyl]-3-(5-[(5-chlorothiophen- 531 a2-yl)methyl]amino-1-[(furan-3-yl)carbonyl]-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 421-[(5-chlorothiophen-2-yl)methyl]-3-(5-[(5-chlorothiophen- 437 e2-yl)methyl]amino-1H-pyrazol-3-yl)-1,2-dihydropyridin-2- one 431-benzyl-3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 481 adimethylpropanoyl)-1H-pyrazol-3-yl)-1,2-dihydropyridin-2- one 441-benzyl-3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3- 511 amethoxy-2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 451-benzyl-3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 559 a[(2,3-dihydro-1,4-benzodioxin-5-yl)carbonyl]-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 461-benzyl-3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 561 a[(2,4-dimethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 471-benzyl-3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 531 amethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1,2- dihydropyridin-2-one 481-benzyl-3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(4- 523 amethyloxan-4-yl)carbonyl]-1H-pyrazol-3-yl)-1,2- dihydropyridin-2-one 491-benzyl-3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 491 a[(furan-2-yl)carbonyl]-1H-pyrazol-3-yl)-1,2-dihydropyridin- 2-one 501-benzyl-3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 491 a[(furan-3-yl)carbonyl]-1H-pyrazol-3-yl)-1,2-dihydropyridin- 2-one 511-benzyl-3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 507 a[(thiophen-2-yl)carbonyl]-1H-pyrazol-3-yl)-1,2- dihydropyridin-2-one 521-benzyl-3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 507 a[(thiophen-3-yl)carbonyl]-1H-pyrazol-3-yl)-1,2- dihydropyridin-2-one 531-benzyl-3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[4- 586 a(morpholin-4-yl)phenyl]carbonyl-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 541-benzyl-3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H- 397 cpyrazol-3-yl)-1,2-dihydropyridin-2-one 551-benzyl-3-1-[(2-chlorophenyl)carbonyl]-5-[(5- 535 achlorothiophen-2-yl)methyl]amino-1H-pyrazol-3-yl-1,2-dihydropyridin-2-one 562-[3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 430 adimethylpropanoyl)-1H-pyrazol-3-yl)-2-oxo-1,2-dihydropyridin-1-yl]acetonitrile 572-[3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 480 amethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-2-oxo-1,2-dihydropyridin-1-yl]acetonitrile 582-[3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 440 ayl)carbonyl]-1H-pyrazol-3-yl)-2-oxo-1,2-dihydropyridin-1-yl]acetonitrile 592-[3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol- 365 d3-yl)-2-oxo-1,2-dihydropyridin-1-yl]acetic acid 602-[3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol- 346 d3-yl)-2-oxo-1,2-dihydropyridin-1-yl]acetonitrile 613-(1-benzoyl-5-[(5-chlorothiophen-2-yl)methyl]amino-1H- 411 apyrazol-3-yl)-1,2-dihydropyridin-2-one 623-(1-benzoyl-5-[(5-chlorothiophen-2-yl)methyl]amino-1H- 469 apyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 633-(1-benzoyl-5-[(5-chlorothiophen-2-yl)methyl]amino-1H- 491 apyrazol-3-yl)-1-(furan-2-ylmethyl)-1,2-dihydropyridin-2- one 643-(1-benzoyl-5-[(5-chlorothiophen-2-yl)methyl]amino-1H- 491 apyrazol-3-yl)-1-(furan-3-ylmethyl)-1,2-dihydropyridin-2- one 653-(1-benzoyl-5-[(5-chlorothiophen-2-yl)methyl]amino-1H- 503 apyrazol-3-yl)-1-(pyridazin-3-ylmethyl)-1,2-dihydropyridin- 2-one 663-(1-benzoyl-5-[(5-chlorothiophen-2-yl)methyl]amino-1H- 502 apyrazol-3-yl)-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2- one 673-(1-benzoyl-5-[(5-chlorothiophen-2-yl)methyl]amino-1H- 502 apyrazol-3-yl)-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-2- one 683-(1-benzoyl-5-[(5-chlorothiophen-2-yl)methyl]amino-1H- 502 epyrazol-3-yl)-1-(pyridin-4-ylmethyl)-1,2-dihydropyridin-2- one 693-(1-benzoyl-5-[(5-chlorothiophen-2-yl)methyl]amino-1H- 503 apyrazol-3-yl)-1-(pyrimidin-2-ylmethyl)-1,2-dihydropyridin- 2-one 703-(1-benzoyl-5-[(5-chlorothiophen-2-yl)methyl]amino-1H- 507 apyrazol-3-yl)-1-(thiophen-2-ylmethyl)-1,2-dihydropyridin- 2-one 713-(1-benzoyl-5-[(5-chlorothiophen-2-yl)methyl]amino-1H- 507 apyrazol-3-yl)-1-(thiophen-3-ylmethyl)-1,2-dihydropyridin- 2-one 723-(1-benzoyl-5-[(5-chlorothiophen-2-yl)methyl]amino-1H- 501 apyrazol-3-yl)-1-benzyl-1,2-dihydropyridin-2-one 733-(1-benzoyl-5-[(5-chlorothiophen-2-yl)methyl]amino-1H- 425 apyrazol-3-yl)-1-methyl-1,2-dihydropyridin-2-one 743-(5-[(4-fluorophenyl)methyl]amino-1-[(furan-2- 470 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 753-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 449 adimethylpropanoyl)-1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 763-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 495 adimethylpropanoyl)-1H-pyrazol-3-yl)-1-(2-phenylethyl)-1,2-dihydropyridin-2-one 773-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 471 adimethylpropanoyl)-1H-pyrazol-3-yl)-1-(furan-2-ylmethyl)-1,2-dihydropyridin-2-one 783-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 471 adimethylpropanoyl)-1H-pyrazol-3-yl)-1-(furan-3-ylmethyl)-1,2-dihydropyridin-2-one 793-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 531 adimethylpropanoyl)-1H-pyrazol-3-yl)-1-(naphthalen-1-ylmethyl)-1,2-dihydropyridin-2-one 803-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 531 adimethylpropanoyl)-1H-pyrazol-3-yl)-1-(naphthalen-2-ylmethyl)-1,2-dihydropyridin-2-one 813-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 483 adimethylpropanoyl)-1H-pyrazol-3-yl)-1-(pyridazin-3-ylmethyl)-1,2-dihydropyridin-2-one 823-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 482 adimethylpropanoyl)-1H-pyrazol-3-yl)-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 833-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 482 adimethylpropanoyl)-1H-pyrazol-3-yl)-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-2-one 843-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 482 adimethylpropanoyl)-1H-pyrazol-3-yl)-1-(pyridin-4-ylmethyl)-1,2-dihydropyridin-2-one 853-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 483 adimethylpropanoyl)-1H-pyrazol-3-yl)-1-(pyrimidin-2-ylmethyl)-1,2-dihydropyridin-2-one 863-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 487 adimethylpropanoyl)-1H-pyrazol-3-yl)-1-(thiophen-2-ylmethyl)-1,2-dihydropyridin-2-one 873-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 487 adimethylpropanoyl)-1H-pyrazol-3-yl)-1-(thiophen-3-ylmethyl)-1,2-dihydropyridin-2-one 883-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 518 adimethylpropanoyl)-1H-pyrazol-3-yl)-1-[2-(morpholin-4-yl)-2-oxoethyl]-1,2-dihydropyridin-2-one 893-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 504 adimethylpropanoyl)-1H-pyrazol-3-yl)-1-[2-(morpholin-4-yl)ethyl]-1,2-dihydropyridin-2-one 903-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 405 adimethylpropanoyl)-1H-pyrazol-3-yl)-1-methyl-1,2- dihydropyridin-2-one91 3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3-hydroxy- 407 a2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1,2- dihydropyridin-2-one 923-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3-hydroxy- 465 a2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 933-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3-hydroxy- 487 a2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(furan-2-ylmethyl)-1,2-dihydropyridin-2-one 943-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3-hydroxy- 498 a2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-2-one 953-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3-hydroxy- 503 a2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(thiophen-2-ylmethyl)-1,2-dihydropyridin-2-one 963-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3-methoxy- 421 a2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1,2- dihydropyridin-2-one 973-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3-methoxy- 479 a2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 983-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3-methoxy- 501 a2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(furan-2-ylmethyl)-1,2-dihydropyridin-2-one 993-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3-methoxy- 501 a2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(furan-3-ylmethyl)-1,2-dihydropyridin-2-one 1003-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3-methoxy- 513 a2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(pyridazin-3-ylmethyl)-1,2-dihydropyridin-2-one 1013-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3-methoxy- 512 a2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 1023-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3-methoxy- 512 a2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-2-one 1033-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3-methoxy- 512 a2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(pyridin-4-ylmethyl)-1,2-dihydropyridin-2-one 1043-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3-methoxy- 513 a2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(pyrimidin-2-ylmethyl)-1,2-dihydropyridin-2-one 1053-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3-methoxy- 517 a2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(thiophen-2-ylmethyl)-1,2-dihydropyridin-2-one 1063-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3-methoxy- 517 a2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(thiophen-3-ylmethyl)-1,2-dihydropyridin-2-one 1073-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3-methoxy- 534 a2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-[2-(morpholin-4-yl)ethyl]-1,2-dihydropyridin-2-one 1083-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,3-dihydro- 469 a1,4-benzodioxin-5-yl)carbonyl]-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 1093-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,3-dihydro- 527 a1,4-benzodioxin-5-yl)carbonyl]-1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 1103-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,3-dihydro- 549 a1,4-benzodioxin-5-yl)carbonyl]-1H-pyrazol-3-yl)-1-(furan-2-ylmethyl)-1,2-dihydropyridin-2-one 1113-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,3-dihydro- 549 a1,4-benzodioxin-5-yl)carbonyl]-1H-pyrazol-3-yl)-1-(furan-3-ylmethyl)-1,2-dihydropyridin-2-one 1123-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,3-dihydro- 561 a1,4-benzodioxin-5-yl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridazin-3-ylmethyl)-1,2-dihydropyridin-2-one 1133-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,3-dihydro- 560 a1,4-benzodioxin-5-yl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 1143-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,3-dihydro- 560 a1,4-benzodioxin-5-yl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-2-one 1153-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,3-dihydro- 560 a1,4-benzodioxin-5-yl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-4-ylmethyl)-1,2-dihydropyridin-2-one 1163-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,3-dihydro- 561 a1,4-benzodioxin-5-yl)carbonyl]-1H-pyrazol-3-yl)-1-(pyrimidin-2-ylmethyl)-1,2-dihydropyridin-2-one 1173-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,3-dihydro- 565 a1,4-benzodioxin-5-yl)carbonyl]-1H-pyrazol-3-yl)-1-(thiophen-2-ylmethyl)-1,2-dihydropyridin-2-one 1183-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,3-dihydro- 565 a1,4-benzodioxin-5-yl)carbonyl]-1H-pyrazol-3-yl)-1-(thiophen-3-ylmethyl)-1,2-dihydropyridin-2-one 1193-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,3-dihydro- 582 a1,4-benzodioxin-5-yl)carbonyl]-1H-pyrazol-3-yl)-1-[2-(morpholin-4-yl)ethyl]-1,2-dihydropyridin-2-one 1203-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,3-dihydro- 483 a1,4-benzodioxin-5-yl)carbonyl]-1H-pyrazol-3-yl)-1-methyl-1,2-dihydropyridin-2-one 1213-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,4- 471 adimethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1,2- dihydropyridin-2-one 1223-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,4- 529 adimethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 1233-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,4- 551 adimethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(furan-3-ylmethyl)-1,2-dihydropyridin-2-one 1243-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,4- 563 adimethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridazin-3-ylmethyl)-1,2-dihydropyridin-2-one 1253-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,4- 562 adimethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 1263-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,4- 562 adimethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-2-one 1273-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,4- 562 adimethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-4-ylmethyl)-1,2-dihydropyridin-2-one 1283-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,4- 563 edimethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(pyrimidin-2-ylmethyl)-1,2-dihydropyridin-2-one 1293-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,4- 567 adimethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(thiophen-2-ylmethyl)-1,2-dihydropyridin-2-one 1303-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,4- 567 adimethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(thiophen-3-ylmethyl)-1,2-dihydropyridin-2-one 1313-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,4- 584 adimethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-[2-(morpholin-4-yl)ethyl]-1,2-dihydropyridin-2-one 1323-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 441 amethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1,2- dihydropyridin-2-one 1333-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 499 amethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 1343-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 545 amethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(2-phenylethyl)-1,2-dihydropyridin-2-one 1353-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 521 amethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(furan-2-ylmethyl)-1,2-dihydropyridin-2-one 1363-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 521 amethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(furan-3-ylmethyl)-1,2-dihydropyridin-2-one 1373-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 581 amethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(naphthalen-2-ylmethyl)-1,2-dihydropyridin-2-one 1383-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 533 amethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridazin-3-ylmethyl)-1,2-dihydropyridin-2-one 1393-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 532 amethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 1403-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 532 amethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-2-one 1413-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 532 amethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-4-ylmethyl)-1,2-dihydropyridin-2-one 1423-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 533 amethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(pyrimidin-2-ylmethyl)-1,2-dihydropyridin-2-one 1433-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 537 amethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(thiophen-2-ylmethyl)-1,2-dihydropyridin-2-one 1443-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 537 amethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(thiophen-3-ylmethyl)-1,2-dihydropyridin-2-one 1453-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 568 amethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-[2-(morpholin-4-yl)-2-oxoethyl]-1,2-dihydropyridin-2-one 1463-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 554 amethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-[2-(morpholin-4-yl)ethyl]-1,2-dihydropyridin-2-one 1473-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 455 amethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-methyl-1,2-dihydropyridin-2-one 1483-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(3- 419 bmethyloxetan-3-yl)carbonyl]-1H-pyrazol-3-yl)-1-methyl-1,2-dihydropyridin-2-one 1493-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(4- 491 emethyloxan-4-yl)carbonyl]-1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 1503-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(4- 513 amethyloxan-4-yl)carbonyl]-1H-pyrazol-3-yl)-1-(furan-2-ylmethyl)-1,2-dihydropyridin-2-one 1513-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(4- 513 amethyloxan-4-yl)carbonyl]-1H-pyrazol-3-yl)-1-(furan-3-ylmethyl)-1,2-dihydropyridin-2-one 1523-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(4- 525 amethyloxan-4-yl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridazin-3-ylmethyl)-1,2-dihydropyridin-2-one 1533-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(4- 524 amethyloxan-4-yl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 1543-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(4- 524 amethyloxan-4-yl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-2-one 1553-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(4- 524 amethyloxan-4-yl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-4-ylmethyl)-1,2-dihydropyridin-2-one 1563-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(4- 525 amethyloxan-4-yl)carbonyl]-1H-pyrazol-3-yl)-1-(pyrimidin-2-ylmethyl)-1,2-dihydropyridin-2-one 1573-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(4- 529 amethyloxan-4-yl)carbonyl]-1H-pyrazol-3-yl)-1-(thiophen-2-ylmethyl)-1,2-dihydropyridin-2-one 1583-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(4- 529 amethyloxan-4-yl)carbonyl]-1H-pyrazol-3-yl)-1-(thiophen-3-ylmethyl)-1,2-dihydropyridin-2-one 1593-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(4- 546 emethyloxan-4-yl)carbonyl]-1H-pyrazol-3-yl)-1-[2-(morpholin-4-yl)ethyl]-1,2-dihydropyridin-2-one 1603-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-2- 459 eyl)carbonyl]-1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 1613-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-2- 481 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(furan-2-ylmethyl)-1,2-dihydropyridin-2-one 1623-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-2- 481 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(furan-3-ylmethyl)-1,2-dihydropyridin-2-one 1633-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-2- 493 eyl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridazin-3-ylmethyl)-1,2-dihydropyridin-2-one 1643-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-2- 492 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 1653-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-2- 492 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-2-one 1663-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-2- 492 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-4-ylmethyl)-1,2-dihydropyridin-2-one 1673-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-2- 493 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(pyrimidin-2-ylmethyl)-1,2-dihydropyridin-2-one 1683-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-2- 497 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(thiophen-2-ylmethyl)-1,2-dihydropyridin-2-one 1693-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-2- 497 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(thiophen-3-ylmethyl)-1,2-dihydropyridin-2-one 1703-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-2- 514 eyl)carbonyl]-1H-pyrazol-3-yl)-1-[2-(morpholin-4-yl)ethyl]-1,2-dihydropyridin-2-one 1713-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 459 eyl)carbonyl]-1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 1723-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 505 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(2-phenylethyl)-1,2-dihydropyridin-2-one 1733-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 481 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(furan-3-ylmethyl)-1,2-dihydropyridin-2-one 1743-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 541 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(naphthalen-1-ylmethyl)-1,2-dihydropyridin-2-one 1753-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 541 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(naphthalen-2-ylmethyl)-1,2-dihydropyridin-2-one 1763-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 493 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridazin-3-ylmethyl)-1,2-dihydropyridin-2-one 1773-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 492 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-2-one 1783-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 493 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(pyrimidin-2-ylmethyl)-1,2-dihydropyridin-2-one 1793-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 497 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(thiophen-3-ylmethyl)-1,2-dihydropyridin-2-one 1803-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 528 ayl)carbonyl]-1H-pyrazol-3-yl)-1-[2-(morpholin-4-yl)-2-oxoethyl]-1,2-dihydropyridin-2-one 1813-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 514 ayl)carbonyl]-1H-pyrazol-3-yl)-1-[2-(morpholin-4-yl)ethyl]-1,2-dihydropyridin-2-one 1823-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-2- 475 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 1833-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-2- 497 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(furan-2-ylmethyl)-1,2-dihydropyridin-2-one 1843-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-2- 497 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(furan-3-ylmethyl)-1,2-dihydropyridin-2-one 1853-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-2- 509 eyl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridazin-3-ylmethyl)-1,2-dihydropyridin-2-one 1863-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-2- 508 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 1873-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-2- 508 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-2-one 1883-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-2- 508 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-4-ylmethyl)-1,2-dihydropyridin-2-one 1893-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-2- 509 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(pyrimidin-2-ylmethyl)-1,2-dihydropyridin-2-one 1903-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-2- 513 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(thiophen-2-ylmethyl)-1,2-dihydropyridin-2-one 1913-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-2- 513 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(thiophen-3-ylmethyl)-1,2-dihydropyridin-2-one 1923-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-2- 530 eyl)carbonyl]-1H-pyrazol-3-yl)-1-[2-(morpholin-4-yl)ethyl]-1,2-dihydropyridin-2-one 1933-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-3- 417 ayl)carbonyl]-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 1943-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-3- 475 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 1953-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-3- 497 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(furan-2-ylmethyl)-1,2-dihydropyridin-2-one 1963-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-3- 497 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(furan-3-ylmethyl)-1,2-dihydropyridin-2-one 1973-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-3- 509 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridazin-3-ylmethyl)-1,2-dihydropyridin-2-one 1983-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-3- 508 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 1993-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-3- 508 eyl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-2-one 2003-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-3- 508 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-4-ylmethyl)-1,2-dihydropyridin-2-one 2013-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-3- 509 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(pyrimidin-2-ylmethyl)-1,2-dihydropyridin-2-one 2023-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-3- 513 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(thiophen-2-ylmethyl)-1,2-dihydropyridin-2-one 2033-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-3- 513 ayl)carbonyl]-1H-pyrazol-3-yl)-1-(thiophen-3-ylmethyl)-1,2-dihydropyridin-2-one 2043-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(thiophen-3- 530 ayl)carbonyl]-1H-pyrazol-3-yl)-1-[2-(morpholin-4-yl)ethyl]-1,2-dihydropyridin-2-one 2053-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[2- 496 c(morpholin-4-yl)phenyl]carbonyl-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 2063-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[4-(2- 485 amethoxyethoxy)phenyl]carbonyl-1H-pyrazol-3-yl)-1,2- dihydropyridin-2-one207 3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[4- 496 a(morpholin-4-yl)phenyl]carbonyl-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 208 3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[4-554 a (morpholin-4-yl)phenyl]carbonyl-1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 2093-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[4- 576 a(morpholin-4-yl)phenyl]carbonyl-1H-pyrazol-3-yl)-1-(furan-2-ylmethyl)-1,2-dihydropyridin-2-one 2103-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[4- 576 a(morpholin-4-yl)phenyl]carbonyl-1H-pyrazol-3-yl)-1-(furan-3-ylmethyl)-1,2-dihydropyridin-2-one 2113-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[4- 588 a(morpholin-4-yl)phenyl]carbonyl-1H-pyrazol-3-yl)-1-(pyridazin-3-ylmethyl)-1,2-dihydropyridin-2-one 2123-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[4- 587 a(morpholin-4-yl)phenyl]carbonyl-1H-pyrazol-3-yl)-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 2133-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[4- 587 a(morpholin-4-yl)phenyl]carbonyl-1H-pyrazol-3-yl)-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-2-one 2143-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[4- 587 a(morpholin-4-yl)phenyl]carbonyl-1H-pyrazol-3-yl)-1-(pyridin-4-ylmethyl)-1,2-dihydropyridin-2-one 2153-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[4- 588 a(morpholin-4-yl)phenyl]carbonyl-1H-pyrazol-3-yl)-1-(pyrimidin-2-ylmethyl)-1,2-dihydropyridin-2-one 2163-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[4- 592 a(morpholin-4-yl)phenyl]carbonyl-1H-pyrazol-3-yl)-1-(thiophen-2-ylmethyl)-1,2-dihydropyridin-2-one 2173-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[4- 592 a(morpholin-4-yl)phenyl]carbonyl-1H-pyrazol-3-yl)-1-(thiophen-3-ylmethyl)-1,2-dihydropyridin-2-one 2183-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[4- 609 a(morpholin-4-yl)phenyl]carbonyl-1H-pyrazol-3-yl)-1-[2-(morpholin-4-yl)ethyl]-1,2-dihydropyridin-2-one 2193-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol-3- 389 dyl)-1-(1H-1,2,3,4-tetrazol-5-ylmethyl)-1,2-dihydropyridin- 2-one 2203-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol-3- 365 dyl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 2213-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol-3- 411 dyl)-1-(2-phenylethyl)-1,2-dihydropyridin-2-one 2223-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol-3- 387 eyl)-1-(furan-2-ylmethyl)-1,2-dihydropyridin-2-one 2233-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol-3- 387 cyl)-1-(furan-3-ylmethyl)-1,2-dihydropyridin-2-one 2243-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol-3- 447 eyl)-1-(naphthalen-1-ylmethyl)-1,2-dihydropyridin-2-one 2253-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol-3- 447 eyl)-1-(naphthalen-2-ylmethyl)-1,2-dihydropyridin-2-one 2263-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol-3- 399 dyl)-1-(pyridazin-3-ylmethyl)-1,2-dihydropyridin-2-one 2273-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol-3- 398 cyl)-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 2283-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol-3- 398 cyl)-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-2-one 2293-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol-3- 398 cyl)-1-(pyridin-4-ylmethyl)-1,2-dihydropyridin-2-one 2303-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol-3- 399 eyl)-1-(pyrimidin-2-ylmethyl)-1,2-dihydropyridin-2-one 2313-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol-3- 403 cyl)-1-(thiophen-2-ylmethyl)-1,2-dihydropyridin-2-one 2323-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol-3- 403 cyl)-1-(thiophen-3-ylmethyl)-1,2-dihydropyridin-2-one 2333-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol-3- 434 cyl)-1-[2-(morpholin-4-yl)-2-oxoethyl]-1,2-dihydropyridin-2- one 2343-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol-3- 420 dyl)-1-[2-(morpholin-4-yl)ethyl]-1,2-dihydropyridin-2-one 2353-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol-3- 412 dyl)-1-[2-(pyridin-2-yl)ethyl]-1,2-dihydropyridin-2-one 2363-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol-3- 321 dyl)-1-methyl-1,2-dihydropyridin-2-one 2373-[5-(benzylamino)-1-[(furan-2-yl)carbonyl]-1H-pyrazol-3- 360 byl]-1,2-dihydropyridin-2-one 2383-[5-(benzylamino)-1-[(furan-2-yl)carbonyl]-1H-pyrazol-3- 452 ayl]-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 2393-[5-(dimethylamino)-1-[(furan-2-yl)carbonyl]-1H-pyrazol- 298 e3-yl]-1,2-dihydropyridin-2-one 2403-[5-(dimethylamino)-1-[(furan-2-yl)carbonyl]-1H-pyrazol- 389 e3-yl]-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 2413-1-[(2-aminophenyl)carbonyl]-5-[(5-chlorothiophen-2- 426 ayl)methyl]amino-1H-pyrazol-3-yl-1,2-dihydropyridin-2-one 2423-1-[(2-chlorophenyl)carbonyl]-5-[(5-chlorothiophen-2- 503 ayl)methyl]amino-1H-pyrazol-3-yl-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 2433-1-[(2-chlorophenyl)carbonyl]-5-[(5-chlorothiophen-2- 525 ayl)methyl]amino-1H-pyrazol-3-yl-1-(furan-2-ylmethyl)-1,2-dihydropyridin-2-one 2443-1-[(2-chlorophenyl)carbonyl]-5-[(5-chlorothiophen-2- 525 ayl)methyl]amino-1H-pyrazol-3-yl-1-(furan-3-ylmethyl)-1,2-dihydropyridin-2-one 2453-1-[(2-chlorophenyl)carbonyl]-5-[(5-chlorothiophen-2- 537 ayl)methyl]amino-1H-pyrazol-3-yl-1-(pyridazin-3-ylmethyl)-1,2-dihydropyridin-2-one 2463-1-[(2-chlorophenyl)carbonyl]-5-[(5-chlorothiophen-2- 536 ayl)methyl]amino-1H-pyrazol-3-yl-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 2473-1-[(2-chlorophenyl)carbonyl]-5-[(5-chlorothiophen-2- 536 ayl)methyl]amino-1H-pyrazol-3-yl-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-2-one 2483-1-[(2-chlorophenyl)carbonyl]-5-[(5-chlorothiophen-2- 536 ayl)methyl]amino-1H-pyrazol-3-yl-1-(pyridin-4-ylmethyl)-1,2-dihydropyridin-2-one 2493-1-[(2-chlorophenyl)carbonyl]-5-[(5-chlorothiophen-2- 537 ayl)methyl]amino-1H-pyrazol-3-yl-1-(pyrimidin-2-ylmethyl)-1,2-dihydropyridin-2-one 2503-1-[(2-chlorophenyl)carbonyl]-5-[(5-chlorothiophen-2- 542 ayl)methyl]amino-1H-pyrazol-3-yl-1-(thiophen-2-ylmethyl)-1,2-dihydropyridin-2-one 2513-1-[(2-chlorophenyl)carbonyl]-5-[(5-chlorothiophen-2- 542 ayl)methyl]amino-1H-pyrazol-3-yl-1-(thiophen-3-ylmethyl)-1,2-dihydropyridin-2-one 2523-1-[(2-chlorophenyl)carbonyl]-5-[(5-chlorothiophen-2- 558 ayl)methyl]amino-1H-pyrazol-3-yl-1-[2-(morpholin-4-yl)ethyl]-1,2-dihydropyridin-2-one 2533-1-[(4-tert-butylphenyl)carbonyl]-5-[(5-chlorothiophen-2- 467 ayl)methyl]amino-1H-pyrazol-3-yl-1,2-dihydropyridin-2-one 2543-1-[(4-tert-butylphenyl)carbonyl]-5-[(5-chlorothiophen-2- 481 ayl)methyl]amino-1H-pyrazol-3-yl-1-methyl-1,2- dihydropyridin-2-one 2553-5-amino-1-[(furan-2-yl)carbonyl]-1H-pyrazol-3-yl-1,2- 270 cdihydropyridin-2-one 2563-5-amino-1-[(furan-2-yl)carbonyl]-1H-pyrazol-3-yl-1- 361 c(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 257 ethyl2-[3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 477 adimethylpropanoyl)-1H-pyrazol-3-yl)-2-oxo-1,2-dihydropyridin-1-yl]acetate 258 ethyl2-[3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 527 amethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-2-oxo-1,2-dihydropyridin-1-yl]acetate 259 ethyl2-[3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 487 a[(furan-3-yl)carbonyl]-1H-pyrazol-3-yl)-2-oxo-1,2-dihydropyridin-1-yl]acetate 260 ethyl2-[3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H- 393 dpyrazol-3-yl)-2-oxo-1,2-dihydropyridin-1-yl]acetate 261 tert-butyl2-[3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 505 a(2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-2-oxo-1,2-dihydropyridin-1-yl]acetate 262 tert-butyl2-[3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 555 a[(2-methoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-2-oxo-1,2-dihydropyridin-1-yl]acetate 263 tert-butyl2-[3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 515 a[(furan-3-yl)carbonyl]-1H-pyrazol-3-yl)-2-oxo-1,2-dihydropyridin-1-yl]acetate 264 tert-butyl2-[3-(5-[(5-chlorothiophen-2-yl)methyl]amino- 421 e1H-pyrazol-3-yl)-2-oxo-1,2-dihydropyridin-1-yl]acetate 2651-[(5-[(5-chlorothiophen-2-yl)methyl]amino-3-(1-methyl-2- 517 aoxo-1,2-dihydropyridin-3-yl)-1H-pyrazol-1- yl)carbonyl]cyclopropylmethyl1- (hydroxymethyl)cyclopropane-1-carboxylate

For Table B following, the disclosed compounds were assayed forinhibition of the protease activity of KLK1 and KLKB1 as describedherein. In Table B, C, and D, the level of inhibition in the KLK1 andKLKB1 assays are indicated as follows: a: IC₅₀<0.1 μM; b: 0.1 μM<IC₅₀<1μM; c: 1 μM<IC₅₀<10 μM; d: 10 μM<IC₅₀<100 μM; e: IC₅₀≥100 μM.Accordingly, in some embodiments, there is provided a compound asexpressly set forth in Table B following.

TABLE B Cmpd KLK1 KLKB1 No. IUPAC name MW Activity Activity 43-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 401 d cyl)carbonyl]-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 53-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 497 cyl)carbonyl]-1H-pyrazol-3-yl)-1-(thiophen-2-ylmethyl)-1,2-dihydropyridin-2-one 191-(5-[(4-fluorophenyl)methyl]amino-3-phenyl-1H- 351 epyrazol-1-yl)-2,2-dimethylpropan-1-one 201-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-2-yl)- 352 e1H-pyrazol-1-yl)-2,2-dimethylpropan-1-one 21 ethyl3-[(4-fluorophenyl)methyl]amino-1-(pyridin-2-yl)- 340 e1H-pyrazole-4-carboxylate 233-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 415 d cyl)carbonyl]-1H-pyrazol-3-yl)-1-methyl-1,2- dihydropyridin-2-one 241-(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3- 399 b(piperidin-4-yl)-1H-pyrazol-1-yl)-2,2-dimethylpropan- 1-one 253-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 492 d byl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 263-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 481 d cyl)carbonyl]-1H-pyrazol-3-yl)-1-(furan-2-ylmethyl)-1,2-dihydropyridin-2-one 461-benzyl-3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 561 d[(2,4-dimethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 481-benzyl-3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 523 e[(4-methyloxan-4-yl)carbonyl]-1H-pyrazol-3-yl)-1,2- dihydropyridin-2-one49 1-benzyl-3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 491 b[(furan-2-yl)carbonyl]-1H-pyrazol-3-yl)-1,2- dihydropyridin-2-one 501-benzyl-3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 491 d[(furan-3-yl)carbonyl]-1H-pyrazol-3-yl)-1,2- dihydropyridin-2-one 511-benzyl-3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 507 e[(thiophen-2-yl)carbonyl]-1H-pyrazol-3-yl)-1,2- dihydropyridin-2-one 521-benzyl-3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 507 b[(thiophen-3-yl)carbonyl]-1H-pyrazol-3-yl)-1,2- dihydropyridin-2-one 531-benzyl-3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 586 e[4-(morpholin-4-yl)phenyl]carbonyl-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one 592-[3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H- 365 e cpyrazol-3-yl)-2-oxo-1,2-dihydropyridin-1-yl]acetic acid 623-(1-benzoyl-5-[(5-chlorothiophen-2-yl)methyl]amino- 469 c1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2- dihydropyridin-2-one 733-(1-benzoyl-5-[(5-chlorothiophen-2-yl)methyl]amino- 425 e1H-pyrazol-3-yl)-1-methyl-1,2-dihydropyridin-2-one 773-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 471 edimethylpropanoyl)-1H-pyrazol-3-yl)-1-(furan-2-ylmethyl)-1,2-dihydropyridin-2-one 813-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(2,2- 483 e cdimethylpropanoyl)-1H-pyrazol-3-yl)-1-(pyridazin-3-ylmethyl)-1,2-dihydropyridin-2-one 923-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3- 465 dhydroxy-2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 933-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3- 487 dhydroxy-2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(furan-2-ylmethyl)-1,2-dihydropyridin-2-one 943-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3- 498 chydroxy-2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-2-one 973-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3- 479 dmethoxy-2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 983-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3- 501 emethoxy-2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(furan-2-ylmethyl)-1,2-dihydropyridin-2-one 1003-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3- 513 cmethoxy-2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(pyridazin-3-ylmethyl)-1,2-dihydropyridin-2-one 1013-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3- 512 dmethoxy-2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 1023-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3- 512 dmethoxy-2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-2-one 1033-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3- 512 dmethoxy-2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(pyridin-4-ylmethyl)-1,2-dihydropyridin-2-one 1043-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3- 513 cmethoxy-2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(pyrimidin-2-ylmethyl)-1,2-dihydropyridin-2-one 1053-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3- 517 emethoxy-2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(thiophen-2-ylmethyl)-1,2-dihydropyridin-2-one 1063-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-(3- 517 emethoxy-2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)-1-(thiophen-3-ylmethyl)-1,2-dihydropyridin-2-one 1093-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,3- 527 cdihydro-1,4-benzodioxin-5-yl)carbonyl]-1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 1133-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,3- 560 d bdihydro-1,4-benzodioxin-5-yl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 1163-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,3- 561 cdihydro-1,4-benzodioxin-5-yl)carbonyl]-1H-pyrazol-3-yl)-1-(pyrimidin-2-ylmethyl)-1,2-dihydropyridin-2-one 1173-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,3- 565 edihydro-1,4-benzodioxin-5-yl)carbonyl]-1H-pyrazol-3-yl)-1-(thiophen-2-ylmethyl)-1,2-dihydropyridin-2-one 1223-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,4- 529 cdimethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 1233-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,4- 551 ddimethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(furan-3-ylmethyl)-1,2-dihydropyridin-2-one 1253-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,4- 562 cdimethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 1263-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,4- 562 e cdimethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-2-one 1313-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,4- 584 bdimethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-[2-(morpholin-4-yl)ethyl]-1,2-dihydropyridin-2-one 1323-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 441 e cmethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1,2- dihydropyridin-2-one 1383-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 533 e bmethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridazin-3-ylmethyl)-1,2-dihydropyridin-2-one 1403-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 532 bmethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-2-one 1453-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 568 e cmethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)-1-[2-(morpholin-4-yl)-2-oxoethyl]-1,2-dihydropyridin-2-one 1493-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(4- 491 e cmethyloxan-4-yl)carbonyl]-1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 1573-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(4- 529 emethyloxan-4-yl)carbonyl]-1H-pyrazol-3-yl)-1-(thiophen-2-ylmethyl)-1,2-dihydropyridin-2-one 1603-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-2- 459 byl)carbonyl]-1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 1793-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(furan-3- 497 dyl)carbonyl]-1H-pyrazol-3-yl)-1-(thiophen-3-ylmethyl)-1,2-dihydropyridin-2-one 1823-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 475 c[(thiophen-2-yl)carbonyl]-1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 1843-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 497 d[(thiophen-2-yl)carbonyl]-1H-pyrazol-3-yl)-1-(furan-3-ylmethyl)-1,2-dihydropyridin-2-one 1943-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 475 b[(thiophen-3-yl)carbonyl]-1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 1963-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 497 b[(thiophen-3-yl)carbonyl]-1H-pyrazol-3-yl)-1-(furan-3-ylmethyl)-1,2-dihydropyridin-2-one 1983-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 508 b[(thiophen-3-yl)carbonyl]-1H-pyrazol-3-yl)-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 2013-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 509 b[(thiophen-3-yl)carbonyl]-1H-pyrazol-3-yl)-1-(pyrimidin-2-ylmethyl)-1,2-dihydropyridin-2-one 2033-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 513 b[(thiophen-3-yl)carbonyl]-1H-pyrazol-3-yl)-1-(thiophen-3-ylmethyl)-1,2-dihydropyridin-2-one 2083-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[4- 554 c(morpholin-4-yl)phenyl]carbonyl-1H-pyrazol-3-yl)-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 2103-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[4- 576 d(morpholin-4-yl)phenyl]carbonyl-1H-pyrazol-3-yl)-1-(furan-3-ylmethyl)-1,2-dihydropyridin-2-one 2133-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[4- 587 e b(morpholin-4-yl)phenyl]carbonyl-1H-pyrazol-3-yl)-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-2-one 2143-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[4- 587 b(morpholin-4-yl)phenyl]carbonyl-1H-pyrazol-3-yl)-1-(pyridin-4-ylmethyl)-1,2-dihydropyridin-2-one 2183-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[4- 609 b(morpholin-4-yl)phenyl]carbonyl-1H-pyrazol-3-yl)-1-[2-(morpholin-4-yl)ethyl]-1,2-dihydropyridin-2-one 2273-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol- 398 e3-yl)-1-(pyridin-2-ylmethyl)-1,2-dihydropyridin-2-one 2293-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol- 398 e3-yl)-1-(pyridin-4-ylmethyl)-1,2-dihydropyridin-2-one 2353-(5-[(5-chlorothiophen-2-yl)methyl]amino-1H-pyrazol- 412 d3-yl)-1-[2-(pyridin-2-yl)ethyl]-1,2-dihydropyridin-2-one 2373-[5-(benzylamino)-1-[(furan-2-yl)carbonyl]-1H- 360 dpyrazol-3-yl]-1,2-dihydropyridin-2-one 2383-[5-(benzylamino)-1-[(furan-2-yl)carbonyl]-1H- 452 cpyrazol-3-yl]-1-(pyridin-2-ylmethyl)-1,2- dihydropyridin-2-one 2423-1-[(2-chlorophenyl)carbonyl]-5-[(5-chlorothiophen-2- 503 e byl)methyl]amino-1H-pyrazol-3-yl-1-(2-methoxyethyl)-1,2-dihydropyridin-2-one 2433-1-[(2-chlorophenyl)carbonyl]-5-[(5-chlorothiophen-2- 525 byl)methyl]amino-1H-pyrazol-3-yl-1-(furan-2-ylmethyl)-1,2-dihydropyridin-2-one 2443-1-[(2-chlorophenyl)carbonyl]-5-[(5-chlorothiophen-2- 525 byl)methyl]amino-1H-pyrazol-3-yl-1-(furan-3-ylmethyl)-1,2-dihydropyridin-2-one 2473-1-[(2-chlorophenyl)carbonyl]-5-[(5-chlorothiophen-2- 536 e ayl)methyl]amino-1H-pyrazol-3-yl-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-2-one 2483-1-[(2-chlorophenyl)carbonyl]-5-[(5-chlorothiophen-2- 536 e byl)methyl]amino-1H-pyrazol-3-yl-1-(pyridin-4-ylmethyl)-1,2-dihydropyridin-2-one 2651-[(5-[(5-chlorothiophen-2-yl)methyl]amino-3-(1- 517 cmethyl-2-oxo-1,2-dihydropyridin-3-yl)-1H-pyrazol-1-yl)carbonyl]cyclopropylmethyl 1-(hydroxymethyl)cyclopropane-1-carboxylate 2661-(5-[(4-fluorophenyl)methyl]amino-3-(pyridazin-3-yl)- 353 e1H-pyrazol-1-yl)-2,2-dimethylpropan-1-one 2671-(5-[(4-fluorophenyl)methyl]amino-3-(pyrimidin-4-yl)- 353 e1H-pyrazol-1-yl)-2,2-dimethylpropan-1-one 2681-(5-[(4-fluorophenyl)methyl]amino-3-phenyl-1H- 323 epyrazol-1-yl)propan-1-one 2691-(5-[(5-chlorothiophen-2-yl)methyl]amino-3-(3- 393 efluoropyridin-2-yl)-1H-pyrazol-1-yl)-2,2- dimethylpropan-1-one 2701-(5-[(5-chlorothiophen-2-yl)methyl]amino-3-(furan-2- 364 eyl)-1H-pyrazol-1-yl)-2,2-dimethylpropan-1-one 2711-(5-[(5-chlorothiophen-2-yl)methyl]amino-3-(pyridin- 375 e2-yl)-1H-pyrazol-1-yl)-2,2-dimethylpropan-1-one 2721-(5-[(5-chlorothiophen-2-yl)methyl]amino-3-(pyridin- 405 e2-yl)-1H-pyrazol-1-yl)-3-methoxy-2,2-dimethylpropan- 1-one 2731-(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3- 416 d(oxan-4-yl)-1H-pyrazol-1-yl)-3-hydroxy-2,2- dimethylpropan-1-one 2741-(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3- 415 c(piperidin-4-yl)-1H-pyrazol-1-yl)-3-hydroxy-2,2- dimethylpropan-1-one275 1-(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3- 408 ephenyl-1H-pyrazol-1-yl)-3-hydroxy-2,2- dimethylpropan-1-one 2761-[(2-aminophenyl)carbonyl]-N-[(5-chlorothiophen-2- 428 d cyl)methyl]-3-(3-fluoropyridin-2-yl)-1H-pyrazol-5-amine 2771-[(2-aminophenyl)carbonyl]-N-[(5-chlorothiophen-2- 399 d cyl)methyl]-3-(furan-2-yl)-1H-pyrazol-5-amine 2781-[(2-methoxyphenyl)carbonyl]-3-(pyridin-2-yl)-N- 390 e(thiophen-2-ylmethyl)-1H-pyrazol-5-amine 2791-[5-(benzylamino)-4-fluoro-3-(pyridin-2-yl)-1H- 352 epyrazol-1-yl]-2,2-dimethylpropan-1-one 2801-5-[(furan-2-ylmethyl)amino]-3-(pyridin-2-yl)-1H- 324 epyrazol-1-yl-2,2-dimethylpropan-1-one 2812,2-dimethyl-1-[3-(pyridin-2-yl)-5-[(thiophen-2- 340 eylmethyl)amino]-1H-pyrazol-1-yl]propan-1-one 2822-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 446 e cmethoxyphenyl)carbonyl]-1H-pyrazol-3-yl)cyclohexan- 1-ol 283N-(furan-2-ylmethyl)-1-[(2-methoxyphenyl)carbonyl]- 374 e3-(pyridin-2-yl)-1H-pyrazol-5-amine 284N-[(5-chlorothiophen-2-yl)methyl]-1-[(2- 432 emethoxyphenyl)carbonyl]-3-(oxan-4-yl)-1H-pyrazol-5- amine 285N-[(5-chlorothiophen-2-yl)methyl]-1-[(2- 425 d cmethoxyphenyl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol- 5-amine 286N-[(5-chlorothiophen-2-yl)methyl]-1-[(2- 487 ephenoxyphenyl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol- 5-amine 287N-[(5-chlorothiophen-2-yl)methyl]-1-[(4-methyloxan-4- 417 dyl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol-5-amine 288N-[(5-chlorothiophen-2-yl)methyl]-1-[(furan-3- 385 dyl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol-5-amine 289N-[(5-chlorothiophen-2-yl)methyl]-1-[(furan-3- 390 eyl)carbonyl]-3-(thiophen-2-yl)-1H-pyrazol-5-amine 290N-[(5-chlorothiophen-2-yl)methyl]-3-(3-fluoropyridin- 443 e2-yl)-1-[(2-methoxyphenyl)carbonyl]-1H-pyrazol-5- amine 291N-[(5-chlorothiophen-2-yl)methyl]-3-(3-fluoropyridin- 403 e2-yl)-1-[(furan-3-yl)carbonyl]-1H-pyrazol-5-amine 292N-[(5-chlorothiophen-2-yl)methyl]-3-(pyridazin-3-yl)-1- 402 e b[(thiophen-3-yl)carbonyl]-1H-pyrazol-5-amine 293N-[(5-chlorothiophen-2-yl)methyl]-3-(pyridin-2-yl)-1- 401 e b[(thiophen-3-yl)carbonyl]-1H-pyrazol-5-amine 294N-[(5-chlorothiophen-2-yl)methyl]-4-fluoro-1-[(furan-3- 410 e cyl)carbonyl]-3-(oxan-4-yl)-1H-pyrazol-5-amine 295N-[(5-chlorothiophen-2-yl)methyl]-4-fluoro-1-[(furan-3- 402 eyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine 296N-benzyl-4-fluoro-1-[(2-methoxyphenyl)carbonyl]-3- 401 ephenyl-1H-pyrazol-5-amine 297 tert-butyl4-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 481 e(2,2-dimethylpropanoyl)-1H-pyrazol-3-yl)piperidine-1- carboxylate 298tert-butyl 4-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 507 e[(thiophen-3-yl)carbonyl]-1H-pyrazol-3-yl)piperidine-1- carboxylate

In some embodiments, there is provided a compound as expressly set forthin Table C following.

TABLE C Cmpd KLK1 KLKB1 No. IUPAC name MW Activity Activity 71-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)- 325 d1H-1,2,4-triazol-1-yl)propan-1-one 8N-benzyl-1-[(furan-2-yl)carbonyl]-3-(pyridin-2-yl)-1H- 345 c1,2,4-triazol-5-amine 91-[5-(benzylamino)-3-(pyridin-2-yl)-1H-1,2,4-triazol-1- 383 eyl]-3-phenylpropan-1-one 10N-[(4-fluorophenyl)methyl]-3-(pyridin-2-yl)-1- 379 c[(thiophen-2-yl)carbonyl]-1H-1,2,4-triazol-5-amine 11N-[(4-fluorophenyl)methyl]-3-(pyridin-4-yl)-1- 379 c[(thiophen-3-yl)carbonyl]-1H-1,2,4-triazol-5-amine 12N-[(4-fluorophenyl)methyl]-1-[(morpholin-4- 382 eyl)carbonyl]-3-(pyridin-3-yl)-1H-1,2,4-triazol-5-amine 131-[5-(dimethylamino)-3-(pyridin-3-yl)-1H-1,2,4-triazol- 245 e1-yl]propan-1-one 14 3-(5-[(4-fluorophenyl)methyl]sulfanyl-1-[(2- 420 bmethoxyphenyl)carbonyl]-1H-1,2,4-triazol-3- yl)pyridine 151-[(2-methoxyphenyl)carbonyl]-5-(methylsulfanyl)-3- 331 c c(thiophen-2-yl)-1H-1,2,4-triazole 16N-benzyl-1-[(2-methoxyphenyl)carbonyl]-3-(pyrimidin- 386 b4-yl)-1H-1,2,4-triazol-5-amine 17N-benzyl-1-[(2-methoxyphenyl)carbonyl]-3-(pyrimidin- 386 b5-yl)-1H-1,2,4-triazol-5-amine 18N-benzyl-1-[(2-methoxyphenyl)carbonyl]-3-(pyrimidin- 386 d b2-yl)-1H-1,2,4-triazol-5-amine 22N-[(5-chlorothiophen-2-yl)methyl]-1-[(2- 426 d amethoxyphenyl)carbonyl]-3-(pyridin-2-yl)-1H-1,2,4- triazol-5-amine 2991-(1,3-benzothiazol-2-yl)-N-[(4-fluorophenyl)methyl]- 402 e3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 3001-(5-[(4-fluorophenyl)methyl]amino-3-(furan-2-yl)-1H- 342 d1,2,4-triazol-1-yl)-2,2-dimethylpropan-1-one 3011-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-2-yl)- 353 d1H-1,2,4-triazol-1-yl)-2,2-dimethylpropan-1-one 3021-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-2-yl)- 339 d1H-1,2,4-triazol-1-yl)-2-methylpropan-1-one 3031-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-2-yl)- 387 c1H-1,2,4-triazol-1-yl)-2-phenylethan-1-one 3041-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-2-yl)- 353 d1H-1,2,4-triazol-1-yl)-3-methylbutan-1-one 3051-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-2-yl)- 401 d1H-1,2,4-triazol-1-yl)-3-phenylpropan-1-one 3061-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-2-yl)- 339 d1H-1,2,4-triazol-1-yl)butan-1-one 3071-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-2-yl)- 325 d1H-1,2,4-triazol-1-yl)propan-1-one 3081-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)- 353 d1H-1,2,4-triazol-1-yl)-2,2-dimethylpropan-1-one 3091-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)- 341 e1H-1,2,4-triazol-1-yl)-2-methoxyethan-1-one 3101-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)- 339 d1H-1,2,4-triazol-1-yl)-2-methylpropan-1-one 3111-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)- 387 c1H-1,2,4-triazol-1-yl)-2-phenylethan-1-one 3121-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)- 353 d1H-1,2,4-triazol-1-yl)-3-methylbutan-1-one 3131-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)- 401 d1H-1,2,4-triazol-1-yl)-3-phenylpropan-1-one 3141-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)- 339 d1H-1,2,4-triazol-1-yl)butan-1-one 3151-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-4-yl)- 339 d1H-1,2,4-triazol-1-yl)-2-methylpropan-1-one 3161-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-4-yl)- 353 e1H-1,2,4-triazol-1-yl)-3-methylbutan-1-one 3171-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-4-yl)- 339 e1H-1,2,4-triazol-1-yl)butan-1-one 3181-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-4-yl)- 325 e1H-1,2,4-triazol-1-yl)propan-1-one 3191-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-2-yl)- 365 d1H-1,2,4-triazol-1-yl)-2,2-dimethylpropan-1-one 3201-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-2-yl)- 351 e1H-1,2,4-triazol-1-yl)-2-methylpropan-1-one 3211-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-2-yl)- 399 d1H-1,2,4-triazol-1-yl)-2-phenylethan-1-one 3221-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-2-yl)- 365 d1H-1,2,4-triazol-1-yl)-3-methylbutan-1-one 3231-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-2-yl)- 414 d c1H-1,2,4-triazol-1-yl)-3-phenylpropan-1-one 3241-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-2-yl)- 351 d1H-1,2,4-triazol-1-yl)butan-1-one 3251-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-2-yl)- 337 d1H-1,2,4-triazol-1-yl)propan-1-one 3261-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-3-yl)- 365 e1H-1,2,4-triazol-1-yl)-2,2-dimethylpropan-1-one 3271-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-3-yl)- 399 d1H-1,2,4-triazol-1-yl)-2-phenylethan-1-one 3281-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-3-yl)- 365 e1H-1,2,4-triazol-1-yl)-3-methylbutan-1-one 3291-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-3-yl)- 414 e1H-1,2,4-triazol-1-yl)-3-phenylpropan-1-one 3301-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-3-yl)- 351 d1H-1,2,4-triazol-1-yl)butan-1-one 3311-(5-[(5-chlorothiophen-2-yl)methyl]amino-3-(oxolan- 369 c2-yl)-1H-1,2,4-triazol-1-yl)-2,2-dimethylpropan-1-one 3321-[(2-methoxyphenyl)carbonyl]-3-(pyridin-2-yl)-N-(1,3- 392 b dthiazol-2-ylmethyl)-1H-1,2,4-triazol-5-amine 3331-[(2-methoxyphenyl)carbonyl]-3-phenyl-N-(1,3- 391 ethiazol-2-ylmethyl)-1H-1,2,4-triazol-5-amine 3341-[(2-methoxyphenyl)carbonyl]-3-phenyl-N-(thiophen- 390 d2-ylmethyl)-1H-1,2,4-triazol-5-amine 3351-[(2-methoxyphenyl)carbonyl]-3-phenyl-N-(thiophen- 390 d3-ylmethyl)-1H-1,2,4-triazol-5-amine 3361-[(furan-2-yl)carbonyl]-N-[(4-methoxyphenyl)methyl]- 375 c3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 3371-[(furan-2-yl)carbonyl]-N-[(4-methoxyphenyl)methyl]- 375 e3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 3381-[(furan-3-yl)carbonyl]-N-[(4-methoxyphenyl)methyl]- 375 d3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 3391-[(furan-3-yl)carbonyl]-N-[(4-methoxyphenyl)methyl]- 375 e3-(pyridin-3-yl)-1H-1,2,4-triazol-5-amine 3401-[3-(pyridin-3-yl)-5-[(thiophen-2-ylmethyl)amino]-1H- 313 d1,2,4-triazol-1-yl]propan-1-one 3411-[4-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 516 bmethoxyphenyl)carbonyl]-1H-1,2,4-triazol-3-yl)piperidin-1-yl]-2,2-dimethylpropan-1-one 3421-[5-(benzylamino)-3-(furan-2-yl)-1H-1,2,4-triazol-1- 324 eyl]-2,2-dimethylpropan-1-one 3431-[5-(benzylamino)-3-(furan-2-yl)-1H-1,2,4-triazol-1- 358 eyl]-2-phenylethan-1-one 3441-[5-(benzylamino)-3-(pyridin-2-yl)-1H-1,2,4-triazol-1- 335 dyl]-2,2-dimethylpropan-1-one 3451-[5-(benzylamino)-3-(pyridin-2-yl)-1H-1,2,4-triazol-1- 321 dyl]-2-methylpropan-1-one 3461-[5-(benzylamino)-3-(pyridin-2-yl)-1H-1,2,4-triazol-1- 335 dyl]-3-methylbutan-1-one 3471-[5-(benzylamino)-3-(pyridin-2-yl)-1H-1,2,4-triazol-1- 321 dyl]butan-1-one 3481-[5-(benzylamino)-3-(pyridin-2-yl)-1H-1,2,4-triazol-1- 307 dyl]propan-1-one 3491-[5-(benzylamino)-3-(pyridin-3-yl)-1H-1,2,4-triazol-1- 307 dyl]propan-1-one 3501-[5-(benzylamino)-3-(pyridin-4-yl)-1H-1,2,4-triazol-1- 335 eyl]-2,2-dimethylpropan-1-one 3511-[5-(benzylamino)-3-(pyridin-4-yl)-1H-1,2,4-triazol-1- 321 cyl]-2-methylpropan-1-one 3521-[5-(benzylamino)-3-(pyridin-4-yl)-1H-1,2,4-triazol-1- 369 eyl]-2-phenylethan-1-one 3531-[5-(benzylamino)-3-(pyridin-4-yl)-1H-1,2,4-triazol-1- 335 eyl]-3-methylbutan-1-one 3541-[5-(benzylamino)-3-(pyridin-4-yl)-1H-1,2,4-triazol-1- 383 eyl]-3-phenylpropan-1-one 3551-[5-(benzylamino)-3-(pyridin-4-yl)-1H-1,2,4-triazol-1- 321 eyl]butan-1-one 3561-[5-(benzylamino)-3-(pyridin-4-yl)-1H-1,2,4-triazol-1- 307 eyl]propan-1-one 3571-[5-(benzylamino)-3-(thiophen-2-yl)-1H-1,2,4-triazol- 340 e1-yl]-2,2-dimethylpropan-1-one 3581-benzoyl-N-[(4-fluorophenyl)methyl]-3-(pyridin-2-yl)- 373 d b1H-1,2,4-triazol-5-amine 3591-benzoyl-N-[(4-fluorophenyl)methyl]-3-(pyridin-3-yl)- 373 b1H-1,2,4-triazol-5-amine 3601-benzoyl-N-[(4-methoxyphenyl)methyl]-3-(pyridin-2- 385 c cyl)-1H-1,2,4-triazol-5-amine 3611-benzoyl-N-[(4-methoxyphenyl)methyl]-3-(pyridin-3- 385 c cyl)-1H-1,2,4-triazol-5-amine 3621-benzoyl-N-benzyl-3-(pyridin-2-yl)-1H-1,2,4-triazol-5- 355 d b amine363 1-benzoyl-N-benzyl-3-(pyridin-4-yl)-1H-1,2,4-triazol-5- 355 b amine364 3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2- 511 amethoxyphenyl)carbonyl]-1H-1,2,4-triazol-3-yl)-N,N-dimethylazetidine-1-sulfonamide 3653-(pyridin-3-yl)-1-[(pyridin-3-yl)carbonyl]-N-(thiophen- 362 c2-ylmethyl)-1H-1,2,4-triazol-5-amine 3663-1-[(2-methoxyphenyl)carbonyl]-5-(methylsulfanyl)- 326 c c1H-1,2,4-triazol-3-ylpyridine 367 N-[(4-fluorophenyl)methyl]-1-[(2- 403c methoxyphenyl)carbonyl]-3-(pyridin-2-yl)-1H-1,2,4- triazol-5-amine 368N-[(4-fluorophenyl)methyl]-1-[(2- 403 cmethoxyphenyl)carbonyl]-3-(pyridin-3-yl)-1H-1,2,4- triazol-5-amine 369N-[(4-fluorophenyl)methyl]-1-[(furan-2-yl)carbonyl]-3- 363 c(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 370N-[(4-fluorophenyl)methyl]-1-[(furan-2-yl)carbonyl]-3- 363 c(pyridin-3-yl)-1H-1,2,4-triazol-5-amine 371N-[(4-fluorophenyl)methyl]-1-[(furan-3-yl)carbonyl]-3- 363 c(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 372N-[(4-fluorophenyl)methyl]-1-[(furan-3-yl)carbonyl]-3- 363 c(pyridin-3-yl)-1H-1,2,4-triazol-5-amine 373N-[(4-fluorophenyl)methyl]-1-[(furan-3-yl)carbonyl]-3- 363 e(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 374N-[(4-fluorophenyl)methyl]-1-propyl-3-(pyridin-2-yl)- 311 e1H-1,2,4-triazol-5-amine 375N-[(4-fluorophenyl)methyl]-3-(pyridin-2-yl)-1- 379 b[(thiophen-3-yl)carbonyl]-1H-1,2,4-triazol-5-amine 376N-[(4-fluorophenyl)methyl]-3-(pyridin-3-yl)-1- 379 c[(thiophen-2-yl)carbonyl]-1H-1,2,4-triazol-5-amine 377N-[(4-fluorophenyl)methyl]-3-(pyridin-3-yl)-1- 379 b[(thiophen-3-yl)carbonyl]-1H-1,2,4-triazol-5-amine 378N-[(4-fluorophenyl)methyl]-3-(pyridin-4-yl)-1- 379 e[(thiophen-2-yl)carbonyl]-1H-1,2,4-triazol-5-amine 379N-[(4-methoxyphenyl)methyl]-3-(pyridin-2-yl)-1- 391 e[(thiophen-2-yl)carbonyl]-1H-1,2,4-triazol-5-amine 380N-[(4-methoxyphenyl)methyl]-3-(pyridin-2-yl)-1- 391 c[(thiophen-3-yl)carbonyl]-1H-1,2,4-triazol-5-amine 381N-[(4-methoxyphenyl)methyl]-3-(pyridin-3-yl)-1- 391 e[(thiophen-2-yl)carbonyl]-1H-1,2,4-triazol-5-amine 382N-[(4-methoxyphenyl)methyl]-3-(pyridin-3-yl)-1- 391 c[(thiophen-3-yl)carbonyl]-1H-1,2,4-triazol-5-amine 383N-[(5-chlorofuran-2-yl)methyl]-1-[(2- 409 emethoxyphenyl)carbonyl]-3-phenyl-1H-1,2,4-triazol-5- amine 384N-[(5-chlorothiophen-2-yl)methyl]-1-[(2,4- 463 d bdimethoxyphenyl)carbonyl]-3-(oxan-4-yl)-1H-1,2,4- triazol-5-amine 385N-[(5-chlorothiophen-2-yl)methyl]-1-[(2- 433 bmethoxyphenyl)carbonyl]-3-(oxan-4-yl)-1H-1,2,4- triazol-5-amine 386N-[(5-chlorothiophen-2-yl)methyl]-1-[(2- 419 bmethoxyphenyl)carbonyl]-3-(oxolan-2-yl)-1H-1,2,4- triazol-5-amine 387N-[(5-chlorothiophen-2-yl)methyl]-1-[(2- 432 d amethoxyphenyl)carbonyl]-3-(piperidin-4-yl)-1H-1,2,4- triazol-5-amine 388N-[(5-chlorothiophen-2-yl)methyl]-1-[(2- 537 amethoxyphenyl)carbonyl]-3-[1-(pyrrolidine-1-sulfonyl)azetidin-3-yl]-1H-1,2,4-triazol-5-amine 389N-[(5-chlorothiophen-2-yl)methyl]-1-[(2- 510 cmethoxyphenyl)carbonyl]-3-[4-(morpholin-4-yl)phenyl]-1H-1,2,4-triazol-5-amine 390N-[(5-chlorothiophen-2-yl)methyl]-1-[(2- 425 bmethoxyphenyl)carbonyl]-3-phenyl-1H-1,2,4-triazol-5- amine 391N-[(5-chlorothiophen-2-yl)methyl]-1-[(2- 410 d bmethylphenyl)carbonyl]-3-(pyridin-2-yl)-1H-1,2,4- triazol-5-amine 392N-[(5-chlorothiophen-2-yl)methyl]-1-[(furan-3- 379 byl)carbonyl]-3-(oxolan-2-yl)-1H-1,2,4-triazol-5-amine 393N-[(5-chlorothiophen-2-yl)methyl]-3-[4- 468 d b(dimethylamino)phenyl]-1-[(2-methoxyphenyl)carbonyl]-1H-1,2,4-triazol-5-amine 394N-benzyl-1-[(2,6-difluorophenyl)carbonyl]-3-(pyridin- 391 e2-yl)-1H-1,2,4-triazol-5-amine 395N-benzyl-1-[(2-chlorophenyl)carbonyl]-3-(pyridin-2- 390 byl)-1H-1,2,4-triazol-5-amine 396N-benzyl-1-[(2-chlorophenyl)carbonyl]-3-(thiophen-2- 395 byl)-1H-1,2,4-triazol-5-amine 397N-benzyl-1-[(2-methoxyphenyl)carbonyl]-3-(pyridin-2- 385 cyl)-1H-1,2,4-triazol-5-amine 398N-benzyl-1-[(2-methoxyphenyl)carbonyl]-3-(thiophen- 390 c2-yl)-1H-1,2,4-triazol-5-amine 399N-benzyl-1-[(4-chlorophenyl)carbonyl]-3-(pyridin-2- 390 byl)-1H-1,2,4-triazol-5-amine 400N-benzyl-1-[(furan-2-yl)carbonyl]-3-(pyridin-4-yl)-1H- 345 c1,2,4-triazol-5-amine 401N-benzyl-1-[(furan-3-yl)carbonyl]-3-(pyridin-2-yl)-1H- 345 e1,2,4-triazol-5-amine 402N-benzyl-1-[(furan-3-yl)carbonyl]-3-(pyridin-4-yl)-1H- 345 d1,2,4-triazol-5-amine 403 N-benzyl-3-(furan-2-yl)-1-[(2- 374 cmethoxyphenyl)carbonyl]-1H-1,2,4-triazol-5-amine 404N-benzyl-3-(pyridin-2-yl)-1-[(thiophen-2-yl)carbonyl]- 361 c1H-1,2,4-triazol-5-amine 405N-benzyl-3-(pyridin-2-yl)-1-[(thiophen-3-yl)carbonyl]- 361 d1H-1,2,4-triazol-5-amine 406N-benzyl-3-(pyridin-4-yl)-1-[(thiophen-2-yl)carbonyl]- 361 e1H-1,2,4-triazol-5-amine 407N-benzyl-3-(pyridin-4-yl)-1-[(thiophen-3-yl)carbonyl]- 361 e b1H-1,2,4-triazol-5-amine 408 methyl5-[(4-methylbenzene)amido]-1H-1,2,4-triazole- 260 e 3-carboxylate 409phenyl 5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3- 389 eyl)-1H-1,2,4-triazole-1-carboxylate 410 propan-2-yl5-[(4-fluorophenyl)methyl]amino-3- 355 e(pyridin-3-yl)-1H-1,2,4-triazole-1-carboxylate 411 tert-butyl3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 504 b[(2-methoxyphenyl)carbonyl]-1H-1,2,4-triazol-3-yl)azetidine-1-carboxylate 412 tert-butyl4-(5-[(5-chlorothiophen-2-yl)methyl]amino-1- 532 b[(2-methoxyphenyl)carbonyl]-1H-1,2,4-triazol-3-yl)piperidine-1-carboxylate 413 tert-butyl5-[(4-fluorophenyl)methyl]amino-3-(pyridin- 369 e3-yl)-1H-1,2,4-triazole-1-carboxylate

In some embodiments, there is provided a compound as expressly set forthin Table D following.

TABLE D Cmpd No. IUPAC name MW KLKB1 Activity 414(3R)—N-[(3-chloro-1H-indol-5-yl)methyl]-1-[(4- 416 echlorophenyl)methyl]-5-oxopyrrolidine-3-carboxamide 415(3S)-1-benzyl-N-[(3-chloro-1H-indol-5-yl)methyl]-5- 382 eoxopyrrolidine-3-carboxamide 416(3S)—N-[(3-chloro-1-methyl-1H-indol-5-yl)methyl]-1- 430 d[(4-chlorophenyl)methyl]-5-oxopyrrolidine-3- carboxamide 417(3S)—N-[(3-chloro-1H-indol-5-yl)methyl]-1-[(2- 416 dchlorophenyl)methyl]-5-oxopyrrolidine-3-carboxamide 418(3S)—N-[(3-chloro-1H-indol-5-yl)methyl]-1-[(3- 416 echlorophenyl)methyl]-5-oxopyrrolidine-3-carboxamide 4192-N-[(2R)-5-amino-1,2,3,4-tetrahydronaphthalen-2-yl]- 378 e4-N-(2-fluorophenyl)-4-N,6-dimethylpyrimidine-2,4- diamine 4202-N-[(2R)-5-amino-1,2,3,4-tetrahydronaphthalen-2-yl]- 378 e4-N-(3-fluorophenyl)-4-N,6-dimethylpyrimidine-2,4- diamine 4212-N-[(2R)-5-amino-1,2,3,4-tetrahydronaphthalen-2-yl]- 378 e4-N-(4-fluorophenyl)-4-N,6-dimethylpyrimidine-2,4- diamine 4222-N-[(2S)-5-amino-1,2,3,4-tetrahydronaphthalen-2-yl]- 360 e4-N,6-dimethyl-4-N-phenylpyrimidine-2,4-diamine 4232-N-[(2S)-5-amino-1,2,3,4-tetrahydronaphthalen-2-yl]- 394 d4-N-(2-chlorophenyl)-4-N,6-dimethylpyrimidine-2,4- diamine 4242-N-[(2S)-5-amino-1,2,3,4-tetrahydronaphthalen-2-yl]- 394 e4-N-(3-chlorophenyl)-4-N,6-dimethylpyrimidine-2,4- diamine 4252-N-[(2S)-5-amino-1,2,3,4-tetrahydronaphthalen-2-yl]- 394 e4-N-(4-chlorophenyl)-4-N,6-dimethylpyrimidine-2,4- diamine

Compounds disclosed herein also include racemic mixtures, stereoisomersand mixtures of the compounds, including isotopically-labeled andradio-labeled compounds. See e.g., Goding, 1986, MONOCLONAL ANTIBODIESPRINCIPLES AND PRACTICE; Academic Press, p. 104. Such isomers can beisolated by standard resolution techniques, including e.g., fractionalcrystallization, chiral chromatography, and the like. See e.g., Eliel,E. L. & Wilen S. H., 1993, STEREOCHEMISTRY IN ORGANIC COMPOUNDS; JohnWiley & Sons, New York.

In some embodiments, compounds disclosed herein have asymmetric centersand can occur as racemates, racemic mixtures, and as individualenantiomers or diastereoisomers, with all isomeric forms as well asmixtures thereof being contemplated for use in the compounds and methodsdescribed herein. The compounds contemplated for use in the compoundsand methods described herein do not include those that are known in theart to be too unstable to synthesize and/or isolate.

The compounds disclosed herein can also contain unnatural proportions ofatomic isotopes at one or more of the atoms that constitute suchcompounds. For example, the compounds can be radiolabeled withradioactive isotopes, such as for example tritium (³H), iodine-125(¹²⁵I), or carbon-14 (¹⁴C). All isotopic variations of the compoundsdisclosed herein, whether radioactive or not, are encompassed within thecontemplated scope.

In some embodiments, metabolites of the compounds disclosed herein areuseful for the methods disclosed herein.

In some embodiments, compounds contemplated herein are provided in theform of a prodrug. The term “prodrug” refers to a compound that can beconverted into a compound (e.g., a biologically active compound)described herein in vivo. Prodrugs can be useful for a variety of reasonknown in the art, including e.g., ease of administration due e.g., toenhanced bioavailability in oral administration, and the like. Theprodrug can also have improved solubility in pharmaceutical compositionsover the biologically active compounds. An example, without limitation,of a prodrug is a compound which is administered as an ester (i.e., the“prodrug”) to facilitate transmittal across a cell membrane where watersolubility is detrimental to mobility but which then is metabolicallyhydrolyzed to the carboxylic acid, the active entity, once inside thecell where water solubility is beneficial. Conventional procedures forthe selection and preparation of suitable prodrug derivatives aredescribed, for example, in DESIGN OF PRODRUGS, (ed. H. Bundgaard,Elsevier, 1985), which is hereby incorporated herein by reference forthe limited purpose describing procedures and preparation of suitableprodrug derivatives.

Accordingly, in some embodiments, compounds contemplated herein areprovided in the form of a prodrug ester. The term “prodrug ester” refersto derivatives of the compounds disclosed herein formed by the additionof any of a variety of ester-forming groups, e.g., groups known in theart, that are hydrolyzed under physiological conditions. Examples ofprodrug ester groups include pivaloyloxymethyl, acetoxymethyl,phthalidyl, indanyl and methoxymethyl, as well as other such groupsknown in the art, including a (5-R-2-oxo-1,3-dioxolen-4-yl)methyl group.Other examples of prodrug ester groups can be found in, for example, T.Higuchi and V. Stella, in “Pro-drugs as Novel Delivery Systems”, Vol.14, A.C.S. Symposium Series, American Chemical Society (1975); andBIOREVERSIBLE CARRIERS IN DRUG DESIGN: THEORY AND APPLICATION, edited byE. B. Roche, Pergamon Press: New York, 14-21 (1987) (providing examplesof esters useful as prodrugs for compounds containing carboxyl groups).Each of the above-mentioned references is herein incorporated byreference for the limited purpose of disclosing ester-forming groupsthat can form prodrug esters.

In some embodiments, prodrugs can be slowly converted to the compoundsdescribed herein useful for the methods described herein when placed ina transdermal patch reservoir with a suitable enzyme or chemicalreagent.

Certain compounds disclosed herein can exist in unsolvated forms as wellas solvated forms, including hydrated forms. In general, the solvatedforms are equivalent to unsolvated forms and are encompassed within thescope of contemplated compounds. Certain compounds of the presentinvention can exist in multiple crystalline or amorphous forms. Ingeneral, all physical forms are equivalent for the compounds and methodscontemplated herein and are intended to be within the scope disclosedherein.

III. Biological Activities

In some embodiments, compounds described herein exhibit inhibitoryactivity against thrombin with activities≥1 μM, e.g., about 1, 2, 3, 4,5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32,34, 36, 38, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 μM, oreven greater. In some embodiments, the compounds exhibit inhibitoryactivity against thrombin with activities between 0.1 μM and 1 μM, e.g.,about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1.0 μM. In someembodiments, compounds described herein exhibit inhibitory activityagainst thrombin with activities≤0.1 μM, e.g., about 1, 2, 5, 10, 15,20, 30, 40, 50, 60, 70, 80, 90, or 100 nM. Ranges of values using acombination of any of the values recited herein as upper and/or lowerlimits are also contemplated, for example, but not limited to, 1-10 nM,10-100 nM, 0.1-1 μM, 1-10 μM, 10-100 μM, 100-200 μM, 200-500 μM, or even500-1000 μM. In some embodiments, the inhibitory activity is in therange of about 1-10 nM, 10-100 nM, 0.1-1 μM, 1-10 μM, 10-100 μM, 100-200μM, 200-500 μM, or even 500-1000 μM. It is understood that for purposesof quantification, the terms “activity,” “inhibitory activity,”“biological activity,” “thrombin activity and the like in the context ofan inhibitory compound disclosed herein can be quantified in a varietyof ways known in the art. Unless indicated otherwise, as used hereinsuch terms refer to IC₅₀ in the customary sense (i.e., concentration toachieve half-maximal inhibition).

Inhibitory activity against thrombin in turn inhibits the bloodcoagulation process. Accordingly, compounds disclosed herein areindicated in the treatment or management of thrombotic disorders. Insome embodiments, a dose or a therapeutically effective dose of acompound disclosed herein will be that which is sufficient to achieve aplasma concentration of the compound or its active metabolite(s) withina range set forth herein, e.g., about 1-10 nM, 10-100 nM, 0.1-1 μM, 1-10μM, 10-100 μM, 100-200 μM, 200-500 μM, or even 500-1000 μM, preferablyabout 1-10 nM, 10-100 nM, or 0.1-1 μM. Without wishing to be bound byany theory, it is believe that such compounds are indicated in thetreatment or management of thrombotic disorders.

In some embodiments, compounds described herein exhibit inhibitoryactivity against KLK1 and KLKB1 with activities between 1 μM and 10 μM,e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 μM. In some embodiments,compounds described herein exhibit inhibitory activity against KLK1 andKLKB1 with activities≥10 μM, e.g., about 10, 20, 50, 100, 150, 200, 300,400, 500, 600, 700, 800, 900, 1000 μM or even greater. In someembodiments, compounds described herein exhibit inhibitory activityagainst KLK1 and KLKB1 with activities≤1 μM, e.g., about 900, 800, 700,600, 500, 400, 300, 200, 100, 50 nM or even lower. Ranges of valuesusing a combination of any of the values recited herein as upper and/orlower limits are also contemplated, for example, but not limited to,1-10 nM, 10-100 nM, 0.1-1 μM, 1-10 μM, 10-100 μM, 100-200 μM, 200-500μM, or even 500-1000 μM. In some embodiments, the inhibitory activity isin the range of about 1-10 nM, 10-100 nM, 0.1-1 μM, 1-10 μM, 10-100 μM,100-200 μM, 200-500 μM, or even 500-1000 μM. It is understood that forpurposes of quantification, the terms “activity,” “inhibitory activity,”“biological activity,” “KLK1 activity,” “KLKB1 activity” and the like inthe context of an inhibitory compound disclosed herein can be quantifiedin a variety of ways known in the art. Unless indicated otherwise, asused herein such terms refer to IC₅₀ in the customary sense (i.e.,concentration to achieve half-maximal inhibition).

Inhibitory activity against KLKB1 has an effect on the coagulationcascade and the inflammatory response. Thus, it has been proposed thatKLKB1 inhibitors can be useful in the treatment of thrombotic andfibrinolytic diseases and disease conditions.

Accordingly, compounds disclosed herein are indicated in the treatmentor management of a variety of diseases or disorders. In someembodiments, a dose or a therapeutically effective dose of a compounddisclosed herein will be that which is sufficient to achieve a plasmaconcentration of the compound or its active metabolite(s) within a rangeset forth herein, e.g., about 1-10 nM, 10-100 nM, 0.1-1 μM, 1-10 μM,10-100 μM, 100-200 μM, 200-500 μM, or even 500-1000 μM, preferably about1-10 nM, 10-100 nM, or 0.1-1 μM. Without wishing to be bound by anytheory, it is believe that such compounds are indicated in the treatmentor management of diseases associated with thrombin or kallikrein.

IV. Methods of Treating and Preventing Disease

Kallikrein-related diseases or disorders are biological conditionsassociated with or moderated by kallikrein. They include, but are notlimited by, those conditions associated with biological pathways thatare moderated by tissue and plasma kallikrein. An example of such apathway is the kallikrein-kinin system (Moreau, M. E. 2005, Journal ofPharmacological Sciences, 99, 6). Kallikrein-related diseases ordisorders include, but are not limited to, fibrosis, inflammation,thrombosis, hereditary angioedema, skin disorders, cancer, andophthalmic diseases. Ophthalmic diseases include, but are not limitedto, diabetic macular edema, diabetic retinopathy, and age-relatedmacular degeneration.

Diabetic Macular Edema.

In rodent models, it has been shown that activation of KLKB1 in the eyeincreases retinal vascular permeability; whereas inhibition of thekallikrein-kinin system reduces retinal leakage induced by diabetes andhypertension. These findings suggest that intraocular activation of theKLKB1 pathway can contribute to excessive retinal vascular permeabilitythat can lead to diabetic macular edema. Thus, evidence suggests thatKLKB1 inhibitors can provide a new therapeutic opportunity to reduceretinal vascular permeability (Feener, E. P. 2010, Curr Diab Rep 10,270).

Hereditary Angioedema.

Ecallantide (Kalbitor) is a 60-amino acid recombinant protein that actsas a potent reversible inhibitor of KLKB1 (Schneider L, et al. 2007, JAllergy Clin Immunol, 120, 416) and has been approved by the FDA for thetreatment of acute attacks of hereditary angioedema (HAE). Thus plasmakallikrein inhibition can be a useful treatment for HAE, and there isstrong interest in the development of plasma kallikrein inhibitors as atherapy for HAE.

Skin.

Overexpression of various KLKs in the skin has led to the recognitionthat certain kallikrein inhibitors can be useful for certaindermatological conditions, including atopic dermatitis, psoriasis andrare skin diseases such as Netherton Syndrome (Freitas et al. Bioorganic& Medicinal Chemistry Letters 2012, 22, 6072-6075).

Thrombosis.

Thrombotic diseases are the primary indications for thrombin inhibition,because of thrombin's location in the coagulation cascade and, in turn,the importance of the coagulation cascade in the progression of bloodclotting processes. However, without wishing to be bound by any theory,it is believed the coagulation cascade in general, and thrombin inparticular, is important in a variety other disease states.

It has been discovered that compounds described herein, e.g.,multisubstituted aromatic compounds, exhibit inhibitory action againstthrombin (activated blood-coagulation factor II; EC 3.4.21.5). This, inturn inhibits the blood coagulation process.

This inhibitory action is useful in the treatment of a variety ofthrombotic disorders, such as, but not limited to, acute vasculardiseases such as acute coronary syndromes; venous-, arterial- andcardiogenic thromboembolisms; the prevention of other states such asdisseminated intravascular coagulation, or other conditions that involvethe presence or the potential formation of a blood clot thrombus. Otherindications for methods described herein include the following.

Cancer.

Tissue kallikreins (KLKs) are subdivided into various types, and havebeen extensively investigated in cancer and inflammation biology.Various kallikrein KLKs have been found to be up- or down-regulated invarious cancer types, such as cervical-, testicular-, and non-small-celllung adenocarcinoma (Caliendo et al. J. Med. Chem., 2012, 55, 6669). Ithas been proposed that KLK1 inhibitors will be useful in certaincancers.

It has long been recognized that cancer progression is accompanied byvenous thrombosis, but it has not been understood how each disease isrelated. From several clinical trials studying the treatment of VTE,meta-analyses have shown that low molecular weight heparins (LMWHs)improve overall survival in subgroups of cancer patients. See e.g.,Zacharski, L. R. & Lee, A. Y., 2008, Expert Opin Investig Drugs,17:1029-1037; Falanga, A. & Piccioli, A., 2005, Current Opinion inPulmonary Medicine, 11:403-407; Smorenburg, S. M., et al., 1999, ThrombHaemost, 82:1600-1604; Hettiarachchi, R. J., et al., 1999, ThrombHaemost, 82:947-952. This finding was substantiated in later clinicaltrials that measured specifically the survival of cancer patients. Seee.g., Lee, A. Y. et al., 2005, J Clin Oncol, 23:2123-2129; Klerk, C. P.et al., J Clin Oncol 2005, 23:2130-2135; Kakkar, A. K., et al., 2004, JClin Oncol, 22:1944-1948; Altinbas, M., et al., 2004, J Thromb Haemost,2:1266-1271.

More recently, researchers have focused on the specific anticancereffect of DTIs. For example, it was shown that heparin significantlyprolonged the survival of patients with limited small cell lung cancer.See e.g., Akl, E. A., et al., 2008, J Exp Clin Cancer Res, 27:4. Otherinvestigators found that systemic use of argatroban reduced tumor massand prolonged survival time in rat glioma models leading to theconclusion that argatroban should be considered as a novel therapeuticfor glioma, a notoriously difficult to treat cancer type. See e.g., Hua,Y., et al., 2005, Acta Neurochir, Suppl 2005, 95:403-406; Hua, Y., etal., 2005, J Thromb Haemost, 3:1917-1923. Very recently, it wasdemonstrated that dabigatran etexilate, a DTI recently FDA-approved (seee.g., Hughes, B., 2010, Nat Rev Drug Discov, 9:903-906) for DVTindications, inhibited both the invasion and metastasis of malignantbreast tumors. See e.g., DeFeo, K. et al., 2010, Thrombosis Research,125 (Supplement 2): S188-S188; Defeo, K., et al., 2010, Cancer BiolTher, 10:1001-1008. Thus, dabigatran etexilate treatment led to a 50%reduction in tumor volume at 4 weeks with no weight loss in treatedmice. Dabigatran etexilate also reduced tumor cells in the blood andliver micrometastases by 50-60%. These investigators concluded thatdabigatran etexilate can be beneficial in not only preventing thromboticevents in cancer patients, but also as adjunct therapy to treatmalignant tumors.

Further, hirudin and the LMWH nadroparin dramatically reduced the numberof lung metastases when administered prior to cancer cell inoculation.See e.g., Hu, L., et al., 2004, Blood, 104:2746-51.

The de novo thrombin inhibitor d-Arg-Oic-Pro-d-Ala-Phe(p-Me) has beenfound to block thrombin-stimulated invasion of prostate cancer cell linePC-3 in a concentration dependent manner. See e.g., Nieman, M. T., etal., 2008, J Thromb Haemost, 6:837-845. A reduced rate of tumor growthwas observed in mice dosed with the pentapeptide through their drinkingwater. The mice also showed reduced fold rate in tumor size and reducedoverall tumor weight compared to untreated mice. Microscopic examinationof treated tumors showed reduced number of large blood vessels thusconcluding that the pentapeptide interfered with tumor angiogenesis.Nieman, M. T., et al., Thromb Haemost, 104:1044-8.

In view of these and related studies, it is suggested thatanticoagulants affect tumor metastasis; that is, angiogenesis, cancercell adhesion, migration and invasion processes. See e.g., Van Noorden,C. J., et al., 2010, Thromb Res, 125 Suppl 2:S77-79.

Fibrosis.

Kallikreins are a subgroup of serine proteases, divided into plasmakallikrein (KLKB1) and tissue kallikreins. KLKB1 liberates kinins(bradykinin and kallidin) from the kininogens, peptides responsible forthe regulation of blood pressure and activation of inflammation. In theContact Activation Pathway of the coagulation cascade, KLKB1 assists inthe conversion of factor XII to factor XIIa (Keel, M.; Trentz, O. Injury2005, 36, 691-709). Factor XIIa converts FXI into FXIa, which in turnactivates FIX, which with its co-factor FVIIIa forms the tenase complex,which finally activates FX to FXa. In the fibrinolysis part of thecoagulation cascade, KLKB1 serves to convert plasminogen to plasmin.Thus, it has been proposed that KLKB1 inhibitors can be useful in thetreatment of thrombotic and fibrinolytic diseases and disease conditions(U.S. Pat. No. 7,625,944; Bird et al. Thrombosis and Hemostasis 2012,107, 1141).

Several studies have shown the utility of anticoagulant therapy infibrotic disorders. For example, in a rat model of CCl₄-induced chronicliver injury, the DTI SSR182289 decreased liver fibrogenesissignificantly after 7 weeks of administration. Similar observations weremade in other studies using the LMWHs nadroparin, tinzaparin,enoxaparin, and dalteparin sodium. See e.g., Duplantier, J. G., et al.,2004, Gut, 53:1682-1687; Abdel-Salam, O. M., et al., 2005, PharmacolRes, 51:59-67; Assy, N., et al., 2007, Dig Dis Sci, 52:1187-1193; Abe,W., et al., 2007, J Hepatol, 46:286-294. Thus a thrombin inhibitor as ananticoagulant can be useful in the treatment of fibrinolytic diseases.

In another example, the DTI melagatran greatly reduced ischemiareperfusion injury in a kidney transplant model in the large white pig.This led to a drastically improved kidney graft survival at 3 months.See e.g., Favreau, F., et al., 2010, Am J Transplant, 10:30-39.

Recent studies have shown that in a bleomycin-induced mouse model ofpulmonary fibrosis, dabigatran etexilate treatment reduced importantprofibrotic events in lung fibroblasts, including the production ofcollagen and connective tissue growth factor. See e.g., Silver, R. M.,et al., 2010, Am. J. Respir. Crit. Care Med., 181:A6780; Bogatkevich, G.S., et al., 2009, Arthritis Rheum, 60:3455-3464.

The above experimental evidence points to a close relationship betweenthrombin and fibrosis and suggests novel therapeutic opportunities forfibrosis using thrombin inhibitors. See e.g., Calvaruso, V., et al.,2008, Gut, 57:1722-1727; Chambers, R. C., 2008, Br J Pharmacol, 153Suppl 1:S367-378; Chambers, R. C. & Laurent, G. J., 2002, Biochem SocTrans, 30:194-200; Howell, D. C., et al., 2001, Am J Pathol,159:1383-1395.

Inflammation.

Kallikrein has long been implicated in inflammation (Clements, J. A. TheMolecular Biology of the Kallikreins and Their Roles in Inflammation,Academic Press: San Diego, Calif., 1997; Vol. 5). There is experimentalevidence that KLKB1 is associated with sepsis and inflammatory arthritis(Colman, R. W., 1998, Clinical Reviews in Allergy and Immunology, 16:365). Thus a KLKB1 inhibitor can be useful in the treatment ofinflammatory conditions associated with the kallikrein-kinin system,such as systemic inflammatory response syndrome, sepsis, rheumatoidarthritis, and inflammatory bowel disease.

Age-Related Macular Degeneration.

KLK1 has been linked to blood vessel growth moderated by the VEGFpathway (Miura S., 2003, Hypertension, 41, 1118). Age-related maculardegeneration (AMD) is associated with the proliferation of abnormalblood vessels and VEGF expression (Lopez, P. F., 1996, InvestigativeOphthalmology & Visual Science, 37, 855). Thus, KLK1 inhibitors havebeen proposed for the treatment of AMD (US Patent #20120264798; Ferrara,N., 2000, Current Opinion in Biotechnology, 11, 617).

Alzheimer's Disease.

Very recent experiments confirm higher thrombin levels in brainendothelial cells of patients with Alzheimer's disease. While ‘normal’thrombin levels are connected to regulatory CNS functions, thrombinaccumulation in the brain is toxic. It has also been found that theneural thrombin inhibitor Protease Nexin 1 (PN-1) is significantlyreduced in the Alzheimer's disease brain, despite the fact that PN-1mRNA levels are unchanged. These observations have led someinvestigators to suggest that reduction of CNS-resident thrombin willprove useful in Alzheimer's Disease (AD) treatment. See e.g., Vaughan,P. J., et al., 1994, Brain Res, 668:160-170; Yin, X., et al., 2010, Am JPathol, 176:1600-1606; Akiyama, H., et al., 1992, Neurosci Lett,146:152-154.

Multiple Sclerosis.

Investigators found that hirudin treatment in an animal model ofMultiple Sclerosis (MS) showed a dramatic improvement in diseaseseverity. See e.g., Han, M. H., et al., 2008, Nature, 451:1076-1081.Similar results were obtained following treatment with heparin (a DTI)and dermatan sulfate, another coagulation inhibitor. See e.g.,Chelmicka-Szorc, E. & Amason, B. G., 1972, Arch Neurol, 27:153-158;Inaba, Y., et al., 1999, Cell Immunol, 198:96-102. Other evidence showsthat naturally occurring antithrombin III has anti-inflammatory effectsin diseases such as endotoxemia and other sepsis-related conditions. Seee.g., Wiedermann, C. J. & Romisch, J., 2002, Acta Med Austriaca,29:89-92. Naturally occurring thrombin inhibitors are presumablysynthesized in situ and have protective roles in CNS inflammation.Therefore, therapeutic thrombin inhibition has been proposed as apotential MS treatment. See e.g., Luo, W., et al., 2009, In: THROMBIN,Maragoudakis, M. E.; Tsopanoglou, N. E., Eds. Springer New York: 2009;pp 133-159.

Pain.

In a rat pain model with partial lesion of the sciatic nerve,intrathecal hirudin prevented the development of neuropathic pain andcurbed pain responses for 7 days. The investigators found that followinginjury, neuropathic pain was mediated by thrombin generation, which inturn activated PAR-1 receptor in the spinal cord. Hirudin inhibitedthrombin generation and ultimately led to pain relief. See e.g., Garcia,P. S., et al., 2010, Thromb Haemost, 103:1145-1151; Narita, M., et al.,2005, J Neurosci, 25:10000-10009. Researchers hypothesize that thrombinand the PARs are involved not just as part of the coagulation cascade,but in inflammation, nociception and neurodevelopment. Development of aDTI to intersect an unexploited pharmacology will lead to paintherapeutics distinct from opioids and NSAIDs, whose shortcomings arewell documented. See e.g., Garcia 2010, Id.

Accordingly, in a further aspect, there is provided a method fortreating a disease or disorder in a subject in need thereof. The methodincludes administering a compound of any of Formulae (Ia), (Ib), (IIa),(IIb), (IIc), (III), (IV), (V), (VI) or (VII) as disclosed herein, acompound as set forth in Table A, B, C, or D, pharmaceuticallyacceptable salt, ester, solvate, or prodrug thereof, or pharmaceuticalcomposition thereof, to a subject in need thereof in an amount effectiveto treat the disease or disorder. The terms “therapeutically effectiveamount,” “amount effective to treat,” “amount effective to prevent” andthe like refer to that amount of drug or pharmaceutical agent (e.g.,compound or pharmaceutical composition disclosed herein) that willelicit the biological or medical response of a tissue, system, animal,or human that is being sought by a researcher, veterinarian, medicaldoctor or other clinician.

Compounds useful for methods disclosed herein include the compounds setforth for Formulae (Ia), (Ib), (IIa), (IIb), (IIc), (III), (IV), (V),(VI) or (VII) and for the compounds set forth in Table A, B, C, or Dabove.

In some embodiments, the diseases or disorders are fibrinolyticdiseases. In some embodiments the disease is a fibrotic disorder. Insome embodiments, the disease is cancer. In some embodiments, thediseases are inflammatory diseases. In some embodiments the disease issepsis. In some embodiments the disease is inflammatory arthritis. Insome embodiments, the disease is diabetic macular edema. In someembodiments, the disease is hereditary angioedema. In some embodiments,the disease is diabetic retinopathy. In some embodiments, the disease isage-related macular degeneration. In some embodiments, the diseases arevarious skin diseases which include but are not limited to atopicdermatitis, psoriasis and rare skin diseases such as Netherton Syndrome.In some embodiments, the diseases or disorder is Alzheimer's disease. Insome embodiments, the disease is multiple sclerosis. In someembodiments, the disease is pain.

In some embodiments, the disease or disorder is cancer. In someembodiments, the cancer is limited small cell lung cancer. In someembodiments, the cancer is a glioma. In some embodiments, the cancer ismalignant breast cancer. In some embodiments, the cancer is amicrometastasis. In some embodiments, the micrometastasis is of theblood or liver. In some embodiments, the cancer is a lung metastasis. Insome embodiments, the cancer is prostatic cancer.

In another aspect, there is provided a method for preventing a diseaseor disorder in a subject. The method includes administering a compoundof any of Formulae (Ia), (Ib), (IIa), (IIb), (IIc), (III), (IV), (V),(VI) or (VII) as disclosed herein, compound as set forth in any of TableA, B, C, or D herein, pharmaceutically acceptable salt, ester, solvate,or prodrug thereof, or pharmaceutical composition thereof, to a subjectin need thereof in an amount effective to prevent the disease ordisorder.

V. Assays

Compounds described herein can be assayed, by a variety of methods knownin the art and described herein, for inhibition of biological activity,e.g., protease activity, of a variety of proteins, e.g., thrombin, KLKB1and KLK1.

The KLKB1 kallikrein activity reported herein (e.g., Tables B, C, and D)was obtained as follows. Human KLKB1 protein was obtained from EnzymeResearch Labs. The chromogenic substrate S-2302 was obtained fromDiaPharma. KLKB1 was assayed in buffer containing 0.05 M Tris (pH 7.4),0.01 M NaCl and 0.2% w/v PEG-8000. The final concentration of enzymeused was 3 nM KLKB1. The final concentration of substrate used was 250μM S-2302 for KLKB1. All assays were performed in 96-well microtiterplates at room temperature (RT). The enzyme and inhibitor werepre-incubated for 10 minutes then substrate was added and read at 405 nmin a SpectraMax Plus Spectrophotometer (Molecular Devices). InhibitorIC₅₀ values were determined by adding test compound as ten point,three-fold serial dilutions in buffer solution, as known in the art. Theplate was read at 10 minutes after substrate addition. The IC₅₀ wascalculated by plotting the percent (%) inhibition against compoundconcentration and fitting the data to a constrained four parametersigmoidal curve, as known in the art.

The KLK1 kallikrein activity reported herein (e.g., Tables B and C) wasobtained as follows. Recombinant human tissue kallikrein (KLK1) wasobtained from R&D Systems. Pro-Phe-Arg-AMC (1-1295) substrate wasobtained from Bachem. KLK1 enzyme is activated by incubating 0.5 mg/mlKLK1 combined with 0.1 μg/ml thermolysin in a buffer of 0.05 M Tres (pH7.5), 0.15 M NaCl, and 0.01 M CaCl₂ for one hour at 37° C. Thethermolysin is then deactivated by the addition of equal parts 20 mM 1,10 phenanthroline solution in water. The activated KLK1 solution is thenadded to CHES buffer (0.05 M CHES, 0.15 M NaCl, 0.01 M CaCl₂, pH 10) fora final concentration of 5 nM along with the test article and incubatedfor 10 minutes. Substrate is then added at a concentration of 2.75 μM.Substrate activation is read 10 minutes after substrate addition using aSynergy H1 multifunction plate reader (Biotek) programmed with a 360 nmexcitation wavelength and a 480 nm emission wavelength. Inhibitorresponse was established by adding test compound as ten point,three-fold serial dilutions, as known in the art. The IC₅₀ wascalculated by plotting the percent (%) inhibition against compoundconcentration and fitting the data to a constrained four parametersigmoidal curve, as known in the art.

The thrombin activity reported herein (e.g., Table A) was obtained asfollows. Human thrombin was obtained from Haematologic Technologies Inc.The chromogenic substrate S-2238 was obtained from DiaPharma. Thrombinwas assayed in buffer containing 0.05 M Tris (pH 7.4), 0.015 M NaCl and0.01% PEG-8000. The final concentration of enzyme used was 3 nMthrombin. The final concentration of substrate used was 125 μM S-2238for thrombin. All assays were performed in 96-well microtiter plates atroom temperature (RT). The enzyme and inhibitor were pre-incubated for10 minutes then substrate was added and read at 405 nm in a SpectraMaxPlus Spectrophotometer (Molecular Devices). Inhibitor IC₅₀ values weredetermined by adding test compound as ten point, three-fold serialdilutions in buffer solution, as known in the art. The plate was read at10 minutes after substrate addition. The IC₅₀ was calculated by plottingthe percent (%) inhibition against compound concentration and fittingthe data to a constrained four parameter sigmoidal curve, as known inthe art.

VI. Pharmaceutical Compositions

In another aspect, there is provided a pharmaceutical compositioncomprising a compound disclosed herein and a pharmaceutically acceptableexcipient. The compound is a compound of any of Formulae (Ia), (Ib),(IIa), (IIb), (IIc), (III), (IV), (V), (VI) or (VII) as disclosedherein, a compound as set forth in Table A, B, C, or D herein, orpharmaceutically acceptable salt, ester, solvate, or prodrug thereof. Insome embodiments, the compound is set forth in Table A, B, C, or Dherein.

The term “pharmaceutically acceptable salts” is meant to include saltsof the active compounds that are prepared with relatively nontoxic acidsor bases, depending on the particular substituents found on thecompounds described herein. When compounds disclosed herein containrelatively acidic functionalities, base addition salts can be obtainedby contacting the neutral form of such compounds with a sufficientamount of the desired base, either neat or in a suitable inert solvent.Examples of pharmaceutically acceptable base addition salts includesodium, potassium, calcium, ammonium, organic amino, or magnesium salt,or a similar salt. When compounds disclosed herein contain relativelybasic functionalities, acid addition salts can be obtained by contactingthe neutral form of such compounds with a sufficient amount of thedesired acid, either neat or in a suitable inert solvent. Examples ofpharmaceutically acceptable acid addition salts include those derivedfrom inorganic acids like hydrochloric, hydrobromic, nitric, carbonic,monohydrogencarbonic, phosphoric, monohydrogenphosphoric,dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, orphosphorous acids and the like, as well as the salts derived fromrelatively nontoxic organic acids like acetic, propionic, isobutyric,maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic,phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, oxalic,methanesulfonic, and the like. Also included are salts of amino acidssuch as arginate and the like, and salts of organic acids likeglucuronic or galacturonic acids and the like (see, for example, Bergeet al., “Pharmaceutical Salts”, Journal of Pharmaceutical Science, 1977,66, 1-19). Certain specific compounds disclosed herein contain bothbasic and acidic functionalities that allow the compounds to beconverted into either base or acid addition salts.

Compounds disclosed herein can exist as salts, such as withpharmaceutically acceptable acids. Accordingly, the compoundscontemplated herein include such salts. Examples of such salts includehydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates,maleates, acetates, citrates, fumarates, tartrates (e.g., (+)-tartrates,(−)-tartrates, or mixtures thereof including racemic mixtures),succinates, benzoates, and salts with amino acids such as glutamic acid.These salts can be prepared by methods known to those skilled in theart.

The neutral forms of the compounds are preferably regenerated bycontacting the salt with a base or acid and isolating the parentcompound in the conventional manner. The parent form of the compounddiffers from the various salt forms in certain physical properties, suchas solubility in polar solvents.

Pharmaceutically acceptable salts of the compounds above, where a basicor acidic group is present in the structure, are also included withinthe scope of compounds contemplated herein. When an acidic substituentis present, such as —NHSO₃H, —COOH and —P(O)(OH)₂, there can be formedthe ammonium, sodium, potassium, calcium salt, and the like, for use asthe dosage form. Basic groups, such as amino or basic heteroarylradicals, or pyridyl and acidic salts, such as hydrochloride,hydrobromide, acetate, maleate, palmoate, methanesulfonate,p-toluenesulfonate, and the like, can be used as the dosage form.

Also, in the embodiments in which R—COOH is present, pharmaceuticallyacceptable esters can be employed, e.g., methyl, ethyl, tert-butyl,pivaloyloxymethyl, and the like, and those esters known in the art formodifying solubility or hydrolysis characteristics for use as sustainedrelease or prodrug formulations.

A. Formulations

The compounds disclosed herein can be prepared and administered in awide variety of ophthalmic, oral, parenteral, and topical dosage forms.The compounds described herein can be administered by eye drop. Also,compounds described herein can be administered by injection (e.g.intravenously, intramuscularly, intravitreally, intracutaneously,subcutaneously, intraduodenally, or intraperitoneally). As such,compounds described herein can also be administered by intravitrealinjection. Also, the compounds described herein can be administered byinhalation, for example, intranasally. Additionally, the compoundsdisclosed herein can be administered transdermally. It is alsoenvisioned that multiple routes of administration (e.g., intramuscular,oral, ocular) can be used to administer the compounds disclosed herein.

In some embodiments, the compounds disclosed herein can be prepared inliquid pharmaceutical compositions for ocular administration. Thecomposition for ocular use can contain one or more agents selected fromthe group of buffering agents, solubilizing agents, coloring agents,viscosity enhancing agents, and preservation agents in order to producepharmaceutically elegant and convenient preparations.

In some embodiments, the composition for ocular use can containpreservatives for protection against microbiological contamination,including but not limited to benzalkodium chloride and/or EDTA. Otherpossible preservatives include but are not limited to benzyl alcohol,methyl parabens, propyl parabens, and chlorobutanol. Preferably, apreservative, or combination of preservatives, will be employed toimpart microbiological protection in addition to protection againstoxidation of components.

In some embodiments, the compounds disclosed herein can be administeredorally as tablets, aqueous or oily suspensions, lozenges, troches,powders, granules, emulsions, capsules, syrups or elixirs. Thecomposition for oral use can contain one or more agents selected fromthe group of sweetening agents, flavoring agents, coloring agents andpreserving agents in order to produce pharmaceutically elegant andpalatable preparations. Accordingly, there are also providedpharmaceutical compositions comprising a pharmaceutically acceptablecarrier or excipient and one or more compounds disclosed herein.

In some embodiments, tablets contain the acting ingredient in admixturewith non-toxic pharmaceutically acceptable excipients that are suitablefor the manufacture of tablets. These excipients can be, for example,(1) inert diluents, such as calcium carbonate, lactose, calciumphosphate, carboxymethylcellulose, or sodium phosphate; (2) granulatingand disintegrating agents, such as corn starch or alginic acid; (3)binding agents, such as starch, gelatin or acacia; and (4) lubricatingagents, such as magnesium stearate, stearic acid or talc. These tabletscan be uncoated or coated by known techniques to delay disintegrationand absorption in the gastrointestinal tract and thereby provide asustained action over a longer period. For example, a time delaymaterial such as glyceryl monostearate or glyceryl distearate can beemployed.

For preparing pharmaceutical compositions from the compounds disclosedherein, pharmaceutically acceptable carriers can be either solid orliquid. Solid form preparations include powders, tablets, pills,capsules, cachets, suppositories, and dispersible granules. A solidcarrier can be one or more substance that can also act as diluents,flavoring agents, binders, preservatives, tablet disintegrating agents,or an encapsulating material.

A compound disclosed herein, in the form of a free compound or apharmaceutically-acceptable pro-drug, metabolite, analogue, derivative,solvate or salt, can be administered, for in vivo application,parenterally by injection or by gradual perfusion over time.Administration can be intravenously, intraperitoneally, intramuscularly,subcutaneously, intracavity, or transdermally. For in vitro studies thecompounds can be added or dissolved in an appropriate biologicallyacceptable buffer and added to a cell or tissue.

In powders, the carrier is a finely divided solid in a mixture with thefinely divided active component. In tablets, the active component ismixed with the carrier having the necessary binding properties insuitable proportions and compacted in the shape and size desired.

The powders and tablets preferably contain from 5% to 70% of the activecompound. Suitable carriers are magnesium carbonate, magnesium stearate,talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth,methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoabutter, and the like. The term “preparation” is intended to include theformulation of the active compound with encapsulating material as acarrier providing a capsule in which the active component with orwithout other carriers, is surrounded by a carrier, which is thus inassociation with it. Similarly, cachets and lozenges are included.Tablets, powders, capsules, pills, cachets, and lozenges can be used assolid dosage forms suitable for oral administration.

For preparing suppositories, a low melting wax, such as a mixture offatty acid glycerides or cocoa butter, is first melted and the activecomponent is dispersed homogeneously therein, as by stirring. The moltenhomogeneous mixture is then poured into convenient sized molds, allowedto cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, and emulsions,for example, water or water/propylene glycol solutions. For parenteralinjection, liquid preparations can be formulated in solution in aqueouspolyethylene glycol solution.

When parenteral application is needed or desired, particularly suitableadmixtures for the compounds disclosed herein are injectable, sterilesolutions, preferably oily or aqueous solutions, as well as suspensions,emulsions, or implants, including suppositories. In particular, carriersfor parenteral administration include aqueous solutions of dextrose,saline, pure water, ethanol, glycerol, propylene glycol, peanut oil,sesame oil, polyoxyethylene-block polymers, and the like. Ampoules areconvenient unit dosages. The compounds disclosed herein can also beincorporated into liposomes or administered via transdermal pumps orpatches. Pharmaceutical admixtures suitable for use in thepharmaceuticals compositions and methods disclosed herein include thosedescribed, for example, in PHARMACEUTICAL SCIENCES (17th Ed., Mack Pub.Co., Easton, Pa.) and WO 96/05309, the teachings of both of which arehereby incorporated by reference.

In some embodiments, preparations for parenteral administration includesterile aqueous or non-aqueous solutions, suspensions, and emulsions.Examples of non-aqueous solvents are propylene glycol, polyethyleneglycol, vegetable oils such as olive oil, and injectable organic esterssuch as ethyl oleate. Aqueous carriers include water, alcoholic/aqueoussolutions, emulsions or suspensions, including saline and bufferedmedia. Parenteral vehicles include sodium chloride solution, Ringer'sdextrose, dextrose and sodium chloride, lactated Ringer's intravenousvehicles include fluid and nutrient replenishers, electrolytereplenishers (such as those based on Ringer's dextrose), and the like.Preservatives and other additives can also be present such as, forexample, antimicrobials, anti-oxidants, chelating agents, growth factorsand inert gases and the like.

Aqueous solutions suitable for oral use can be prepared by dissolvingthe active component in water and adding suitable colorants, flavors,stabilizers, and thickening agents as desired. Aqueous suspensionssuitable for oral use can be made by dispersing the finely dividedactive component in water with viscous material, such as natural orsynthetic gums, resins, methylcellulose, sodium carboxymethylcellulose,and other well-known suspending agents.

Also included are solid form preparations that are intended to beconverted, shortly before use, to liquid form preparations for oraladministration. Such liquid forms include solutions, suspensions, andemulsions. These preparations can contain, in addition to the activecomponent, colorants, flavors, stabilizers, buffers, artificial andnatural sweeteners, dispersants, thickeners, solubilizing agents, andthe like.

The pharmaceutical preparation is preferably in unit dosage form. Insuch form the preparation is subdivided into unit doses containingappropriate quantities of the active component. The unit dosage form canbe a packaged preparation, the package containing discrete quantities ofpreparation, such as packeted tablets, capsules, and powders in vials orampoules. Also, the unit dosage form can be a capsule, tablet, cachet,or lozenge itself, or it can be the appropriate number of any of thesein packaged form.

The quantity of active component in a unit dose preparation can bevaried or adjusted from 0.1 mg to 10000 mg, more typically 1.0 mg to1000 mg, most typically 10 mg to 500 mg, according to the particularapplication and the potency of the active component. The compositioncan, if desired, also contain other compatible therapeutic agents.

Some compounds can have limited solubility in water and therefore canrequire a surfactant or other appropriate co-solvent in the composition.Such co-solvents include: Polysorbate 20, 60, and 80; Pluronic F-68,F-84, and P-103; cyclodextrin; and polyoxyl 35 castor oil. Suchco-solvents are typically employed at a level between about 0.01% andabout 2% by weight.

Viscosity greater than that of simple aqueous solutions can be desirableto decrease variability in dispensing the formulations, to decreasephysical separation of components of a suspension or emulsion offormulation, and/or otherwise to improve the formulation. Such viscositybuilding agents include, for example, polyvinyl alcohol, polyvinylpyrrolidone, methyl cellulose, hydroxy propyl methylcellulose,hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propylcellulose, chondroitin sulfate and salts thereof, hyaluronic acid andsalts thereof, and combinations of the foregoing. Such agents aretypically employed at a level between about 0.01% and about 2% byweight.

The compositions disclosed herein can additionally include components toprovide sustained release and/or comfort. Such components include highmolecular weight, anionic mucomimetic polymers, gelling polysaccharides,and finely-divided drug carrier substrates. These components arediscussed in greater detail in U.S. Pat. Nos. 4,911,920; 5,403,841;5,212,162; and 4,861,760. The entire contents of these patents areincorporated herein by reference in their entirety for all purposes.

By the present, there are provided methods for ameliorating woundhealing and for mediating tissue repair (including but not limited totreatment of peripheral and coronary vascular disease). According tothese methods, a subject having a wound or in need of tissue repair, istreated at the site of the wound or damaged tissue or treatedsystemically, with a compound disclosed herein in the form of a freecompound or a pharmaceutically-acceptable prodrug, metabolite, analogue,derivative, solvate or salt.

Generally, the terms “treating”, “treatment” and the like are usedherein to mean affecting a subject, tissue or cell to obtain a desiredpharmacologic and/or physiologic effect. The effect can be prophylacticin terms of completely or partially preventing a disease or disorder orsign or symptom thereof, and/or can be therapeutic in terms of a partialor complete cure for a disorder and/or adverse effect attributable toit. “Treating” as used herein covers any treatment of, or prevention ofa disease or disorder in a vertebrate, a mammal, particularly a human,and includes: (a) preventing the disease or disorder from occurring in asubject that can be predisposed to the disease or disorder, but has notyet been diagnosed as having it; (b) inhibiting the disease or disorder,i.e., arresting its development; or (c) relieving or ameliorating thedisease or disorder, i.e., cause regression of the disease or disorder.

There are provided various pharmaceutical compositions useful forameliorating certain diseases and disorders. The pharmaceuticalcompositions according to one embodiment are prepared by formulating acompound disclosed herein in the form of a free compound or apharmaceutically-acceptable pro-drug, metabolite, analogue, derivative,solvate or salt, either alone or together with other pharmaceuticalagents, suitable for administration to a subject using carriers,excipients and additives or auxiliaries. Frequently used carriers orauxiliaries include magnesium carbonate, titanium dioxide, lactose,mannitol and other sugars, talc, milk protein, gelatin, starch,vitamins, cellulose and its derivatives, animal and vegetable oils,polyethylene glycols and solvents, such as sterile water, alcohols,glycerol and polyhydric alcohols. Intravenous vehicles include fluid andnutrient replenishers.

Preservatives include antimicrobial, anti-oxidants, chelating agents andinert gases. Other pharmaceutically acceptable carriers include aqueoussolutions, non-toxic excipients, including salts, preservatives, buffersand the like, as described, for instance, in Remington's PharmaceuticalSciences, 15th ed. Easton: Mack Publishing Co., 1405-1412, 1461-1487(1975) and The National Formulary XIV., 14th ed. Washington: AmericanPharmaceutical Association (1975), the contents of which are herebyincorporated by reference. The pH and exact concentration of the variouscomponents of the pharmaceutical composition are adjusted according toroutine skills in the art. See e.g., Goodman and Gilman (eds.), 1990,THE PHARMACOLOGICAL BASIS FOR THERAPEUTICS (7th ed.).

The pharmaceutical compositions are preferably prepared and administeredin dose units. Solid dose units are tablets, capsules and suppositories.For treatment of a subject, depending on activity of the compound,manner of administration, nature and severity of the disease ordisorder, age and body weight of the subject, different daily doses canbe used.

Under certain circumstances, however, higher or lower daily doses can beappropriate. The administration of the daily dose can be carried outboth by single administration in the form of an individual dose unit orelse several smaller dose units and also by multiple administrations ofsubdivided doses at specific intervals.

The pharmaceutical compositions contemplated herein can be administeredlocally or systemically in a therapeutically effective dose. Amountseffective for this use will, of course, depend on the severity of thedisease or disorder and the weight and general state of the subject.Typically, dosages used in vitro can provide useful guidance in theamounts useful for in situ administration of the pharmaceuticalcomposition, and animal models can be used to determine effectivedosages for treatment of particular disorders.

Various considerations are described, e.g., in Langer, 1990, Science,249: 1527; Goodman and Gilman's (eds.), 1990, Id., each of which isherein incorporated by reference and for all purposes. Dosages forparenteral administration of active pharmaceutical agents can beconverted into corresponding dosages for oral administration bymultiplying parenteral dosages by appropriate conversion factors. As togeneral applications, the parenteral dosage in mg/mL times 1.8=thecorresponding oral dosage in milligrams (“mg”). As to oncologyapplications, the parenteral dosage in mg/mL times 1.6=the correspondingoral dosage in mg. An average adult weighs about 70 kg. See e.g.,Miller-Keane, 1992, ENCYCLOPEDIA & DICTIONARY OF MEDICINE, NURSING &ALLIED HEALTH, 5th Ed., (W. B. Saunders Co.), pp. 1708 and 1651.

The method by which the compound disclosed herein can be administeredfor oral use would be, for example, in a hard gelatin capsule whereinthe active ingredient is mixed with an inert solid diluent, or softgelatin capsule, wherein the active ingredient is mixed with aco-solvent mixture, such as PEG 400 containing Tween-20. A compounddisclosed herein can also be administered in the form of a sterileinjectable aqueous or oleaginous solution or suspension. The compoundcan generally be administered intravenously or as an oral dose of 0.1 μgto 20 mg/kg given, for example, every 3-12 hours.

Formulations for oral use can be in the form of hard gelatin capsuleswherein the active ingredient is mixed with an inert solid diluent, forexample, calcium carbonate, calcium phosphate or kaolin. They can alsobe in the form of soft gelatin capsules wherein the active ingredient ismixed with water or an oil medium, such as peanut oil, liquid paraffinor olive oil.

Aqueous suspensions normally contain the active materials in admixturewith excipients suitable for the manufacture of aqueous suspension. Suchexcipients can be (1) suspending agent such as sodium carboxymethylcellulose, methyl cellulose, hydroxypropylmethylcellulose, sodiumalginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; (2)dispersing or wetting agents which can be (a) naturally occurringphosphatide such as lecithin; (b) a condensation product of an alkyleneoxide with a fatty acid, for example, polyoxyethylene stearate; (c) acondensation product of ethylene oxide with a long chain aliphaticalcohol, for example, heptadecaethylenoxycetanol; (d) a condensationproduct of ethylene oxide with a partial ester derived from a fatty acidand hexitol such as polyoxyethylene sorbitol monooleate, or (e) acondensation product of ethylene oxide with a partial ester derived fromfatty acids and hexitol anhydrides, for example polyoxyethylene sorbitanmonooleate.

The pharmaceutical compositions can be in the form of a sterileinjectable aqueous or oleagenous suspension. This suspension can beformulated according to known methods using those suitable dispersing orwetting agents and suspending agents that have been mentioned above. Thesterile injectable preparation can also a sterile injectable solution orsuspension in a non-toxic parenterally-acceptable diluent or solvent,for example, as a solution in 1,3-butanediol. Among the acceptablevehicles and solvents that can be employed are water, Ringer's solution,and isotonic sodium chloride solution. In addition, sterile, fixed oilsare conventionally employed as a solvent or suspending medium. For thispurpose, any bland fixed oil can be employed including synthetic mono-or diglycerides. In addition, fatty acids such as oleic acid find use inthe preparation of injectables.

A compound disclosed herein can also be administered in the form ofophthalmic compositions applied topically to the eye, preferably in theform of eye drops. A compound disclosed herein can also be administeredin the form of intravitreal injection.

A compound disclosed herein can also be administered in the form ofsuppositories for rectal administration of the drug. These compositionscan be prepared by mixing the drug with a suitable non-irritatingexcipient that is solid at ordinary temperature but liquid at the rectaltemperature and will therefore melt in the rectum to release the drug.Such materials include cocoa butter and polyethylene glycols.

The compounds disclosed herein as used in the methods disclosed hereincan also be administered in the form of liposome delivery systems, suchas small unilamellar vesicles, large unilamellar vesicles, andmultilamellar vesicles. Liposomes can be formed from a variety ofphospholipids, such as cholesterol, stearylamine, orphosphatidylcholines.

For topical use, creams, ointments, jellies, solutions or suspensions,etc., containing the compounds disclosed herein, are employed.

In addition, some of the compounds disclosed herein can form solvateswith water or common organic solvents. Such solvates are encompassedwithin the scope of the methods contemplated herein.

B. Effective Dosages

Pharmaceutical compositions provided herein include compositions whereinthe active ingredient is contained in a therapeutically effectiveamount, i.e., in an amount effective to achieve its intended purpose.The actual amount effective for a particular application will depend,inter alia, on the condition being treated.

The dosage and frequency (single or multiple doses) of compoundadministered can vary depending upon a variety of factors, includingroute of administration; size, age, sex, health, body weight, body massindex, and diet of the recipient; nature and extent of symptoms of thedisease being treated (e.g., the disease responsive to inhibition ofthrombin, KLK1, and/or KLKB1); presence of other diseases or otherhealth-related problems; kind of concurrent treatment; and complicationsfrom any disease or treatment regimen. Other therapeutic regimens oragents can be used in conjunction with the methods and compoundsdisclosed herein.

For any compound described herein, the therapeutically effective amountcan be initially determined from a variety of techniques known in theart, e.g., biochemical characterization of inhibition of enzyme(thrombin, KLK1, or KLKB1), cell culture assays, and the like. Targetconcentrations will be those concentrations of active compound(s) thatare capable of decreasing enzymatic activity as measured, for example,using the methods described.

Therapeutically effective amounts for use in humans can be determinedfrom animal models. For example, a dose for humans can be formulated toachieve a concentration that has been found to be effective in animals.The dosage in humans can be adjusted by monitoring enzymatic inhibitionand adjusting the dosage upwards or downwards, as described above.

Dosages can be varied depending upon the requirements of the patient andthe compound being employed. The dose administered to a patient, in thecontext of the methods disclosed herein, should be sufficient to affecta beneficial therapeutic response in the patient over time. The size ofthe dose also will be determined by the existence, nature, and extent ofany adverse side effects. Generally, treatment is initiated with smallerdosages, which are less than the optimum dose of the compound.Thereafter, the dosage is increased by small increments until theoptimum effect under circumstances is reached. In some embodiments of amethod disclosed herein, the dosage range is 0.001% to 10% w/v. In someembodiments, the dosage range is 0.1% to 5% w/v.

Dosage amounts and intervals can be adjusted individually to providelevels of the administered compound effective for the particularclinical indication being treated. This will provide a therapeuticregimen that is commensurate with the severity of the individual'sdisease state.

Utilizing the teachings provided herein, an effective prophylactic ortherapeutic treatment regimen can be planned that does not causesubstantial toxicity and yet is entirely effective to treat the clinicalsymptoms demonstrated by the particular patient. This planning shouldinvolve the careful choice of active compound by considering factorssuch as compound potency, relative bioavailability, patient body weight,presence and severity of adverse side effects, preferred mode ofadministration, and the toxicity profile of the selected agent.

Accordingly, in some embodiments, dosage levels of the compoundsdisclosed herein as used in the present methods are of the order ofe.g., about 0.1 mg to about 1 mg, about 1 mg to about 10 mg, about 0.5mg to about 20 mg per kilogram body weight, an average adult weighing 70kilograms, with a preferred dosage range between about 0.1 mg to about20 mg per kilogram body weight per day (from about 7.0 mg to about 1.4gm per patient per day). The amount of the compound disclosed hereinthat can be combined with the carrier materials to produce a singledosage will vary depending upon the host treated and the particular modeof administration. For example, a formulation intended for oraladministration to humans can contain about 5 μg to 1 g of a compounddisclosed herein with an appropriate and convenient amount of carriermaterial that can vary from about 5 to 95 percent of the totalcomposition. Dosage unit forms will generally contain between from about0.1 mg to 500 mg of a compound disclosed herein.

It will be understood, however, that the specific dose level for anyparticular patient will depend upon a variety of factors including theactivity of the specific compound employed, the age, body weight,general health, sex, diet, time of administration, route ofadministration, rate of excretion, drug combination and the severity ofthe particular disease undergoing therapy.

C. Toxicity

The ratio between toxicity and therapeutic effect for a particularcompound is its therapeutic index and can be expressed as the ratiobetween LD₅₀ (the amount of compound lethal in 50% of the population)and ED₅₀ (the amount of compound effective in 50% of the population).Compounds that exhibit high therapeutic indices are preferred.Therapeutic index data obtained from in vitro assays, cell cultureassays and/or animal studies can be used in formulating a range ofdosages for use in humans. The dosage of such compounds preferably lieswithin a range of plasma concentrations that include the ED₅₀ withlittle or no toxicity. The dosage can vary within this range dependingupon the dosage form employed and the route of administration utilized.See, e.g. Fingl et al., In: THE PHARMACOLOGICAL BASIS OF THERAPEUTICS,Ch. 1, p. 1, 1975. The exact formulation, route of administration, anddosage can be chosen by the individual practitioner in view of thepatient's condition and the particular method in which the compound isused. For in vitro formulations, the exact formulation and dosage can bechosen by the individual practitioner in view of the patient's conditionand the particular method in which the compound is used.

VII. Examples

The examples below are meant to illustrate certain embodiments of theinvention and not to limit the scope of the invention. Abbreviationsused herein have their conventional meaning in the art, unless indicatedotherwise. Specific abbreviations include the following: Å=Ångström;Ac₂O=acetic anhydride; AcOH=acetic acid; aq=aqueous; Bt=benzotriazole;BOC=N-tert-butoxycarbonyl; br=broad; t-BuOH=tert-butanol; ° C.=degreeCelsius; d=doublet; DABCO=1,4-diazabicyclo[2.2.2]octane;DCE=1,2-dichloroethane; DCM=dichloromethane; dd=doublet of doublets;DIEA=diethylisopropylamine; DMAP=4-dimethylaminopyridine;DMF=N,N-dimethylformamide; DMSO=dimethylsulfoxide; δ=chemical shift(given in ppm, unless otherwise indicated);EDCI=1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; eq=equivalent;Et₂O=diethyl ether; Et₃N=triethylamine; EtOAc=ethyl acetate;EtOH=ethanol; g=gram; h (or hr)=hour; HOBt=hydroxybenzotriazole;HPLC=high performance liquid chromatography; Hz=Hertz; IC₅₀=inhibitoryconcentration at 50% inhibition; J=coupling constant (given in Hz,unless otherwise indicated); LC=liquid chromatography; LHMDS=lithiumhexamethyldisilazide; m=multiplet; M=molar; [M+H]⁺=parent mass spectrumpeak plus H+; MS=mass spectrum; ms=molecular sieves; MP=melting point;Me₂NH=dimethylamine; MeOH=methanol; mg=milligram; mL=milliliter;mM=millimolar; mmol=millimole; min=minute; μL=microliter; μM=micromolar;ng=nanogram; nM=nanomolar; NMR=nuclear magnetic resonance; ppm=parts permillion; q=quartet; R_(f)=retention factor; RT=room temperature;s=singlet; t=triplet; TFA=trifluoroacetic acid; THF=tetrahydrofuran;TLC=thin layer chromatography.

General Scheme I.

A synthetic scheme useful for synthesis of compounds described herein isdisclosed in General Scheme I following, wherein the terms “R^(X)”,“R^(y)”, . . . and “R^(z)” are independently hydrogen, substituted orunsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted heterocycloalkenyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl, or other groups obvious to those skilled in the art.

Example 1—Preparation of Intermediate 1

The synthesis of Intermediate 1 followed General Procedure 1 following.

General Procedure 1

To a solution of 2-hydroxynicotinic acid (50.0 g, 0.359 moles, 1.0 eq.)in dichloromethane (500 mL) at 0° C. was added thionyl chloride (133.6mL, 1.798 moles, 5.0 eq.) dropwise. After 30 min tetrahydrofuran (500mL) was added and the reaction stirred for 14-15 hours at ambienttemperature. The reaction mixture was cooled to 0° C., to it was addedmethanol (150 mL) dropwise, and the mixture was stirred for a further 30min at room temperature. The reaction mixture was concentrated underreduced pressure to obtain a solid, which was then neutralized withaqueous sodium bicarbonate (pH 7-8), and again concentrated to obtainsolid product. The solid was dissolved in methanol, filtered, and thefiltrate concentrated to give desired product 45.0 g, (yield; 81.8%) m/z153.99 [M+H]⁺ 1H NMR (DMSO-d6, 400 MHz) δ 8.051-074 (1H, q), 7.661-7.682(1H, q), 6.259-6.292 (1H, m), 3.734 (3H, s) ppm.

Example 2—Preparation of Intermediate 2

The synthesis of Intermediate 2 followed the procedure of GeneralProcedure 2 following.

General Procedure 2

To a cold (−78° C.) solution of acetonitrile (8.18 mL, 0.156 moles, 1.2eq.) in tetrahydrofuran (300 mL) was added n-BuLi (2.5M in Hexane; 62.68mL, 0.156 moles, 1.2 eq) dropwise over a period of 60 min. Afteraddition, the reaction was stirred for another 60 min, then to it addedmethyl 2-oxo-1,2-dihydropyridine-3-carboxylate (Intermediate 1, 20.0 g,130 mmol, 1.0 eq) portionwise to reaction mixture and maintained −78° C.for 3 hrs. The reaction was quenched with water and washed with ethylacetate. The aqueous layer was evaporated to obtain crude product, whichwas suspended in methanol and stirred for 30 min at room temperature.The solid was filtered through suction and dried over high vacuum toafford Intermediate 2 (11.5 g, 54%).

Example 3—Preparation of Compound 1

The synthesis of Compound 1 followed the procedure of General Procedure3 following.

General Procedure 3

To a solution of Intermediate 2 (20.0 g, 0.123 moles, 1.0 eq) inisopropanol (600 mL) and acetic acid (22.2 mL) was added hydrazinemonohydrate (7.40 mL, 0.148 moles, 1.2 eq) dropwise and the reaction washeated at 85° C. for 4-5 Hrs. After cooling, the reaction mixture wasconcentrated to give crude product, which was purified by columnchromatography using neutral silica gel (60-120 mesh), eluting with10-25% methanol in dichloromethane as gradient to give the desiredproduct Compound 1 13.25 g (yield-61%) m/z 177.06 [M+H]+ 1H NMR(DMSO-d6, 400 MHz) δ 11.831 (1H, s), 7.857-7.879 (1H, q), 7.383-7.403(1H, q), 6.303-6.336 (1H, m), 6.048 (1H, s) 4.633 (2H, s) ppm.

Example 4—Preparation of Compound 2

The synthesis of Compound 2 followed the procedure of General Procedure4 following.

General Procedure 4

To a solution of Compound 1 in dimethylformamide (100 mL) at 10-15° C.was added acetic acid (11.2 mL) dropwise, followed by5-chlorothiophene-2-carbaldehyde (9.15 g, 0.0624 moles, 1.1 eq) addedportionwise. The reaction was stirred for 30-45 min at room temperature.Sodium cyanoborohydride (5.35 g, 0.0851 moles, 1.5 eq.) was addedportionwise over a period of 45 min and reaction was stirred for 2hours. After completion of reaction, the mixture was poured into icecold water under stirring and the product was extracted with ethylacetate. The organic layer was dried over sodium sulfate andconcentrated under reduced pressure to obtain crude product, which waspurified by column chromatography using neutral silica gel and productwas eluted with 10-12% Methanol in dichloromethane as mobile phase toyield pure desired product compound 2 (7.3 g, yield: 42.7%) m/z[M+H]+307.10 1H NMR (DMSO-d6, 400 MHz) δ 12.034 (1H, s), 11.815 (1H, s),7.869-7.882 (1H, q), 7.404-7.415 (1H, d), 6.922-6.931 (1H, d),6.862-6.871 (1H, d), 6.314-6.331 (1H, d), 6.117 (1H, s), 5.867-5.898(1H, t), 4.348-4.363 (2H, d) ppm.

Example 5—Preparation of Compound 3

The synthesis of Compound 3 followed the procedure of General Procedure5 following.

General Procedure 5

To a cooled (0° C.) solution of compound 2 in triethylamine (2.98 mL,0.0215 moles, 3.0 eq.) and dichloromethane (40 mL) was added pivaloylchloride (0.776 g, 0.00647 moles, 0.9 eq) dropwise over a period of 30minutes. The reaction was stirred for 2-3 hours by maintaining thetemperature below 10° C. After completion, the reaction was diluted withice cold water under stirring and the product was extracted withdichloromethane. The organic phase was dried over sodium sulfate andconcentrated under reduced pressure. The resultant crude product waspurified by column chromatography using neutral silica gel, eluting with5-8% methanol in dichloromethane to furnish pure desired product(compound 3, 0.76 g, yield: 43.6%) m/z[M+H]⁺ 391.24 1H NMR (DMSO-d6, 400MHz) δ 11.250 (1H, s), 8.086-8.109 (1H, q), 7.731-7.761 (1H, t), 7.484(1H, s), 6.974-6.984 (1H, d), 6.934-6.944 (1H, d), 6.317-6.350 (1H, t),6.213 (1H, s), 4.471-4.486 (2H, d), 1.47 (9H, s) ppm.

Example 6—Preparation of Compound 4

The synthesis of Compound 4 followed the procedure of General Procedure6 following.

General Procedure 6

To a solution of furan-3-carboxylic acid (0.338 g, 0.00301 moles, 1.2eq) in dimethylformamide (5.0 mL) was added EDCI.HCl (0.724 g, 0.00337moles, 1.5 eq), DIEA (0.811 g, 0.00629 moles, 2.5 eq) and finally HOBt(0.074 g, 0.00048 moles, 0.5 eq). The reaction mixture was stirred atroom temperature for 30 min, followed by the addition of compound 2(0.770 g, 0.00251 moles, 1.0 eq). The mixture was stirred at 14 hours atroom temperature. After checking that the reaction had reachedcompletion by LC-MS, the mixture was poured into ice cold water understirring. The product was extracted with ethyl acetate. The organicphase was dried over sodium sulfate, concentrated under reduced pressureand purified by column chromatography using neutral silica gel (60-120mesh), eluting with 15-25% ethyl acetate in n-hexane as gradient to givepure desired compound 4 (0.45 g, yield: 45%) m/z[M+H]+ 401.84 1H NMR(DMSO-d6, 400 MHz) δ 11.923 (1H, s), 9.024-9.029 (1H, q), 8.274-8.297(1H, q), 7.888-7.893 (1H, d), 7.833-7.884 (1H, q), 7.500-7.512 (1H, d),7.085-7.091 (1H, q), 6.965-6.990 (2H, q), 6.313-6.347 (2H, t), 5.771(1H, s), 4.445-4.560 (1H, d) ppm.

Example 7—Preparation of Compound 5

The synthesis of Compound 5 followed the procedure of General Procedure7 following.

General Procedure 7

To a solution of compound 4 (0.150 g, 0.375 mmoles, 1.0 eq) in DMF (5.0mL) was added anhydrous potassium carbonate (0.129 g, 0.937 mmoles, 2.5eq) and then stirred for 30 minutes at room temperature.2-(Chloromethyl)thiophene (0.059 g, 0.45 mmoles, 1.2 eq) was added tothe reaction mixture and the reaction stirred for a further 2-3 hours atroom temperature. The mixture was monitored by TLC and LCMS. Aftercompletion of reaction, the reaction mixture was poured into ice coldwater under stirring and extracted with ethyl acetate. The organic phasewas dried over sodium sulfate, concentrated under reduced pressure andpurified by column chromatography using neutral silica gel. The productwas eluted with 1-5% ethyl acetate as gradient in n-hexane to furnishcompound 5 (0.036 g, yield-19.3%) m/z[M+H]+ 497.23. 1H NMR (DMSO-d6, 400MHz) δ 9.020 (1H, s), 8.274-8.297 (1H, dd), 7.960-7.981 (1H, dd),7.885-7.893 (1H, t), 7.833-7.864 (1H, t), 7.519-7.539 (1H, dd),7.430-7.434 (1H, d), 7.117-7.133 (1H, dd), 7.087-7.091 (1H, d),6.975-6.987 (1H, t), 6.380-6.427 (1H, t), 6.435 (1H, s), 5.189 (2H, s),4.550-4.565 (2H, d) ppm.

Example 8—Preparation of Compound 6

The synthesis of Compound 6 followed the procedure of General Procedure8 following.

General Procedure 8

To a solution of compound 4 (0.150 g, 0.375 mmoles, 1.0 eq.) in DMF (5.0mL) was added cesium carbonate (0.304 g, 0.937 mmoles, 2.5 eq.). Thereaction mixture was stirred for 30 min at room temperature, followed bythe addition of 4-(chloromethyl)pyridine hydrochloride (0.073 g, 0.45mmoles, 1.2 eq). The reaction was stirred for 3-4 hours at 70° C. Thereaction was monitored by TLC and LCMS. After completion of thereaction, the mixture was poured into ice cold water under stirring andextracted into ethyl acetate. The organic phase was dried over sodiumsulfate, filtered and concentrated under reduced pressure. The crudeproduct was purified by column chromatography using neutral silica gel,eluting with 40-55% ethyl acetate as gradient in n-hexane to furnishcompound 6 (0.032 g, yield: 17.4%) m/z [M+H]+ 491.95. 1H NMR (DMSO-d6,400 MHz) δ 9.030 (1H, s), 8.541-8.526 (2H, d), 8.379-8.356 (1H, dd),8.020-7.999 (1H, dd), 7.893-7.836 (2H, m), 7.210-7.195 (2H, d),7.093-7.089 (1H, d), 6.968-6.948 (2H, t), 6.498-6.463 (1H, t), 6.294(1H, s), 5.255 (2H, s), 4.542-4.526 (2H, d) ppm.

Example 9—Preparation of Intermediate 3

General Scheme II.

A synthetic scheme useful for synthesis of compounds described herein isdisclosed in General Scheme II following, wherein the terms “R^(x)”,“R^(y)”, and “R^(z)” are independently hydrogen, substituted orunsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted heterocycloalkenyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl, or other groups obvious to those skilled in the art.

The synthesis of Intermediate 3 followed General Procedure 9 following.

General Procedure 9

A solution of nicotinic acid (9.9 g, 80.9 mmol) in water (30 mL) wasadded slowly portion-wise to a previously stirred mixture ofaminoguanidine sulfate (10 g, 73.5 mmol) in concentrated H₂SO₄ (8.8 mL,162 mmol), and the reaction mixture was stirred at 140° C. for 72 h. Thereaction mixture was diluted with water (50 mL) and neutralized withsaturated aqueous K₂CO₃ (30 mL), and the resultant solid was filtered.The residue was washed with water (2×30 mL), Et₂O (2×30 mL) and driedunder vacuum to afford Intermediate 3 (4.6 g, 39%) as an off-whitesolid. ¹H NMR: (DMSO-d₆) δ 12.23 (s, 1H), 9.05 (s, 1H), 8.54 (d, J=2.8Hz, 1H), 8.17 (d, J=7.4 Hz, 1H), 7.42-7.52 (m, 1H), 6.19 (s, 2H); MS:162 [M+H]⁺; MP: 234-236° C.; TLC: 20% MeOH/NH₃ in CHCl₃: R_(f): 0.40.

Example 10—Preparation of Intermediate 4

General Procedure 9 was followed to obtain Intermediate 4 (8.5 g, 46%).¹H NMR: (DMSO-d₆) δ 8.60 (d, J=4.4 Hz, 1H), 7.86-7.91 (m, 2H), 7.37 (brs, 1H), 5.79 (br s, 2H); MS: 162 [M+H]⁺; MP: 218-220° C.; TLC: 20%MeOH/NH₃ in CHCl₃: R_(f): 0.40.

Example 11—Preparation of Intermediate 5

General Procedure 9 was followed to obtain Intermediate 5 (12 g, 67%).¹H NMR: (DMSO-d₆) δ 12.35 (br s, 1H), 8.59 (d, J=5.5 Hz, 2H), 7.76-7.78(m, 2H), 6.23 (s, 2H); MS: 162 [M+H]⁺; TLC: 20% MeOH/NH₃ in CHCl₃:R_(f): 0.40.

Example 12—Preparation of Intermediate 6

The synthesis of Intermediate 6 followed the procedure of GeneralProcedure 10 following.

General Procedure 10

4-Fluorobenzaldehyde (3.1 g, 24.8 mmol, 2 eq) and molecular sieves (4 Åpowder) were added to a solution of Intermediate 3 (2 g, 12.4 mmol) inEtOH (20 mL) at RT and refluxed for 8 h. Then was added a catalyticquantity of AcOH, NaCNBH₃ (1.6 g, 24.8 mmol, 2 eq) at 0° C. and withstirring for 15 h at RT. The solvent was distilled off, and the residuewas dissolved in EtOAc (200 mL) and filtered through a Celite® pad toremove inorganic materials. The filtrate was washed with saturatedaqueous NaHCO₃ (2×20 mL), water (20 mL), brine (20 mL), dried overNa₂SO₄, filtered and concentrated in vacuo. The resultant compound waspurified by column chromatography over silica gel (100-200 mesh) byusing a solvent gradient of 0-10% MeOH—CHCl₃ as the eluent to affordIntermediate 6 (1.7 g, 51%). ¹H NMR: (DMSO-d₆) δ 12.50 (s, 1H), 9.06 (d,J=1.4 Hz, 1H), 8.53-8.55 (m, 1H), 8.17-8.20 (m, 1H), 7.33-7.45 (m, 4H),7.12-7.19 (m, 2H), 4.40 (d, J=6.4 Hz, 2H); MS: 270 [M+H]⁺; MP: 185-186°C.; TLC: 10% MeOH in CHCl₃: R_(f): 0.25.

Example 13—Preparation of Intermediate 7

General Procedure 10 was followed to obtain Intermediate 7 (2.8 g, 60%).MS: 252 [M+H]⁺; MP: 226-228° C.; TLC: 10% MeOH in CHCl₃: R_(f): 0.30.

Example 14—Preparation of Intermediate 8

General Procedure 10 was followed to obtain Intermediate 8 (1.6 g, 48%).¹H NMR: (DMSO-d₆) δ 13.15 (br s, 1H), 8.60 (d, J=4.0 Hz, 1H), 7.86-7.93(m, 2H), 7.30-7.42 (m, 3H), 7.02-7.15 (m, 2H), 6.84 (br s, 1H), 4.37 (d,J=6.2 Hz, 2H); MS: 270 [M+H]⁺; MP: 219-220° C.; TLC: 10% MeOH in CHCl₃:R_(f): 0.25.

Example 15—Preparation of Intermediate 9

General Procedure 10 was followed to obtain Intermediate 9 (1.4 g, 42%).MS: 270 [M+H]⁺; TLC: 10% MeOH in CHCl₃: R_(f): 0.25.

Example 16—Preparation of Compound 7

The synthesis of Compound 7 followed General Procedure 11 following.

General Procedure 11

Propionyl chloride (39 μL, 0.44 mmol, 1.2 eq) was added to a solution ofIntermediate 6 (100 mg, 0.37 mmol) in triethylamine (3 mL) at RT andstirred for 5 h. The reaction mixture was diluted with water (5 mL) andextracted with EtOAc (20 mL). The organic layer washed with water (2×5mL), saturated aqueous NaHCO₃ (5 mL), brine (5 mL), dried over Na₂SO₄,filtered and concentrated in vacuo. The crude compound was purified bycolumn chromatography over silica gel (100-200 mesh) by using a gradientmixture of 0-30% EtOAc-hexane as the eluent to afford Compound 7 (40 mg,33%). ¹H NMR: (DMSO-d₆) δ 9.14 (d, J=1.8 Hz, 1H), 8.66-8.67 (m, 1H),8.28-8.34 (m, 2H), 7.47-7.53 (m, 3H), 7.13-7.17 (m, 2H), 4.63 (d, J=6.2Hz, 2H), 3.05 (q, J=7.5 Hz, 2H), 1.16 (t, J=7.5 Hz, 3H); MS: 326 [M+H]⁺;TLC: 50% EtOAc in hexane: R_(f): 0.60.

Example 17—Preparation of Compound 8

General Procedure 11 was followed to obtain Compound 8 (48 mg, 35%). ¹HNMR: (DMSO-d₆) δ 8.71 (d, J=4.0 Hz, 1H), 8.46 (br s, 1H), 8.13-8.23 (m,3H), 7.92-7.96 (m, 1H), 7.24-7.52 (m, 6H), 6.88-6.89 (m, 1H), 4.74 (d,J=6.2 Hz, 2H); MS: 346 [M+H]⁺; MP: 143-145° C.; TLC: 50% EtOAc inhexane: R_(f): 0.60.

Example 18—Preparation of Compound 9

General Procedure 11 was followed to obtain Compound 9 (25 mg, 16%). ¹HNMR: (DMSO-d₆) δ 8.65 (d, J=4.0 Hz, 1H), 8.26 (br s, 1H), 8.03 (d, J=8.1Hz, 1H), 7.90 (t, J=7.7 Hz, 1H), 7.19-7.48 (m, 11H), 4.67 (d, J=6.0 Hz,2H), 3.30-3.41 (m, 2H), 2.99-3.03 (m, 2H); MS: 384 [M+H]⁺; MP: 118-120°C.; TLC: 50% EtOAc in hexane: R_(f): 0.40.

Example 19—Preparation of Compound 10

General Procedure 11 was followed to obtain Compound 10 (40 mg, 28%). ¹HNMR: (DMSO-d₆) δ 8.72 (d, J=4.6 Hz, 1H), 8.47-8.54 (m, 2H), 8.12-8.23(m, 2H), 7.94-7.98 (m, 1H), 7.48-7.52 (m, 3H), 7.34-7.36 (m, 1H), 7.16(t, J=9.0 Hz, 2H), 4.71 (d, J=6.1 Hz, 2H); MS: 380 [M+H]⁺; MP: 159-160°C.; TLC: 50% EtOAc in hexane: R_(f): 0.60.

Example 20—Preparation of Compound 11

General Procedure 11 was followed to obtain Compound 11 (20 mg, 14%). ¹HNMR: (DMSO-d₆) δ 9.19 (d, J=1.3 Hz, 1H), 8.63-8.73 (m, 3H), 8.00 (d,J=5.7 Hz, 2H), 7.72-7.88 (m, 2H), 7.50-7.54 (m, 2H), 7.17 (t, J=8.8 Hz,2H), 4.70 (d, J=6.2 Hz, 2H); MS: 380 [M+H]⁺; MP: 187-188° C.; TLC: 50%EtOAc in hexane: R_(f): 0.60.

Example 21—Preparation of Compound 12

The synthesis of Compound 12 followed General Procedure 12 following.

General Procedure 12

A solution of Intermediate 6 (100 mg, 0.37 mmol) in dry DMF (2 mL) wasadded to a solution of morpholinecarbonyl chloride (86 μL, 0.74 mmol, 2eq), DABCO (124 mg, 1.11 mmol, 3 eq) in DMF (3 mL) at RT and stirred for2 h. The reaction mixture was diluted with water (10 mL) and extractedwith EtOAc (30 mL). The organic layer washed with water (2×5 mL),saturated aqueous NaHCO₃ (2×5 mL), brine (10 mL), dried over Na₂SO₄,filtered and concentrated in vacuo to get a crude residue. The crudecompound was purified by column chromatography over silica gel (100-200mesh) by using a gradient mixture of 0-50% EtOAc-hexane as the eluent toafford Compound 12 (33 mg, 23%). ¹H NMR: (DMSO-d₆) δ 9.11 (s, 1H), 8.64(d, J=4.8 Hz, 1H), 8.25 (d, J=7.9 Hz, 1H), 7.90 (s, 1H), 7.46-7.52 (m,3H), 7.16 (t, J=8.8, 2H), 4.59 (d, J=6.2 Hz, 2H), 3.70-3.99 (m, 8H); MS:383 [M+H]⁺; TLC: 50% EtOAc in hexane: R_(f): 0.40.

Example 22—Preparation of Compound 13

A useful scheme for the preparation of compounds of the type of Compound13 is provided in Scheme 1 following.

A detailed description of the preparation of Intermediates 10-13 andCmpd 24 follows.

Preparation of Intermediate 10

A solution of cyanogen bromide (1.3 g, 12.6 mmol) in acetone (5 mL) wasadded portion-wise slowly to a mixture of benzotriazole (3 g, 25.2 mmol,2 eq) in EtOH (50 mL) followed by 10% aqueous NaOH (6 mL, 12.6 mmol, 1eq) at 0° C. The reaction mixture was then stirred at RT for 30 min.Solid formation was observed. The solid was filtered and washed withcold EtOH. The resulting material was recrystallized from benzene toafford Intermediate 10 (2.2 g, 33%) as a white solid. ¹H NMR: (DMSO-d₆)δ 11.76 (s, 1H), 8.29-8.39 (m, 2H), 7.86-8.09 (m, 2H), 7.44-7.72 (m,4H), MS: 264 [M+H]⁺; TLC: 30% EtOAc in hexane: R_(f): 0.50.

Preparation of Intermediate 11

Dimethylamine (1.59 mL, 7.60 mmol, 1 eq) was added to Intermediate 10 (2g, 7.60 mmol) in THF (30 mL) at RT and the resulting mixture was allowedto stir for 24 h. The solvent was evaporated and the residue wasdissolved in DCM (100 mL). The organic layer was washed with 10% Na₂CO₃(3×5 mL), brine (10 mL), dried over Na₂SO₄, filtered and concentrated invacuo to afford Intermediate 11 (1.2 g, 71%) as a light yellow liquidwhich was used without additional purification. ¹H NMR: (DMSO-d₆) δ 8.17(d, J=8.4 Hz, 1H), 7.65-7.80 (m, 3H), 7.49-7.53 (m, 1H), 2.87 (s, 6H);MS: 190 [M+H]⁺; TLC: 30% EtOAc in hexane: R_(f): 0.30.

Preparation of Intermediate 12

Oxalyl chloride (2 mL, 23.3 mmol, 1.4 eq) was added to a solution ofnicotinic acid (2 g, 16.3 mmol) in DCM followed by catalytic amount ofDMF (0.5 mL) at 0° C. and stirred for 5 h at RT. The solvent was thenevaporated to afford nicotinic acid chloride as a yellow solid.Nicotinic acid chloride (1.1 g, 7.93 mmol, 1.5 eq) was then added to asolution of Intermediate 11 (1 g, 5.29 mmol) in CHCl₃ (30 mL) followedby Et₃N (0.7 mL, 5.29 mmol, 1 eq) at 0° C. The reaction mixture wasallowed to warm to RT for stir for 18 h. The mixture was then dilutedwith CHCl₃ (20 mL). The organic layer was washed with water (10 mL),brine (10 mL), dried over Na₂SO₄, filtered and concentrated in vacuo.The resulting compound was purified by column chromatography over silicagel (100-200 mesh) by using a gradient mixture of 0-50% EtOAc-hexane asthe eluent to afford Intermediate 12 (900 mg, 60%) as a white solid. MS:295 [M+H]⁺; TLC: 50% EtOAc in DCM: R_(f): 0.40.

Preparation of Intermediate 13

Hydrazine hydrate (5 mL) was added solution of Intermediate 12 (900 mg,25.2 mmol) in chloroform (20 mL) at RT and the resulting mixture wasallowed to stir for 24 h. The mixture was diluted with excess CHCl₃ (20mL). The organic layer was then washed with water (15 mL), brine (10mL), dried over Na₂SO₄, filtered and concentrated in vacuo. The cruderesidue was partially purified by column chromatography over silica gel(100-200 mesh) by using a gradient mixture of 0-50% EtOAc-hexane as theeluent to afford Intermediate 13 (150 mg) as a thick brown mass. MS: 190[M+H]⁺; TLC: 10% MeOH in CHCl₃: R_(f): 0.30.

Preparation of Compound 13

General Procedure 11 was followed to obtain Compound 13 (13 mg, 6%). ¹HNMR: (DMSO-d₆) δ 9.15 (s, 1H), 8.68 (d, J=3.5 Hz, 1H), 8.31 (d, J=7.9Hz, 1H), 7.53 (dd, J=7.9, 4.8 Hz, 1H), 3.04-3.14 (m, 8H), 1.15 (t, J=7.3Hz, 3H); MS: 246 [M+H]⁺; TLC: 50% EtOAc in DCM: R_(f): 0.50.

Example 23—Preparation of Compound 14

A general chemical scheme for the formation of compounds of the type ofCompound 14 is provided in General Scheme III following, wherein theterms “R^(X)”, “R^(y)”, and “R^(z)” are independently hydrogen,substituted or unsubstituted alkyl, substituted or unsubstitutedheteroalkyl, substituted or unsubstituted cycloalkyl, substituted orunsubstituted heterocycloalkyl, substituted or unsubstitutedheterocycloalkenyl, substituted or unsubstituted aryl, or substituted orunsubstituted heteroaryl, or other groups obvious to those skilled inthe art.

A detailed description of the preparation of Intermediates 14, 15 andCompound 14 follows.

Preparation of Intermediate 14

Oxlayl chloride (5.4 mL, 61.0 mmol, 1.5 eq) and DMF (3 mL) was addedsequentially to a solution of nicotinic acid (5 g, 40.7 mmol) in dry DCM(300 mL) at RT. The reaction mixture was allowed to stir at RT for 2 h.The solvent was removed and co-distilled with dry toluene (2×50 mL) andto afford 5 g of crude nicotinic acid chloride (5 g, 35.5 mmol). Thismaterial was added slowly portion-wise to a solution ofthiosemicarbazide (5 g, 54.9 mmol, 1.5 eq) in pyridine (50 mL) at 0° C.over a period of 1 h and then allowed to stir at RT for 14 h. Thereaction mixture was neutralized with saturated aqueous NaHCO₃ (30 mL)and extracted with t-BuOH (3×100 mL) and dried over Na₂SO₄, filtered andconcentrated in vacuo. The crude residue was dissolved in water (20 mL)along with 10% aqueous KOH (50 mL) and the resulting mixture was allowedto stir at 100° C. for 3 h. The reaction mixture was then cooled to 0°C. and neutralized with 10% aqueous AcOH (60 mL), extracted with EtOAc(2×150 mL), dried over Na₂SO₄, filtered and concentrated in vacuo toafford crude Intermediate 14 (1.2 g) as an off-white solid. MS: 179[M+H]⁺; TLC: 20% MeOH/NH₃ in CHCl₃: R_(f): 0.30.

Preparation of Intermediate 15

4-Fluorobenzyl bromide (0.12 mL, 1.01 mmol, 0.6 eq) was added to asolution of Intermediate 14 (300 mg, 1.68 mmol) in water (5 mL) and THF(15 mL) at −10° C. and the reaction mixture was allowed to stir at −10°C. for 8 h. The solvent was removed and the residue was diluted withwater (10 mL) and extracted with EtOAc (50 mL). The organic layer waswashed with water (15 mL), saturated aqueous NaHCO₃ (10 mL), brine,dried over Na₂SO₄, filtered and concentrated in vacuo. The crudecompound was purified by column chromatography over silica gel (100-200mesh) by using a solvent gradient mixture of 0-10% MeOH—CHCl₃ as theeluent to afford Intermediate 15 (110 mg, 23%) as an off-white solid.MS: 287 [M+H]⁺; TLC: EtOAc: R_(f): 0.40.

Preparation of Compound 14

General Procedure 11 was followed to obtain Compound 14 (20 mg, 30%). ¹HNMR: (DMSO-d₆) δ 9.13 (s, 1H), 8.71 (d, J=4.0 Hz, 1H), 8.26 (d, J=7.9Hz, 1H), 7.53-7.67 (m, 5H), 7.09-7.25 (m, 4H), 4.64 (s, 2H), 3.75 (s,3H); MS: 421 [M+H]⁺; MP: 108-112° C.; TLC: 30% EtOAc in hexane: R_(f):0.40.

Example 24—Preparation of Intermediate 16

2-Thiophene carboxylic acid chloride (6.5 mL, 60.4 mmol) was addedslowly portionwise to a solution of thiosemicarbazide (5 g, 54.9 mmol,1.1 eq) in pyridine (50 mL) at 0° C. over a period of 1 h and thenallowed to stir at RT for 14 h. The reaction mixture was neutralizedwith saturated aqueous NaHCO₃ (50 mL) and extracted with t-BuOH (3×100mL) and dried over Na₂SO₄, filtered and concentrated in vacuo. The cruderesidue was dissolved in water (30 mL) along with 10% aqueous KOH (60mL) and the resulting mixture was allowed to stir at 100° C. for 3 h.The reaction mixture was then cooled to 0° C. and neutralized with 10%aqueous AcOH, extracted with EtOAc (2×150 mL), dried over Na₂SO₄,filtered and concentrated in vacuo to afford crude Intermediate 16 (1.2g) as an off-white solid. MS: 184 [M+H]⁺; TLC: 10% MeOH/NH₃ in CHCl₃:R_(f): 0.60.

Example 25—Preparation of Intermediate 17

A solution of methyl iodide (65 μL, 1.04 mmol, 1.6 eq) in EtOH (2 mL)was added to a solution of Intermediate 16 (120 mg, 0.66 mmol) in 1Maqueous NaOH (3 mL) at RT and the resulting mixture was allowed to stirfor 3 h. The reaction mixture was then neutralized with 10% aqueous AcOH(5 mL) and extracted with EtOAc (30 mL). The organic layer was washedwith water (10 mL), saturated aqueous NaHCO₃ (5 mL), brine, dried overNa₂SO₄, filtered and concentrated in vacuo. The crude compound waspurified by column chromatography over silica gel (100-200 mesh) byusing a solvent gradient mixture of 0-10% MeOH—CHCl₃ as the eluent toafford Intermediate 17 (90 mg, 70%) as an off-white solid. ¹H NMR:(DMSO-d₆) δ 14.19 (br s, 1H), 7.62-7.67 (m, 2H), 7.16-7.18 (m, 1H), 2.60(s, 3H); MS: 198 [M+H]⁺; TLC: 50% EtOAc in hexane: R_(f): 0.50.

Example 26—Preparation of Compound 15

General Procedure 11 was followed to obtain Cmpd 29 (30 mg, 29%). ¹HNMR: (DMSO-d₆) δ 7.72 (d, J=4.8 Hz, 1H), 7.56-7.65 (m, 3H), 7.25 (d,J=8.8 Hz, 1H), 7.09-7.24 (m, 2H), 3.77 (s, 3H), 2.73 (s, 3H); MS: 332[M+H]⁺; MP: 165-167° C.; TLC: 30% EtOAc in hexane: R_(f): 0.40.

Example 27—Preparation of Compound 16

General Scheme IV. A synthetic scheme useful for synthesis of compoundsdescribed herein including Compound 16 is disclosed in General Scheme IVfollowing, wherein the terms “R^(x)”, “R^(y)”, and “R^(z)” areindependently hydrogen, substituted or unsubstituted alkyl, substitutedor unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, orsubstituted or unsubstituted heteroaryl, or other groups obvious tothose skilled in the art.

A description of the synthesis of Intermediates 19-24 and Compound 16follows. Synthesis of Intermediate 19 followed General Procedure 13following.

Preparation of Intermediate 19 [General Procedure 13]

General Procedure 13 was followed in the preparation of Intermediate 19.

General Procedure 13

Thionyl chloride (3.55 mL, 48.4 mmol, 3 eq) was added dropwise to asolution of pyrimidine-4-carboxylic acid (2 g, 16.1 mmol) in EtOH (15mL) and the resulting mixture was heated to reflux for 14 h. The mixturewas then cooled to RT and made alkaline with saturated aqueous NaHCO₃ topH 8. The basic solution was then extracted with EtOAc (4×50 mL). Thecombined organic layers were washed with brine (30 mL), dried overNa₂SO₄, filtered and concentrated in vacuo to afford Intermediate 19(1.7 g, 77%). ¹H NMR: (DMSO-d₆) δ 9.40 (d, J=1.0 Hz, 1H), 9.10 (d, J=5.1Hz, 1H), 8.05 (dd, J=5.1, 1.3 Hz, 1H), 4.39 (q, J=7.1 Hz, 2H), 1.35 (t,J=7.1 Hz, 3H); MS: 153 [M+H]⁺; TLC: 40% hexane in EtOAc: R_(f): 0.40.

Preparation of Intermediate 20

General Procedure 13 was followed to obtain crude Intermediate 20 (950mg, 86%). ¹H NMR: (DMSO-d₆) δ 9.43 (s, 1H), 9.26 (s, 2H), 4.39 (q, J=7.1Hz, 2H), 1.35 (t, J=7.1 Hz, 3H); TLC: 40% EtOAc in hexane: R_(f): 0.50.

Preparation of Intermediate 21 [General Procedure 14]

General Procedure 14 was followed in the preparation of Intermediate 21.

General Procedure 14

Intermediate 19 (1.6 g, 10.5 mmol) was added dropwise to a vigorouslystirring mixture of aminoguanidine sulfate (10.3 g, 42.1 mmol, 4 eq) infreshly prepared NaOMe (using 968 mg, 42.1 mmol of Na in 28 mL of dryMeOH) at 0° C. The resulting mixture was heated to reflux for 20 h. Themixture was then cooled to RT, carefully poured over ice cold water (20mL) and concentrated in vacuo. The crude residue was purified overneutral alumina using 4-10% MeOH—CHCl₃ as the eluent to giveIntermediate 21 (500 mg, 26%). MS: 163 [M+H]⁺; TLC: 20% MeOH in CHCl₃:R_(f): 0.20.

Preparation of Intermediate 22

General Procedure 14 was followed to obtain Intermediate 22 (500 mg,45%). ¹H NMR: (DMSO-d₆) δ 12.44 (br s, 1H), 9.17-9.18 (m, 3H), 6.32 (s,2H); TLC: 20% MeOH in CHCl₃: R_(f): 0.20.

Preparation of Intermediate 23

General Procedure 10 was followed to obtain Intermediate 23 (210 mg,34%). ¹H NMR: (DMSO-d₆) δ 12.80 (s, 1H), 9.18 (s, 1H), 8.83 (s, 1H),7.92 (d, J=4.4 Hz, 1H), 7.25-7.40 (m, 5H), 4.44 (d, J=5.7 Hz, 2H); TLC:EtOAc: R_(f): 0.30.

Preparation of Intermediate 24

General Procedure 10 was followed to obtain Intermediate 24 (160 mg,20%). MS: 253 [M+H]⁺; TLC: EtOAc: R_(f): 0.30.

Preparation of Compound 16 [General Procedure 11]

General Procedure 11 was followed in the preparation of Compound 16.

General Procedure 11

2-Methoxybenzoyl chloride (72 μL, 0.54 mmol, 2 eq) was added to asolution of Intermediate 23 (70 mg, 0.27 mmol) in Et₃N (0.18 mL, 1.35mmol) and DCM (3 mL) at 0° C. The resulting mixture was allowed to stirat RT for 2 h. The reaction mixture was then diluted with water (5 mL)and extracted with DCM (3×15 mL). The combined organic layers werewashed with saturated aqueous NaHCO₃ (10 mL), water (2×5 mL), brine (15mL), dried over Na₂SO₄, filtered and concentrated in vacuo. The crudematerial was purified by column chromatography over silica gel (100-200mesh) using a gradient mixture of 0-70% EtOAc-hexane as the eluent toafford Compound 16 (45 mg, 29%). ¹H NMR: (DMSO-d₆) δ 9.21 (s, 1H), 8.90(d, J=5.1 Hz, 1H), 8.59 (t, J=6.0 Hz, 1H), 7.93 (d, J=5.1 Hz, 1H),7.08-7.60 (m, 10H), 4.72 (d, J=5.7 Hz, 2H), 3.77 (s, 3H); MS: 387[M+H]⁺; MP: 192-195° C.; TLC: 40% hexane in EtOAc: R_(f): 0.30.

Example 28—Preparation of Compound 17

General Procedure 11 was followed by preparative HPLC purification toobtain Compound 17 (30 mg, 16%). ¹H NMR: (DMSO-d₆) δ 9.26 (s, 1H), 9.11(s, 2H), 8.64 (t, J=6.3 Hz, 1H), 7.07-7.60 (m, 9H), 4.71 (d, J=6.3 Hz,2H), 3.78 (s, 3H); MS: 387 [M+H]⁺; MP: 154-157° C.; TLC: 40% EtOAc inhexane: R_(f): 0.20.

Example 29—Preparation of Compound 18

General Scheme V.

A synthetic scheme useful for synthesis of compounds described hereinincluding Compound 18 is disclosed in General Scheme V following,wherein the terms “R^(x)”, “R^(y)”, and “R^(z)” are independentlyhydrogen, substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, orsubstituted or unsubstituted heteroaryl, or other groups obvious tothose skilled in the art.

A description of the synthesis of Intermediates 25, 26 and Compound 18follows.

Preparation of Intermediate 25

Oxalyl chloride (2.36 mL, 24.2 mmol, 1.5 eq) and a catalytic quantity ofDMF were added to a solution of pyrimidine-2-carboxylic acid (2 g, 16.1mmol) in dry DCM (30 mL) at 0° C. The resulting mixture was allowed towarm to RT and stir for 3 h. The volatiles were removed in vacuo and theresidue was thoroughly dried to afford pyrimidine-2-carboxylic acidchloride (2.1 g, 14.8 mmol) as a black solid. The crude material wasadded portion-wise to a solution of aminogaunidine sulfate (5.5 g, 22.2mmol, 1.5 eq) in pyridine (20 mL) at 0° C. The resulting mixture wasallowed to warm to RT and stir for 14 h. The mixture was thenneutralized with saturated aqueous NaHCO₃, extracted with t-BuOH (5×50mL), dried over Na₂SO₄, filtered and concentrated in vacuo. The crudematerial was dissolved in water (45 mL) and the resulting solution washeated to 100° C. for 24 h. The reaction mixture was then cooled to RT,extracted with t-BuOH (5×30 mL), dried over Na₂SO₄, filtered andconcentrated in vacuo to afford Intermediate 25 (650 mg, 25%) asoff-white solid. TLC: 30% MeOH in CHCl₃: R_(f): 0.20.

Preparation of Intermediate 26

General Procedure 10 was followed to obtain Intermediate 26 (120 mg,17%). MS: 253 [M+H]⁺; TLC: EtOAc: R_(f): 0.30.

Preparation of Compound 18

General Procedure 11 was followed to obtain Compound 18 (32 mg, 21%). ¹HNMR: (DMSO-d₆) δ 8.86 (d, J=5.1 Hz, 2H), 8.44 (t, J=6.0 Hz, 1H),7.08-7.59 (m, 10H), 4.73 (d, J=6.3 Hz, 2H), 3.77 (s, 3H); MS: 387[M+H]⁺; MP: 203-205° C.; TLC: 40% hexane in EtOAc: R_(f): 0.40.

Example 30—Preparation of Compound 19

General Scheme VI.

A synthetic scheme useful for synthesis of compounds described hereinincluding Compound 19 is disclosed in General Scheme VI following,wherein the terms “R^(x)”, “R^(y)”, and “R^(z)” are independentlyhydrogen, substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, orsubstituted or unsubstituted heteroaryl, or other groups obvious tothose skilled in the art.

Preparation of Intermediate 27

General Procedure 10 was followed in the preparation of Intermediate 27.

General Procedure 10

4-Fluorobenzaldehyde (0.54 mL, 5.03 mmol, 2 eq) and molecular sieves (4Å powder) were added to a solution of 3-amino-5-phenylpyrazole (400 mg,2.51 mmol) in EtOH (20 mL) at RT and the resulting mixture was heated toreflux. After 8 h, the reaction mixture was cooled to 0° C. and AcOH(0.4 mL) and NaCNBH₃ (316 mg, 5.03 mmol, 2 eq) were added. The mixturewas then allowed to warm to RT and stir for 15 h. The solvent wasevaporated and the residue was dissolved in EtOAc (100 mL) and filteredthrough a Celite pad to remove inorganic materials. The filtrate wasthen washed with saturated aqueous NaHCO₃ (2×20 mL), water (20 mL),brine (20 mL), dried over Na₂SO₄, filtered and concentrated in vacuo.The crude material was purified by column chromatography over silica gel(100-200 mesh) by using a solvent gradient of 0-50% EtOAc-petroleumether as the eluent to afford Intermediate 27 (240 mg, 36%) as an offwhite solid. MS: 268 [M+H]⁺; TLC: EtOAc: R_(f): 0.60.

Preparation of Compound 19

General Procedure 15 was followed in the preparation of Compound 19.

General Procedure 15

Pivaloyl chloride (32 μL, 0.26 mmol, 1.2 eq) was added to a solution ofIntermediate 27 (60 mg, 0.22 mmol) in triethylamine (3 mL) at RT andstirred for 3 h. The reaction mixture was diluted with water (5 mL) andextracted with EtOAc (20 mL). The organic layer was washed with water(2×5 mL), saturated aqueous NaHCO₃ (5 mL), brine (5 mL), dried overNa₂SO₄, filtered and concentrated in vacuo. The crude compound waspurified by column chromatography over silica gel (100-200 mesh) byusing a gradient mixture of 0-10% EtOAc-hexane as the eluent to affordCompound 19 (23 mg, 29%). ¹H NMR: (DMSO-d₆) δ 7.79-7.84 (m, 3H),7.37-7.49 (m, 5H), 7.17 (t, J=8.8 Hz, 2H), 5.89 (s, 1H), 4.38 (d, J=6.2Hz, 2H), 1.49 (s, 9H); MS: 352 [M+H]⁺; TLC: 20% EtOAc in hexane: R_(f):0.60.

Example 31—Preparation of Compound 20

General Scheme VII.

A synthetic scheme useful for synthesis of compounds described hereinincluding Compound 20 is disclosed in General Scheme VII following,wherein the terms “R^(x)”, “R^(y)”, and “R^(z)” are independentlyhydrogen, substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, orsubstituted or unsubstituted heteroaryl, or other groups obvious tothose skilled in the art.

A description of the syntheses of Intermediates 28-31 and Compound 20follows.

Preparation of Intermediate 28 [General Procedure 16]

General Procedure 16 was followed in the preparation of Intermediate 28.

General Procedure 16

Thionyl chloride (5.4 mL, 73.2 mmol, 3 eq) was added to a solution ofpicolinic acid (3 g, 24.4 mmol) in EtOH (50 mL) at 0° C. The resultingmixture was heated to reflux and allowed to stir for 2 h. The mixturewas then cooled and the solvent was evaporated. The resulting residuewas poured into saturated aqueous NaHCO₃ and extracted with EtOAc (2×50mL). The combined organic layers were dried over Na₂SO₄, filtered andconcentrated in vacuo. The crude material was purified by columnchromatography over silica gel (100-200 mesh) by using DCM as the eluentto afford Intermediate 28 (3 g, 81%) as a colorless liquid. MS: 152[M+H]⁺; TLC: 10% MeOH/NH₃ in CHCl₃: R_(f): 0.70.

Preparation of Intermediate 29 [General Procedure 17]

General Procedure 17 was followed in the preparation of Intermediate 29.

General Procedure 17

A solution of Intermediate 28 (3 g, 19.6 mmol) and CH₃CN (0.8 mL, 19.6mmol, 1 eq) in dry toluene (10 mL) was slowly added to a mixture of NaH(784 mg, 19.6 mmol, 1 eq, 60% in mineral oil) in toluene (50 mL) at 65°C. The resulting mixture was allowed to stir at 65° C. for 16 h. Thereaction mixture was then cooled to RT and quenched with ice cold water(20 mL). The resulting solid was filtered to afford Intermediate 29 (1.5g, 53%) as a brown solid. ¹H NMR: (CDCl₃) δ 8.70 (d, J=4.8 Hz, 1H), 8.12(d, J=7.5 Hz, 1H), 7.90-7.94 (m, 1H), 7.56-7.60 (m, 1H), 4.41 (s, 2H);MS: 147 [M+H]⁺; TLC: EtOAc: R_(f): 0.40.

Preparation of Intermediate 30 [General Procedure 18]

General Procedure 18 was followed in the preparation of Intermediate 30.

General Procedure 15

Hydrazine hydrate (0.34 mL, 6.8 mmol, 1 eq) was added to a solution ofIntermediate 29 (1 g, 6.8 mmol) in EtOH (30 mL) at RT. The mixture wasthen heated to reflux and allowed to stir for 20 h. The solvent was thenevaporated. The resulting crude material was triturated with Et₂O (2×20mL) and dried under vacuum to afford Intermediate 30 (700 mg, 64%) as abrown liquid. ¹H NMR: (DMSO-d₆) δ 8.53 (d, J=4.4 Hz, 1H), 7.78 (d, J=4.4Hz, 2H), 7.23-7.26 (m, 1H), 5.95 (s, 1H), 4.84 (br s, 2H); MS: 161[M+H]⁺; TLC: EtOAc: R_(f): 0.20.

Preparation of Intermediate 31

General Procedure 10 was followed to afford Intermediate 31 (450 mg).MS: 269 [M+H]⁺; TLC: EtOAc: R_(f): 0.40.

Preparation of Compound 20

General Procedure 11 was followed to afford Compound 20 (40 mg, 30%). ¹HNMR: (DMSO-d₆) δ 8.58 (d, J=4.4 Hz, 1H), 7.86-7.98 (m, 3H), 7.38-7.46(m, 3H), 7.18 (t, J=8.8 Hz, 2H), 5.84 (s, 1H), 4.40 (d, J=6.2 Hz, 2H),1.50 (s, 9H); MS: 353 [M+H]⁺; MP: 102-103° C.; TLC: 20% EtOAc in hexane:R_(f): 0.60.

Example 33—General Scheme VIII

A synthetic scheme useful for synthesis of compounds described herein isdisclosed in General Scheme VIII following, wherein the terms “Ar,” “R¹”and “R²” are as defined in Example 1.

Example 34—Preparation of Intermediate 32

A solution of ethyl cyanoacetate (20 g, 176.8 mmol) and triethylorthoformate (29.4 mL, 176.8 mmol) in acetic anhydride (100 mL) washeated to 140° C. and allowed to stir for 5 h. The solvent was thenevaporated to afford crude Intermediate 32 (23 g, 76%) as a low meltingsolid. MS: 170 [M+H]⁺; TLC: 30% EtOAc in hexane: R_(f): 0.40.

Example 35—Preparation of Intermediate 33

Sodium acetate (8.2 g, 100 mmol, 2 eq) was added to a solution ofIntermediate 32 (8.45 g, 50.0 mmol) and 2-hydrazinopyridine (5 g, 45.5mmol, 0.9 eq) in AcOH (100 mL) and water (20 mL). The resulting mixturewas heated at 110° C. and allowed to stir for 16 h. The mixture was thenallowed to cool and ice-cold water was added. The precipitate wascollected by filtration and washed with Et₂O and dried under vacuum toafford Intermediate 33 (4 g, 38%) as a pale yellow solid. ¹H NMR:(DMSO-d₆) δ 8.48-8.49 (m, 1H), 8.00-8.04 (m, 1H), 7.87 (d, J=8.3 Hz,1H), 7.79 (s, 1H), 7.65 (br s, 2H), 7.33-7.36 (m, 1H), 4.22 (q, J=7.0Hz, 2H), 1.28 (t, J=7.0 Hz, 3H); MS: 233 [M+H]⁺; TLC: 15% EtOAc inhexane: R_(f): 0.50.

Example 36—Preparation of Compound 21

Sodium hydride (603 mg, 15.1 mmol, 1 eq, 60% in mineral oil) was addedto a solution of Intermediate 33 (3.5 g, 15.1 mmol) in DMF (300 mL) at0° C. After 30 minutes, a solution of 4-fluorobenzyl bromide (2.85 g,15.1 mmol, 1 eq) in DMF (50 mL) was added and the resulting mixture wasallowed to warm to RT. After 5 h, the reaction mixture was diluted withwater (100 mL) and extracted with EtOAc (3×100 mL). The combined organiclayers were washed with water (5×50 mL), brine (50 mL), dried overNa₂SO₄, filtered and concentrated in vacuo. The crude material waspurified by column chromatography over silica gel (100-200 mesh) byusing a gradient mixture of 0-5% EtOAc-hexane as the eluent to afford apartially pure product. The material was then recrystallized from Et₂Oand pentane to afford Compound 21 (2.8 g, 55%) as a pale yellow solid.¹H NMR: (DMSO-d₆) δ 9.50 (t, J=6.6 Hz, 1H), 8.45-8.46 (m, 1H), 8.00-8.05(m, 1H), 7.82-7.89 (m, 2H), 7.24-7.38 (m, 3H), 7.11 (t, J=8.8 Hz, 2H),4.88 (d, J=6.6 Hz, 2H), 4.17 (q, J=7.0 Hz, 2H), 1.24 (t, J=7.0 Hz, 3H);MS: 341 [M+H]⁺; MP: 99-100° C.; TLC: 15% EtOAc in hexane: R_(f): 0.40.

Example 37—Trans-Corneal Permeability of Compounds 4 and 22

In this example, trans-corneal permeability of compounds are measuredin-vitro across excised rabbit corneas. Excised rabbit cornea areacquired from Pel-Freez and delivered in DMEM culture media on iceovernight. The test apparatus is a curved 9 mm Franz chamber (Permegear)suitable for rabbit eyes. Test compound is prepared in PBS buffer. Thecompound solution is added to the donor chamber of the Franz chamber andthe entire apparatus placed in an incubator at 37° C. for four hours.During incubation and at every subsequent hour, a sample is removed fromthe receiver chamber and analyzed by HPLC (Shimadzu Prominence) using aC18 column (Phenomenex 00F-4605-E0) in reverse phase with acetonitrilein water. The apparent permeability coefficient P_(app) (cm/s) iscalculated as

$P_{app} = {\frac{1}{A\; C_{0}} \times \frac{dM}{dt}}$where dM/dt is the flux (nmol/s) across the cell layers or comea, A isthe exposed surface area (cm²) of the insert membrane of rabbit cornea,and C₀ is the initial drug concentration (μM) in the donor compartment.

In Table E following, measured trans-corneal permeability P_(app) inunits of cm/s is presented for example compounds.

TABLE E Cmpd No. P_(app) 4 2.5 × 10⁻⁶ 22 5.7 × 10⁻⁶

Example 38—Pharmacokinetics in Mice

In this example, pharmacokinetics in mice is presented for series ofexample compounds #4, #23, #24, #25, #26. Each compound is administeredintravenously (i.v.) as a single dose via tail vein or orally (p.o.) asa single dose via gastric gavage to male CD-1 mice of nominal weightsbetween 20 g and 26 g. Nominal doses are 1 mg/kg and 5 mg/kg for i.v.and p.o., respectively. In some examples (dose type A), both p.o. andi.v. doses are prepared by dissolving the test compound in 5% dimethylacetamide and diluted in tetraethylene glycol for a final concentrationof 0.25 mg/mL. In other examples (dose type B), i.v. doses are preparedby dissolving test compounds in 20% dimethyl acetamide, 40% polyethyleneglycol 300 and 40% phosphate buffered saline, and p.o. doses areprepared by dissolving test compounds in carboxymethyl cellulosesuspension (1% by weight) in water and 2.5% dimethyl acetamide.

Animals are housed in standard holding cages with food and wateravailable ad libitum except for animals used for p.o. dosing which arefasted overnight prior to dosing. Samples are taken in triplicate viacardiac puncture at times prior to dosing and at 0.083 (i.v. only),0.25, 0.5, 1, 2, 4, 8, and 24 hours after administration. Plasma isobtained by centrifuge and stored frozen until analyzed by LC-MS/MSusing a Shimadzu VP System HPLC coupled to a Applied Biosystems MDSSCIEX API 3000 triple quadrapole MS. Assay results are calibrated usingreference samples prepared in a range between 1.5 and 5000 ng/mL.

Pharmacokinetic parameters are calculated from mean concentration valuesusing a non-compartmental analysis as described in the following and asapparent to those of ordinary skill in the art. Half-lives (t_(1/2)) andelimination rate constants (λ) are determined by log linear regressionusing equal weighting on the last three finite sample time points.Concentration at time zero (C₀) for the i.v. data is established by theextrapolation of log linear regression using equal weighting on thefirst three sample time points. Area under the curve (AUC) values arecalculated using linear trapezoidal integration. Systemic clearance (CL)is calculated as the ratio of dosage and AUC. The apparent volume ofdistribution (V_(d)) is calculated as the ratio of CL and λ. Percentoral bioavailability (% F) is determined from the ratio of i.v. and p.o.AUC values weighted by dosage.

In Table F following resulting pharmacokinetic parameters are listed forfive example compounds, rounded to the nearest significant digit.

TABLE F Cmpd No 4 23 24 25 26 Dose type A A A B B i.v. t_(1/2) (h) 1 0.51 0.3 0.3 i.v. C₀ (ng/ml) 300 400 200 100 200 i.v. AUC (h · ng/ml) 100100 200 40 50 i.v. V_(d) (ml/kg) 10000 5000 8000 6000 5000 i.v. CL(ml/kg/h) 10000 8000 5000 10000 10000 p.o. t_(1/2) (h) 6 0.6 1 >0.3 >0.3p.o. AUC (h · ng/ml) 300 80 600 10 20 % F 60 10 70 9 8

The contents of all references, patents, and published applicationscited herein are hereby incorporated by reference in their entirety andfor all purposes.

While the invention has been described in detail with reference tocertain preferred embodiments thereof, it will be understood thatmodifications and variations are within the spirit and scope of thatwhich is described and claimed.

What is claimed is:
 1. A method for treating a disease or disorder,comprising administering a kallikrein-inhibiting compound to a subjectin need thereof in an amount effective to treat said disease ordisorder, wherein the kallikrein-inhibiting compound has the followingformula:

or pharmaceutically acceptable salt thereof; wherein L¹ is —NR⁵—; L² isa bond; L³ is a bond, substituted or unsubstituted alkylene, substitutedor unsubstituted heteroalkylene, —S—, —SO—, —SO₂—, —O—, —NHSO₂—, or—NR⁵—; L⁴ is a bond, substituted or unsubstituted alkylene, substitutedor unsubstituted heteroalkylene, —S—, —SO—, —SO₂—, —O—, —NHSO₂—, or—NR⁵—; R¹ is substituted alkyl having one or more substituent groups,wherein any substituent group for said R¹ substituted alkyl is selectedfrom the group consisting of —OH, —NH₂, —SH, —CN, —CF₃, —NO₂, halogen,—COOH, substituted or unsubstituted alkyl, substituted or unsubstitutedheteroalkyl, substituted or unsubstituted cycloalkyl, substituted orunsubstituted heterocycloalkyl, substituted or unsubstituted aryl, andsubstituted or unsubstituted heteroaryl; R² is substituted orunsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedcycloalkenyl, substituted or unsubstituted heterocycloalkyl, substitutedor unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl,substituted or unsubstituted fused ring aryl, or substituted orunsubstituted heteroaryl, wherein the substituted alkyl, substitutedcycloalkyl, substituted cycloalkenyl, substituted heterocycloalkyl,substituted heterocycloalkenyl, substituted aryl, substituted fused ringaryl, or substituted heteroaryl has one or more substituent groupselected from the group consisting of oxo, —OH, —NH₂, —SH, —CN, —CF₃,—NO₂, -halogen, —COOH, substituted or unsubstituted alkyl, substitutedor unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,and substituted or unsubstituted heterocycloalkyl; R³ is substitutedalkyl, substituted or unsubstituted heteroalkyl, substituted orunsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl, wherein when R³ is substituted heteroaryl, any substituentgroup of said R³ substituted heteroaryl is selected from the groupconsisting of NH₂, —SH, —CN, —CF₃, —NO₂, halogen, —COOH, substituted orunsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted aryl, and substituted orunsubstituted heteroaryl; R⁴ is hydrogen, substituted or unsubstitutedalkyl, substituted or unsubstituted heteroalkyl, substituted orunsubstituted cycloalkyl, substituted or unsub stitutedheterocycloalkyl, substituted aryl, or substituted or unsubstitutedheteroaryl; and R⁵ is hydrogen, or substituted or unsubstituted alkyl,wherein the disease or disorder is an ophthalmic disease, adermatological condition, or hereditary angioedema.
 2. The methodaccording to claim 1, wherein said compound is selected from the groupconsisting of: Compound 19,1-(5-{[(4-fluorophenyl)methyl]amino}-3-phenyl-1H-pyrazol-1-yl)-2,2-dimethylpropan-1-one;Compound 20,1-(5-{[(4-fluorophenyl)methyl]amino}-3-(pyridin-2-yl)-1H-pyrazol-1-yl)-2,2-dimethylpropan-1-one;Compound 266,1-(5-{[(4-fluorophenyl)methyl]amino}-3-(pyridazin-3-yl)-1H-pyrazol-1-yl)-2,2-dimethylpropan-1-one;Compound 267,1-(5-{[(4-fluorophenyl)methyl]amino-3-(pyrimidin-4-yl)-1H-pyrazol-1-yl)-2,2-dimethylpropan-1-one;Compound 268,1-(5-{[(4-fluorophenyl)methyl]amino}-3-phenyl-1H-pyrazol-1-yl)propan-1-one;Compound 269,1-(5-{[(5-chlorothiophen-2-yl)methyl]amino}-3-(3-fluoropyridin-2-yl)-1H-pyrazol-1-yl)-2,2-dimethylpropan-1-one;Compound 270,1-(5-{[(5-chlorothiophen-2-yl)methyl]amino}-3-(furan-2-yl)-1H-pyrazol-1-yl)-2,2-dimethylpropan-1-one;Compound 271, 1454[(5-chlorothiophen-2-yl)methyl]amino}-3-(pyridin-2-yl)-1H-pyrazol-1-yl)-2,2-dimethylpropan-1-one;Compound 272,1-(5-{[(5-chlorothiophen-2-yl)methyl]amino}-3-(pyridin-2-yl)-1H-pyrazol-1-yl)-3-methoxy-2,2-dimethylpropan-1-one;Compound 276,1-[(2-aminophenyl)carbonyl]-N-[(5-chlorothiophen-2-yl)methyl]-3-(3-fluoropyridin-2-yl)-1H-pyrazol-5-amine;Compound 277,1-[(2-aminophenyl)carbonyl]-N-[(5-chlorothiophen-2-yl)methyl]-3-(furan-2-yl)-1H-pyrazol-5-amine;Compound 278,1-[(2-methoxyphenyl)carbonyl]-3-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)-1H-pyrazol-5-amine;Compound 280,1-{5-[(furan-2-ylmethyl)amino]-3-(pyridin-2-yl)-1H-pyrazol-1-yl}-2,2-dimethylpropan-1-one;Compound 281,2,2-dimethyl-1-[3-(pyridin-2-yl)-5-[(thiophen-2-ylmethyl)amino]-1H-pyrazol-1-yl]propan-1-one;Compound 282,2-(5-{[(5-chlorothiophen-2-yl)methyl]amino}-1-[(2-methoxyphenyl)carbonyl]-1H-pyrazol-3-yl)cyclohexan-1-ol;Compound 283,N-(furan-2-ylmethyl)-1-[(2-methoxyphenyl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol-5-amine;Compound 285,N-[(5-chlorothiophen-2-yl)methyl]-1-[(2-methoxyphenyl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol-5-amine;Compound 286,N-[(5-chlorothiophen-2-yl)methyl]-1-[(2-phenoxyphenyl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol-5-amine;Compound 287,N-[(5-chlorothiophen-2-yl)methyl]-1-[(4-methyloxan-4-yl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol-5-amine;Compound 288,N-[(5-chlorothiophen-2-yl)methyl]-1-[(furan-3-yl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol-5-amine;Compound 289,N-[(5-chlorothiophen-2-yl)methyl]-1-[(furan-3-yl)carbonyl]-3-(thiophen-2-yl)-1H-pyrazol-5-amine;Compound 290,N-[(5-chlorothiophen-2-yl)methyl]-3-(3-fluoropyridin-2-yl)-1-[(2-methoxyphenyl)carbonyl]-1H-pyrazol-5-amine;Compound 291,N-[(5-chlorothiophen-2-yl)methyl]-3-(3-fluoropyridin-2-yl)-1-[(furan-3-yl)carbonyl]-1H-pyrazol-5-amine;Compound 292,N-[(5-chlorothiophen-2-yl)methyl]-3-(pyridazin-3-yl)-1-[(thiophen-3-yl)carbonyl]-1H-pyrazol-5-amine;and Compound 293,N-[(5-chlorothiophen-2-yl)methyl]-3-(pyridin-2-yl)-1-[(thiophen-3-yl)carbonyl]-1H-pyrazol-5-amine.3. The method according to claim 1, wherein said disease or disordercomprises an ophthalmic disease.
 4. The method of claim 3, wherein saidophthalmic disease comprises at least one of diabetic macular edema,age-related macular degeneration, and diabetic retinopathy.
 5. Themethod according to claim 3, wherein said compound or pharmaceuticalcomposition is administered orally, in the form of an ophthalmiccomposition applied topically to the eye, or in the form of anophthalmic composition via intravitreal injection.
 6. The methodaccording to claim 5, wherein said ophthalmic composition is in the formof eye drops.
 7. The method according to claim 3, wherein said compoundacts by reducing retinal vascular permeability.
 8. The method accordingto claim 1, wherein said disease or disorder comprises a dermatologicalcondition.
 9. The method according to claim 1, wherein said disease ordisorder comprises hereditary angioedema.
 10. The method according toclaim 9, wherein said disease or disorder is hereditary angioedema andsaid compound is administered orally.
 11. The method according to claim8, wherein said dermatological condition comprises at least one ofatopic dermatitis, psoriasis, and Netherton Syndrome.
 12. The methodaccording to claim 1, wherein said compound acts by inhibitingkallikrein.
 13. The method according to claim 12, wherein said compoundacts by inhibiting tissue kallikrein.
 14. The method according to claim12, wherein said compound acts by inhibiting plasma kallikrein.